No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519870 |
1. Apply sex-specific ruleNone |
519870 |
2. Check conditions
|
509 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
3 out of 7 registries used, show all original rules. |
509 |
4. Check minimum number of eventsNone |
509 |
5. Include endpoints |
509 |
6. Filter based on genotype QC (FinnGen only) |
470 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
- Control conditions
- not HLP_C3_AML
Extra metadata
- First used in FinnGen datafreeze
- DF12
Similar endpoints
↥List of similar endpoints to
Acute myeloid leukaemia, including Hilmo
based on the number of shared cases.
Similar with more cases:
- Acute myeloid leukaemia
- Acute myeloid leukaemia, helper endpoint
- Acute myeloid leukaemia and myelodysplastic syndromes
- Liquid cancers
- Liquid cancers, including Hilmo
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded (different definition than used in FinnGen).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 470 | 200 | 270 |
| Unadjusted period prevalence (%) | 0.10 | 0.07 | 0.12 |
| Median age at first event (years) | 68.46 | 65.06 | 70.98 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 509
- Matched controls
- 5090
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
A04AA01
ATC
ondansetron; systemic, rectal
57.9
317.3
188
51
C92.0
ICD-10 Finland
Acute myeloblastic leukaemia [AML]
+∞
307.7
457
*
9861/3-C42.1
ICD-O-3
Acute myeloid leukemia, NOS, of bone marrow
+∞
307.7
344
*
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
6849.1
307.7
373
*
XW000
NOMESCO Finland
Bone marrow biopsy
148.5
307.7
308
52
WW500
NOMESCO Finland
Blood transfusion
87.5
307.7
202
38
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
53.3
236.7
140
36
127
Kela drug reimbursment
Transplant complication
73.7
166.8
91
15
A05AA02
ATC
ursodeoxycholic acid; oral
54.3
148.6
86
19
Z51.5
ICD-10 Finland
Palliative care
15.1
137.9
137
121
L03AA02
ATC
filgrastim; parenteral
1597.8
131.3
122
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
8.8
116.3
189
320
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
13.2
111.3
118
114
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
1073.5
94.0
89
*
H02AB02
ATC
dexamethasone; systemic
38.4
92.6
58
17
JN4AD
NOMESCO Finland
Body CT examination
9.9
88.0
114
144
ZX112
NOMESCO Finland
Subcutaneous
42.1
86.9
53
14
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
7.2
85.5
159
303
J05AB11
ATC
valaciclovir; oral
6.5
84.9
182
399
C95.0
ICD-10 Finland
Acute leukaemia of unspecified cell type
+∞
84.8
79
*
R50.9
ICD-10 Finland
Fever, unspecified
6.3
83.0
185
420
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
42.5
82.2
50
13
Z94.8
ICD-10 Finland
Other transplanted organ and tissue status
902.6
80.7
77
*
D69.6
ICD-10 Finland
Thrombocytopenia, unspecified
20.4
79.8
63
35
M04AA01
ATC
allopurinol; systemic
5.9
77.9
193
480
J01MA12
ATC
levofloxacin; systemic
5.5
74.2
204
553
L04AD01
ATC
ciclosporin; systemic
29.1
73.4
50
19
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
8.8
71.3
100
138
JN4BD
NOMESCO Finland
Extensive body CT
10.1
68.2
84
98
ZX120
NOMESCO Finland
Intravenous
8.0
67.2
102
154
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
714.7
65.4
63
*
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
14.3
65.2
62
49
J02AC03
ATC
voriconazole; systemic
361.7
63.9
63
*
D64.9
ICD-10 Finland
Anaemia, unspecified
5.5
63.9
157
381
L01XX05
ATC
hydroxycarbamide; oral
637.7
58.9
57
*
L01BB02
ATC
mercaptopurine; oral
28.9
58.7
40
15
D46.9
ICD-10 Finland
Myelodysplastic syndrome, unspecified
321.4
57.5
57
*
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
8.0
56.4
84
123
D70.89
ICD-10 Finland
Neutropenic splenomegaly
111.0
55.1
59
6
N02AA05
ATC
oxycodone; systemic
4.6
54.2
172
508
A04AA02
ATC
granisetron; systemic, transdermal
550.4
51.4
50
*
A03FA01
ATC
metoclopramide; systemic, rectal
4.9
49.4
135
352
WD135
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
48.7
46
*
D46.2
ICD-10 Finland
Refractory anaemia with excess of blasts [RAEB]
+∞
46.6
44
*
A41.9
ICD-10 Finland
Sepsis, unspecified
7.8
45.6
68
99
121
Kela drug reimbursment
Severe hypofunction of sexual glands
16.8
45.6
39
25
TPX10
NOMESCO Finland
Implantation of vascular injection port
13.7
44.9
43
34
T86.0
ICD-10 Finland
Bone-marrow transplant rejection
465.6
43.9
43
*
D46.7
ICD-10 Finland
Other myelodysplastic syndromes
228.3
41.5
42
*
TGC00
NOMESCO Finland
Bronchial lavation
9.5
40.3
50
58
WW200
NOMESCO Finland
Immunization
10.4
40.1
46
48
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
70.3
39.8
45
7
B73
ICPC
Leukaemia
+∞
39.1
37
*
J01MA14
ATC
moxifloxacin; systemic
4.9
39.0
99
240
399
Kela drug reimbursment
Venetoclax
+∞
38.0
36
*
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
+∞
36.9
35
*
1518, ,
Kela drug reimbursment
+∞
35.9
34
*
9891/3-C42.1
ICD-O-3
Acute monocytic leukemia of bone marrow
+∞
35.9
34
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
35.9
34
*
B03XA02
ATC
darbepoetin alfa; parenteral
12.4
35.5
36
31
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.6
35.3
156
563
L03AA13
ATC
pegfilgrastim; parenteral
193.3
35.2
36
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.2
34.7
320
1773
L04AA06
ATC
mycophenolic acid; systemic
12.9
34.5
34
28
WD325
NOMESCO Finland
Demanding therapy of methastized malignancy with biomodifiers
360.1
34.3
34
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
360.1
34.3
34
*
WZC00
NOMESCO Finland
Treatment plan or consultation
3.2
34.1
197
835
L01XX52
ATC
venetoclax; oral
+∞
33.7
32
*
J02AC04
ATC
posaconazole; systemic
+∞
33.7
32
*
WW306
NOMESCO Finland
Transfer of stem cells from foreign registered donator
+∞
33.7
32
*
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
6.5
33.4
58
99
C92.5
ICD-10 Finland
Acute myelomonocytic leukaemia
+∞
31.6
30
*
C92.1
ICD-10 Finland
Chronic myeloid leukaemia [CML], BCR/ABL-positive
+∞
30.5
29
*
C95.9
ICD-10 Finland
Leukaemia, unspecified
+∞
30.5
29
*
Y84.8
ICD-10 Finland
Other medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
34.1
29.5
38
12
C91.0
ICD-10 Finland
Acute lymphoblastic leukaemia [ALL]
+∞
29.5
28
*
C92.4
ICD-10 Finland
Acute promyelocytic leukaemia [PML]
+∞
28.4
27
*
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
6.1
27.5
50
89
A41.5
ICD-10 Finland
Sepsis due to other Gram-negative organisms
6.2
27.3
49
86
NEA10
NOMESCO Finland
Exploration of soft tissue of pelvis, percutaneous
79.7
27.1
30
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
4.7
26.7
67
159
212
Kela drug reimbursment
Gout
7.8
26.6
38
52
D47.1
ICD-10 Finland
Chronic myeloproliferative disease
+∞
26.3
25
*
115
Kela drug reimbursment
Breast cancer
+∞
26.3
25
*
WW302
NOMESCO Finland
Allogenic transfer of stem cells from relative
+∞
26.3
25
*
J05AB01
ATC
aciclovir; systemic
3.0
26.2
149
613
H02AB09
ATC
hydrocortisone; systemic
8.9
25.1
32
38
GD1AD
NOMESCO Finland
Thorax CT examination
4.9
25.0
58
129
TPH30
NOMESCO Finland
Insertion of central venous catheter through periferal vein
10.5
24.9
28
28
D45
ICD-10 Finland
Polycythaemia vera
262.3
24.9
25
*
WW409
NOMESCO Finland
Other aferesis
+∞
23.1
22
*
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
23.1
22
*
D47.3
ICD-10 Finland
Essential (haemorrhagic) thrombocythaemia
+∞
23.1
22
*
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
4.3
22.9
64
165
D70.82
ICD-10 Finland
Drug-induced neutropenia
87.5
22.9
25
*
TPH00
NOMESCO Finland
Phlebotomy
125.7
22.8
24
*
2050A
ICD-9 Finland
Myeloid leukaemia, Acute
+∞
22.0
21
*
C92.9
ICD-10 Finland
Myeloid leukaemia, unspecified
+∞
22.0
21
*
9989/3-C42.1
ICD-O-3
Myelodysplastic syndrome, NOS, of bone marrow
+∞
22.0
21
*
9873/3-C42.1
ICD-O-3
Acute myeloid leukemia without maturation of bone marrow
+∞
22.0
21
*
D72.8
ICD-10 Finland
Other specified disorders of white blood cells
35.5
21.3
27
8
JN6AD
NOMESCO Finland
CT of torso and neck
29.5
21.2
28
10
116
Kela drug reimbursment
Prostate cancer
+∞
21.0
20
*
EP1AE
NOMESCO Finland
Neck ultrasound examination
5.4
20.6
42
83
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
50.2
20.3
24
5
D64.8
ICD-10 Finland
Other specified anaemias
8.8
20.3
26
31
QX2XE
NOMESCO Finland
Ultrsound examination of soft tissue not elsewhere classified
7.1
20.2
31
46
A41.1
ICD-10 Finland
Sepsis due to other specified staphylococcus
21.9
20.2
29
14
9961/3-C42.1
ICD-O-3
Primary myelofibrosis of bone marrow
+∞
19.9
19
*
9920/3-C42.1
ICD-O-3
Therapy-related myeloid neoplasm of bone marrow
+∞
19.9
19
*
9895/3-C42.1
ICD-O-3
Acute myeloid leukemia with myelodysplasia-related changes of bone marrow
+∞
19.9
19
*
WD515
NOMESCO Finland
Demanding therapy of malignancy with enzyme inhibitors and similar treatments
+∞
19.9
19
*
A41.8
ICD-10 Finland
Other specified sepsis
8.1
19.7
27
35
C90.0
ICD-10 Finland
Multiple myeloma
207.7
19.7
20
*
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
3.8
18.9
62
179
9950/3-C42.1
ICD-O-3
Polycythemia vera of bone marrow
+∞
18.9
18
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
72.7
18.8
21
*
J02AC01
ATC
fluconazole; systemic
2.4
18.8
200
1094
WF002
NOMESCO Finland
Radical radiotherapy
103.9
18.7
20
*
ZX121
NOMESCO Finland
Central venous catheter
197.0
18.7
19
*
L02AE02
ATC
leuprorelin; implant, parenteral
69.2
17.8
20
*
Z51.1
ICD-10 Finland
Chemotherapy session for neoplasm
+∞
17.8
17
*
8500/3-C50.9
ICD-O-3
Infiltrating duct carcinoma, NOS, of breast, NOS
+∞
17.8
17
*
8090/3-C44.3
ICD-O-3
Basal cell carcinoma, NOS, of skin of other and unspecified parts of face
+∞
17.8
17
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
186.2
17.6
18
*
UGC12
NOMESCO Finland
Flexible bronchoscopy
3.7
17.6
59
173
L04AD02
ATC
tacrolimus; systemic
30.0
17.6
23
8
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.3
17.5
199
1113
A04.7
ICD-10 Finland
Enterocolitis due to Clostridium difficile
5.5
17.3
34
65
PH1AE
NOMESCO Finland
Ultrasound examination of upper extremity veins
14.7
17.0
28
20
JN3AD
NOMESCO Finland
Abdominal CT examination
3.1
16.9
81
297
ZX090
NOMESCO Finland
Other technic of radiotherapy
65.6
16.8
19
*
WD305
NOMESCO Finland
Simple therapy of methastized malignancy with biomodifiers
+∞
16.8
16
*
PJD52
NOMESCO Finland
Block dissection of axillary lymph nodes
+∞
16.8
16
*
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
+∞
16.8
16
*
9874/3-C42.1
ICD-O-3
Acute myeloid leukemia with maturation of bone marrow
+∞
16.8
16
*
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
3.0
16.6
82
306
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.2
16.5
198
1125
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
6.1
16.4
29
50
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
5.5
16.3
32
61
B02AA02
ATC
tranexamic acid; systemic
3.0
15.7
79
297
C93.0
ICD-10 Finland
Acute monoblastic/monocytic leukaemia
+∞
15.7
15
*
1DB06, ,
NOMESCO Finland
+∞
15.7
15
*
HAC20
NOMESCO Finland
Total mastectomy
+∞
15.7
15
*
9983/3-C42.1
ICD-O-3
Myelodysplastic syndrome with excess blasts of bone marrow
+∞
15.7
15
*
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
2.3
15.6
167
902
WD505
NOMESCO Finland
Simple enzyme inhibitor or similar therapy of methastized malignancy
164.9
15.6
16
*
TPH04
NOMESCO Finland
Cathetrisation of vein
2.4
15.2
134
665
QAE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in head or neck
4.9
15.2
34
73
SPAT1088
SPAT
Blood transfusion
32.8
14.9
19
6
B25.8
ICD-10 Finland
Other cytomegaloviral diseases
58.5
14.9
17
*
J05AX18
ATC
letermovir; oral
+∞
14.7
14
*
130
Kela drug reimbursment
Malignant tumour
+∞
14.7
14
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
14.7
14
*
C44.51
ICD-10 Finland
Basocellular carcinoma of the skin on the torso
154.2
14.5
15
*
XX3DW
NOMESCO Finland
Time consuming IT work
4.4
14.4
37
89
HA1AA
NOMESCO Finland
X-ray mammography
5.3
13.8
28
55
L03AB05
ATC
interferon alfa-2b; parenteral
+∞
13.6
13
*
A04AA55
ATC
palonosetron, combinations; systemic
+∞
13.6
13
*
9867/3-C42.1
ICD-O-3
Acute myelomonocytic leukemia, NOS, of bone marrow
+∞
13.6
13
*
D75.9
ICD-10 Finland
Disease of blood and blood-forming organs, unspecified
35.1
13.6
17
5
L04AA01
ATC
[U] ciclosporin
16.8
13.6
21
13
TAB00
NOMESCO Finland
Lumbar puncture
4.2
13.4
37
94
HA1AE
NOMESCO Finland
Ultrasound examination of mammary glands
6.5
13.4
22
35
L02BG04
ATC
letrozole; oral
29.2
13.0
17
6
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
3.2
12.7
53
178
WW304
NOMESCO Finland
Transfer of stem cells from registered domestic donator
+∞
12.5
12
*
1BC07, ,
NOMESCO Finland
+∞
12.5
12
*
J02AC05
ATC
isavuconazole; systemic
+∞
12.5
12
*
9866/3-C42.1
ICD-O-3
Acute promyelocytic leukemia, t(15;17)(q22;q11-12) of bone marrow
+∞
12.5
12
*
A79
ICPC
Malignancy NOS
+∞
12.5
12
*
C83.31
ICD-10 Finland
Diffuse lymphoma with large B cells
+∞
12.5
12
*
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
12.5
12
*
306
Kela drug reimbursment
Erythropoietin and darbepoetin
133.2
12.5
13
*
L02BA01
ATC
tamoxifen; oral
133.2
12.5
13
*
Y77
ICPC
Malignant neoplasm prostate
133.2
12.5
13
*
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
2.8
12.2
67
263
H02AB06
ATC
prednisolone; systemic
1.9
12.1
255
1734
JN4CD
NOMESCO Finland
Very extensive body CT
10.0
11.9
23
24
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
2.5
11.6
80
352
C92.3
ICD-10 Finland
Myeloid sarcoma
+∞
11.5
11
*
9962/3-C42.1
ICD-O-3
Essential thrombocythemia of bone marrow
+∞
11.5
11
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
11.5
11
*
2AX04, ,
NOMESCO Finland
+∞
11.5
11
*
TNE20
NOMESCO Finland
Bone marrow aspiration, pelvis
122.7
11.5
12
*
EB1CI
NOMESCO Finland
Cone beam imaging of teeth and jaws (3-4 quarters)
17.5
11.3
17
10
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
1.9
10.8
206
1340
XG470
NOMESCO Finland
Measurement of diffusion capastity of the lungs
4.7
10.8
25
55
B03XA01
ATC
erythropoietin; parenteral
18.3
10.8
16
9
B01AB05
ATC
enoxaparin; parenteral
2.0
10.7
162
976
B25.9
ICD-10 Finland
Cytomegaloviral disease, unspecified
61.3
10.7
12
*
C91.1
ICD-10 Finland
Chronic lymphocytic leukaemia of B-cell type
61.3
10.7
12
*
ZXD05
NOMESCO Finland
Urgent procedure
2.0
10.6
159
954
A40.8
ICD-10 Finland
Other streptococcal sepsis
10.4
10.6
20
20
PJ2AE
NOMESCO Finland
Lymphnode ultrasound examination
112.2
10.5
11
*
1DB07, ,
NOMESCO Finland
+∞
10.4
10
*
XW4XT
NOMESCO Finland
Biopsy of other inner organ with radiological guidance guidance
+∞
10.4
10
*
PJA12
NOMESCO Finland
Sentinel node biopsy
+∞
10.4
10
*
L02BB03
ATC
bicalutamide; oral
+∞
10.4
10
*
Z85.6
ICD-10 Finland
Personal history of leukaemia
+∞
10.4
10
*
XZZ00
NOMESCO Finland
Active surveillance of a diagnosed cancer
+∞
10.4
10
*
GD1CT
NOMESCO Finland
Biopsy of the lung with CT guidance
23.9
10.3
14
6
A02BC02
ATC
pantoprazole; systemic
1.9
10.1
338
2608
D75.2
ICD-10 Finland
Essential thrombocytosis
40.9
10.0
12
*
NK6AN
NOMESCO Finland
Total body bone isotope imaging
40.9
10.0
12
*
J01MA02
ATC
ciprofloxacin; systemic
1.8
10.0
212
1420
H02AB04
ATC
methylprednisolone; systemic
2.2
9.9
90
446
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
5.1
9.9
21
43
WPA10
NOMESCO Finland
Proactive palliative care treatment plan
26.6
9.9
13
5
D46.3
ICD-10 Finland
Refractory anemia with excess of blasts with transformation
56.1
9.7
11
*
N05BA06
ATC
lorazepam; systemic, sublingual
3.0
9.6
43
151
D11AH01
ATC
tacrolimus; topical
15.4
9.6
15
10
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
101.9
9.4
10
*
WVA30
NOMESCO Finland
Intramuscular and subcutaneous injection
30.7
9.4
12
*
A49.8
ICD-10 Finland
Other bacterial infections of unspecified site
12.7
9.4
16
13
8090/3-C44.5
ICD-O-3
Basal cell carcinoma, NOS, of skin of trunk
+∞
9.4
9
*
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
+∞
9.4
9
*
C85.9
ICD-10 Finland
Non-Hodgkin lymphoma, unspecified
+∞
9.4
9
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
9.4
9
*
D46.0
ICD-10 Finland
Refractory anaemia without ring sideroblasts, so stated
+∞
9.4
9
*
C50.41
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
+∞
9.4
9
*
174
Kela drug reimbursment
Ruxolitinib
+∞
9.4
9
*
C50.99
ICD-10 Finland
Breast, unspecified
+∞
9.4
9
*
SPAT1074
SPAT
Venesection
37.4
9.0
11
*
J01CR02
ATC
amoxicillin and beta-lactamase inhibitor; systemic
1.8
9.0
249
1790
JN3BD
NOMESCO Finland
Extensive abdominal CT
2.6
9.0
53
216
D72.9
ICD-10 Finland
Disorder of white blood cells, unspecified
50.9
8.7
10
*
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
50.9
8.7
10
*
ZXE00
NOMESCO Finland
One hour or less
1.8
8.6
187
1248
EB1BI
NOMESCO Finland
Cone beam imaging of teeth and jaws (1–2 quarters)
10.3
8.6
16
16
9872/3-C42.1
ICD-O-3
Acute myeloid leukemia, minimal differentiation of bone marrow
+∞
8.4
8
*
C44.32
ICD-10 Finland
Spinocellular carcinoma of the skin on another or unspecified part of the face
+∞
8.4
8
*
YG1AD
NOMESCO Finland
CT examination of thorax for dose design of radiotherapy
+∞
8.4
8
*
374
Kela drug reimbursment
Ruxolitinib
+∞
8.4
8
*
B74
ICPC
Malignant neoplasm blood other
+∞
8.4
8
*
128
Kela drug reimbursment
Cancers of female genital organs
+∞
8.4
8
*
HA003
NOMESCO Finland
Radiotherapy after partial ablation of mammary gland
+∞
8.4
8
*
A04AD12
ATC
aprepitant; systemic
+∞
8.4
8
*
A07AA09
ATC
vancomycin; oral
9.7
8.3
16
17
R4110
NOMESCO Finland
Physiotherapy
1.9
8.1
135
828
WW200, ,
SPAT
0.4
8.0
54
1095
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
2.8
7.9
40
150
GA4YT
NOMESCO Finland
Puncture of pleura with ultrasound guidance
3.8
7.7
23
62
B99
ICD-10 Finland
Other and unspecified infectious diseases
4.6
7.7
18
40
JN5DR
NOMESCO Finland
PET-CT of upper body metabolism
18.7
7.6
11
6
QBA25
NOMESCO Finland
Destruction of lesion of skin of trunk
18.7
7.6
11
6
5BA08, ,
NOMESCO Finland
18.7
7.6
11
6
D48.5
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Skin
3.1
7.6
31
103
J17.3*B59
ICD-10 Finland
Pneumonia due to Pneumocystis carinii
25.4
7.6
10
*
R72
ICD-10 Finland
Abnormality of white blood cells, not elsewhere classified
25.4
7.6
10
*
A07AA02
ATC
nystatin; oral
2.8
7.5
38
143
JN6DR
NOMESCO Finland
PET-CT of whole body metabolism
13.6
7.4
12
9
C50.11
ICD-10 Finland
Malignant tumor of the central part of the mammary gland,ductal tumor
+∞
7.3
7
*
HA013
NOMESCO Finland
Radiotherapy after total ablation of mammary gland
+∞
7.3
7
*
D89.89
ICD-10 Finland
Other specified disorders involving the immune mechanism, not elsewhere classified
+∞
7.3
7
*
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
+∞
7.3
7
*
9945/3-C42.1
ICD-O-3
Chronic myelomonocytic leukemia, NOS, of bone marrow
+∞
7.3
7
*
166
Kela drug reimbursment
Dalteparin and tinzaparin (treatment for more than 6 months)
+∞
7.3
7
*
20500
ICD-8 Finland
Myeloid leukaemia, Acute
+∞
7.3
7
*
N05AX08
ATC
risperidone; systemic
0.2
7.3
8
362
WD415
NOMESCO Finland
Demanding antibody therapy of methastized malignancy
30.5
7.2
9
*
A98
ICPC
Health maint/preventive medicine
0.6
6.9
363
4134
Z3231
NOMESCO Finland
Registered nurse
1.8
6.9
131
833
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
4.2
6.9
18
44
Z76.0
ICD-10 Finland
Issue of repeat prescription
0.4
6.9
40
864
JN1CG
NOMESCO Finland
Extensive MRI examination of upper part of abdomen with high intensity magnet
6.2
6.8
17
28
D61.9
ICD-10 Finland
Aplastic anaemia, unspecified
40.6
6.8
8
*
M87.1
ICD-10 Finland
Osteonecrosis due to drugs
40.6
6.8
8
*
TPX15
NOMESCO Finland
Removal of vascular injection port
40.6
6.8
8
*
ED1AA
NOMESCO Finland
Mandibular X-ray examination
40.6
6.8
8
*
WVA20
NOMESCO Finland
Medicine administration
4.0
6.8
19
49
ZXM00
NOMESCO Finland
Intraoperative use of ultrasonographic imaging
17.0
6.8
10
6
G30.1
ICD-10 Finland
Alzheimer disease with late onset
0.2
6.7
7
327
JN3CD
NOMESCO Finland
Abdominal CT examination both without and with contrast
4.1
6.7
18
45
GCA98
NOMESCO Finland
Other bronchoscopic procedure on bronchus
10.2
6.6
12
12
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
2.8
6.5
33
124
G03BA03
ATC
testosterone; systemic, rectal, sublingual, transdermal
2.4
6.5
43
185
ZX070
NOMESCO Finland
Intensity modified radiotherapy
70.7
6.4
7
*
L02BG06
ATC
exemestane; oral
70.7
6.4
7
*
WZC30
NOMESCO Finland
Teaching
2.1
6.4
64
328
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
1.7
6.4
147
983
ZX100
NOMESCO Finland
Oral
6.7
6.4
15
23
J01FF01
ATC
clindamycin; systemic
1.7
6.3
133
869
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
2.9
6.3
29
104
C92
ICD-10 Finland
Myeloid leukaemia
+∞
6.3
6
*
C54.11
ICD-10 Finland
Adenocarcinoma of the endometrium
+∞
6.3
6
*
Z08.0
ICD-10 Finland
Follow-up examination after surgery for malignant neoplasm
+∞
6.3
6
*
D61.0
ICD-10 Finland
Constitutional aplastic anaemia
+∞
6.3
6
*
C64.88
ICD-10 Finland
Other malignant neoplasm of kidney, except renal pelvis
+∞
6.3
6
*
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
+∞
6.3
6
*
ZX080
NOMESCO Finland
Image guided radiotherapy
+∞
6.3
6
*
T86.9
ICD-10 Finland
Failure and rejection of unspecified transplanted organ and tissue
+∞
6.3
6
*
WB123
NOMESCO Finland
Demanding adjuvant cytostatic therapy
+∞
6.3
6
*
L03AA14
ATC
lipegfilgrastim; parenteral
+∞
6.3
6
*
6BA02, ,
NOMESCO Finland
+∞
6.3
6
*
YX9BD
NOMESCO Finland
Other extensive CT eamination for dose design of radiotherapy
+∞
6.3
6
*
C92.2
ICD-10 Finland
Atypical chronic myeloid leukaemia, BCR/ABL- negative
+∞
6.3
6
*
E89.4
ICD-10 Finland
Postprocedural ovarian failure
+∞
6.3
6
*
WB121
NOMESCO Finland
Demanding neoadjuvant cytostatic therapy
+∞
6.3
6
*
C50.90
ICD-10 Finland
Malignant tumor in other or unspecified location in mammary gland without histology
+∞
6.3
6
*
C92.7
ICD-10 Finland
Other myeloid leukaemia
+∞
6.3
6
*
D46.1
ICD-10 Finland
Refractory anaemia with ring sideroblasts
+∞
6.3
6
*
C44.61
ICD-10 Finland
Basocellular carcinoma of the skin of the upper extremity including the shoulder
+∞
6.3
6
*
L03AB04
ATC
interferon alfa-2a; parenteral
+∞
6.3
6
*
A02BC01
ATC
omeprazole; systemic
1.7
6.3
142
946
JN6BD
NOMESCO Finland
Extensive CT of torso and neck
27.0
6.2
8
*
HA1AT
NOMESCO Finland
Biopsy of mammary glands with ultrasound guidance
27.0
6.2
8
*
N05CF01
ATC
zopiclone; oral
1.6
6.2
171
1198
D07AB08
ATC
desonide; topical
2.1
6.2
58
290
ZY020
NOMESCO Finland
Telephone, letter or other consultation without direct patient contact
2.5
6.1
38
159
TimeCodeWAS
↥TODO / Current known limitations:
- Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
- Legend / how to read the glyphs.
- Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
- Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
- Download CSV.
- No filters and sorters.
- Limited amount of endpoints (~400) having TimeCodeWAS data.
- Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Hematology
82 [38004501]
82 [38004501]
2.6e+00
3.9e+00
5.2e+00
—
—
7.7e+00
6.4e+00
cases:6.81%
controls:0.56%
cases:11.98%
controls:0.26%
cases:15.77%
controls:0.10%
—
—
—
—
cases:79.22%
controls:0.16%
cases:80.66%
controls:0.71%
34
28
465
4933
60
13
441
4958
79
5
422
4966
—
—
286
8
75
4884
171
29
41
4064
Myelocytes/Leukocytes in Blood
26498-6 [3017181]
26498-6 [3017181]
1.3e+00
1.8e+00
4.2e+00
1.0e+50
5.4e+00
3.4e+00
2.1e+00
cases:3.41%
controls:0.95%
cases:5.79%
controls:1.01%
cases:10.58%
controls:0.18%
cases:13.57%
controls:0.00%
cases:18.38%
controls:0.10%
cases:23.27%
controls:1.00%
cases:19.81%
controls:2.98%
17
47
482
4914
29
50
472
4921
53
9
448
4962
68
0
433
4971
86
5
382
4964
84
49
277
4843
42
122
170
3971
Metamyelocytes/Leukocytes in Blood
28541-1 [3002179]
28541-1 [3002179]
1.3e+00
1.8e+00
4.2e+00
1.0e+50
5.3e+00
3.4e+00
2.0e+00
cases:3.01%
controls:0.83%
cases:5.19%
controls:0.91%
cases:9.58%
controls:0.16%
cases:12.97%
controls:0.00%
cases:16.67%
controls:0.10%
cases:22.99%
controls:0.94%
cases:17.45%
controls:2.71%
15
41
484
4920
26
45
475
4926
48
8
453
4963
65
0
436
4971
78
5
390
4964
83
46
278
4846
37
111
175
3982
Blasts/Leukocytes in Blood
26446-5 [3025159]
26446-5 [3025159]
1.2e+00
1.7e+00
4.2e+00
1.0e+50
5.3e+00
3.3e+00
1.9e+00
cases:2.61%
controls:0.77%
cases:4.39%
controls:0.87%
cases:9.58%
controls:0.16%
cases:12.57%
controls:0.00%
cases:17.31%
controls:0.10%
cases:21.61%
controls:0.96%
cases:16.98%
controls:2.91%
13
38
486
4923
22
43
479
4928
48
8
453
4963
63
0
438
4971
81
5
387
4964
78
47
283
4845
36
119
176
3974
Promyelocytes/Leukocytes in Blood
26524-9 [3021440]
26524-9 [3021440]
1.2e+00
1.8e+00
3.9e+00
1.0e+50
5.1e+00
3.1e+00
1.8e+00
cases:3.01%
controls:0.89%
cases:5.39%
controls:0.97%
cases:8.18%
controls:0.18%
cases:10.18%
controls:0.00%
cases:14.10%
controls:0.10%
cases:18.01%
controls:0.98%
cases:15.09%
controls:2.86%
15
44
484
4917
27
48
474
4923
41
9
460
4962
51
0
450
4971
66
5
402
4964
65
48
296
4844
32
117
180
3976
Reticulocytes/Erythrocytes in Blood
4679-7 [3027945]
4679-7 [3027945]
8.5e-01
1.9e+00
—
1.0e+50
6.0e+00
3.8e+00
2.4e+00
cases:5.01%
controls:2.20%
cases:6.59%
controls:1.05%
—
—
cases:13.77%
controls:0.00%
cases:28.42%
controls:0.10%
cases:31.30%
controls:1.02%
cases:27.36%
controls:3.40%
25
109
474
4852
33
52
468
4919
—
69
0
432
4971
133
5
335
4964
113
50
248
4842
58
139
154
3954
Differential panel, method unspecified - Blood
69738-3 [42870588]
69738-3 [42870588]
6.8e-01
1.3e+00
3.3e+00
—
4.3e+00
2.7e+00
2.0e+00
cases:12.02%
controls:6.47%
cases:13.97%
controls:4.24%
cases:16.97%
controls:0.74%
—
—
cases:32.48%
controls:0.64%
cases:38.78%
controls:4.09%
cases:41.51%
controls:8.72%
60
321
439
4640
70
211
431
4760
85
37
416
4934
—
152
32
316
4937
140
200
221
4692
88
357
124
3736
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
77397-8 [46236098]
6.5e-01
1.1e+00
3.0e+00
1.0e+50
5.2e+00
3.1e+00
1.2e+00
cases:7.21%
controls:3.91%
cases:3.79%
controls:1.33%
cases:2.99%
controls:0.16%
cases:8.78%
controls:0.00%
cases:18.38%
controls:0.12%
cases:24.38%
controls:1.47%
cases:14.15%
controls:4.59%
36
194
463
4767
19
66
482
4905
15
8
486
4963
44
0
457
4971
86
6
382
4963
88
72
273
4820
30
188
182
3905
Urate [Moles/volume] in Serum or Plasma
14933-6 [3026493]
14933-6 [3026493]
4.3e-01
7.6e-01
3.1e+00
—
5.3e+00
3.0e+00
1.5e+00
cases:8.02%
controls:5.34%
cases:4.99%
controls:2.39%
cases:7.78%
controls:0.38%
—
—
cases:30.56%
controls:0.22%
cases:34.63%
controls:2.66%
cases:26.42%
controls:7.43%
40
265
459
4696
25
119
476
4852
39
19
462
4952
—
143
11
325
4958
125
130
236
4762
56
304
156
3789
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
34487-9 [3044938]
4.4e-01
4.3e-01
3.7e+00
1.0e+50
5.0e+00
3.3e+00
1.6e+00
cases:3.41%
controls:2.22%
cases:2.00%
controls:1.31%
cases:3.99%
controls:0.10%
cases:7.39%
controls:0.00%
cases:14.96%
controls:0.12%
cases:28.25%
controls:1.47%
cases:22.64%
controls:5.72%
17
110
482
4851
10
65
491
4906
20
5
481
4966
37
0
464
4971
70
6
398
4963
102
72
259
4820
48
234
164
3859
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
14631-6 [3006140]
6.8e-01
1.0e+00
3.4e+00
—
4.2e+00
2.6e+00
1.6e+00
cases:17.43%
controls:9.64%
cases:14.17%
controls:5.51%
cases:15.97%
controls:0.64%
—
—
cases:33.76%
controls:0.72%
cases:43.21%
controls:5.56%
cases:43.87%
controls:14.02%
87
478
412
4483
71
274
430
4697
80
32
421
4939
—
158
36
310
4933
156
272
205
4620
93
574
119
3519
Monocytes/Leukocytes in Blood
26485-3 [3019069]
26485-3 [3019069]
6.8e-01
1.3e+00
3.1e+00
—
4.1e+00
2.6e+00
1.7e+00
cases:17.43%
controls:9.66%
cases:19.56%
controls:6.44%
cases:19.36%
controls:1.03%
—
—
cases:35.68%
controls:0.95%
cases:45.98%
controls:5.85%
cases:45.75%
controls:13.54%
87
479
412
4482
98
320
403
4651
97
51
404
4920
—
167
47
301
4922
166
286
195
4606
97
554
115
3539
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
2601-3 [3012095]
4.4e-01
4.8e-01
2.8e+00
1.0e+50
5.1e+00
3.4e+00
2.0e+00
cases:4.21%
controls:2.76%
cases:2.20%
controls:1.37%
cases:2.00%
controls:0.12%
cases:3.19%
controls:0.00%
cases:23.50%
controls:0.18%
cases:26.32%
controls:1.12%
cases:20.28%
controls:3.42%
21
137
478
4824
11
68
490
4903
10
6
491
4965
16
0
485
4971
110
9
358
4960
95
55
266
4837
43
140
169
3953
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
26450-7 [3006504]
6.7e-01
1.3e+00
3.1e+00
—
4.0e+00
2.6e+00
1.7e+00
cases:17.23%
controls:9.61%
cases:19.56%
controls:6.42%
cases:18.76%
controls:1.03%
—
—
cases:33.76%
controls:0.93%
cases:45.71%
controls:5.85%
cases:45.75%
controls:13.58%
86
477
413
4484
98
319
403
4652
94
51
407
4920
—
158
46
310
4923
165
286
196
4606
97
556
115
3537
Basophils/Leukocytes in Blood
30180-4 [3022096]
30180-4 [3022096]
6.5e-01
1.3e+00
3.1e+00
—
4.0e+00
2.6e+00
1.7e+00
cases:16.83%
controls:9.59%
cases:19.56%
controls:6.32%
cases:18.96%
controls:1.03%
—
—
cases:33.33%
controls:0.91%
cases:45.43%
controls:5.85%
cases:45.75%
controls:13.63%
84
476
415
4485
98
314
403
4657
95
51
406
4920
—
156
45
312
4924
164
286
197
4606
97
558
115
3535
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
34531-4 [3044640]
7.8e-01
6.7e-01
2.8e+00
—
5.4e+00
3.2e+00
1.2e+00
cases:11.22%
controls:5.46%
cases:3.99%
controls:2.09%
cases:4.59%
controls:0.30%
—
—
cases:25.43%
controls:0.16%
cases:31.86%
controls:1.84%
cases:18.87%
controls:6.62%
56
271
443
4690
20
104
481
4867
23
15
478
4956
—
119
8
349
4961
115
90
246
4802
40
271
172
3822
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
57782-5 [40760892]
6.8e-01
1.4e+00
3.3e+00
1.0e+50
4.0e+00
2.4e+00
1.5e+00
cases:7.01%
controls:3.67%
cases:9.18%
controls:2.35%
cases:9.98%
controls:0.42%
cases:10.78%
controls:0.00%
cases:14.74%
controls:0.32%
cases:21.05%
controls:2.41%
cases:22.17%
controls:5.99%
35
182
464
4779
46
117
455
4854
50
21
451
4950
54
0
447
4971
69
16
399
4953
76
118
285
4774
47
245
165
3848
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
26478-8 [3002030]
6.3e-01
1.2e+00
3.1e+00
—
4.0e+00
2.6e+00
1.6e+00
cases:17.03%
controls:9.82%
cases:19.76%
controls:6.60%
cases:18.56%
controls:1.07%
—
—
cases:35.26%
controls:0.99%
cases:45.43%
controls:5.95%
cases:46.23%
controls:14.24%
85
487
414
4474
99
328
402
4643
93
53
408
4918
—
165
49
303
4920
164
291
197
4601
98
583
114
3510
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
1988-5 [3020460]
1.5e-01
5.2e-01
2.4e+00
5.7e+00
3.0e+00
1.4e+00
3.9e-01
cases:33.27%
controls:29.99%
cases:28.94%
controls:19.43%
cases:28.54%
controls:3.62%
cases:31.74%
controls:0.16%
cases:41.03%
controls:3.44%
cases:48.75%
controls:19.62%
cases:48.11%
controls:38.60%
166
1488
333
3473
145
966
356
4005
143
180
358
4791
159
8
342
4963
192
171
276
4798
176
960
185
3932
102
1580
110
2513
Oncology Clinic/Center
261QX0200X [38004268]
261QX0200X [38004268]
4.0e+00
—
1.0e+50
1.0e+50
1.0e+50
4.4e+00
4.1e+00
cases:11.62%
controls:0.24%
—
—
cases:2.79%
controls:0.00%
cases:62.48%
controls:0.00%
cases:35.04%
controls:0.00%
cases:9.42%
controls:0.12%
cases:15.57%
controls:0.29%
58
12
441
4949
—
14
0
487
4971
313
0
188
4971
164
0
304
4969
34
6
327
4886
33
12
179
4081
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
751-8 [3013650]
6.7e-01
1.2e+00
2.6e+00
—
3.9e+00
2.5e+00
1.5e+00
cases:19.64%
controls:11.07%
cases:20.36%
controls:7.32%
cases:16.57%
controls:1.39%
—
—
cases:36.11%
controls:1.19%
cases:46.54%
controls:6.89%
cases:46.70%
controls:15.86%
98
549
401
4412
102
364
399
4607
83
69
418
4902
—
169
59
299
4910
168
337
193
4555
99
649
113
3444
Bacteria identified in Blood by Culture
600-7 [3023368]
600-7 [3023368]
4.4e-01
4.9e-01
3.6e+00
1.0e+50
4.6e+00
2.9e+00
1.2e+00
cases:7.21%
controls:4.78%
cases:4.19%
controls:2.62%
cases:8.58%
controls:0.26%
cases:12.97%
controls:0.00%
cases:27.56%
controls:0.38%
cases:34.07%
controls:2.74%
cases:23.58%
controls:8.21%
36
237
463
4724
21
130
480
4841
43
13
458
4958
65
0
436
4971
129
19
339
4950
123
134
238
4758
50
336
162
3757
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
26511-6 [3018010]
6.2e-01
1.2e+00
2.7e+00
—
3.8e+00
2.5e+00
1.6e+00
cases:16.63%
controls:9.70%
cases:17.96%
controls:6.48%
cases:13.57%
controls:1.09%
—
—
cases:29.49%
controls:0.97%
cases:43.77%
controls:5.87%
cases:43.40%
controls:13.93%
83
481
416
4480
90
322
411
4649
68
54
433
4917
—
138
48
330
4921
158
287
203
4605
92
570
120
3523
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
890-4 [3001079]
5.7e-01
3.9e-01
2.8e+00
—
5.0e+00
2.8e+00
1.0e+00
cases:13.83%
controls:8.30%
cases:4.79%
controls:3.30%
cases:6.39%
controls:0.40%
—
—
cases:29.49%
controls:0.28%
cases:34.90%
controls:3.23%
cases:24.53%
controls:10.36%
69
412
430
4549
24
164
477
4807
32
20
469
4951
—
138
14
330
4955
126
158
235
4734
52
424
160
3669
Thorax X-ray examination
GD1AA [2001303617]
GD1AA [2001303617]
4.4e-01
9.6e-01
2.9e+00
1.0e+50
4.1e+00
2.8e+00
1.4e+00
cases:13.63%
controls:9.21%
cases:7.58%
controls:3.06%
cases:7.39%
controls:0.44%
cases:14.37%
controls:0.00%
cases:13.46%
controls:0.26%
cases:37.67%
controls:3.41%
cases:33.02%
controls:11.31%
68
457
431
4504
38
152
463
4819
37
22
464
4949
72
0
429
4971
63
13
405
4956
136
167
225
4725
70
463
142
3630
Eosinophils [#/volume] in Blood
26449-9 [3013115]
26449-9 [3013115]
5.4e-01
1.1e+00
2.6e+00
—
3.7e+00
2.4e+00
1.6e+00
cases:16.63%
controls:10.46%
cases:18.36%
controls:6.68%
cases:13.57%
controls:1.19%
—
—
cases:29.70%
controls:0.99%
cases:43.77%
controls:6.52%
cases:45.75%
controls:15.15%
83
519
416
4442
92
332
409
4639
68
59
433
4912
—
139
49
329
4920
158
319
203
4573
97
620
115
3473
IgA [Mass/volume] in Serum or Plasma
2458-8 [3007164]
2458-8 [3007164]
3.3e-01
9.4e-01
3.5e+00
1.0e+50
4.9e+00
2.1e+00
1.2e+00
cases:4.01%
controls:2.90%
cases:2.99%
controls:1.19%
cases:3.19%
controls:0.10%
cases:2.99%
controls:0.00%
cases:17.31%
controls:0.16%
cases:6.93%
controls:0.92%
cases:10.85%
controls:3.57%
20
144
479
4817
15
59
486
4912
16
5
485
4966
15
0
486
4971
81
8
387
4961
25
45
336
4847
23
146
189
3947
Monocytes [#/volume] in Blood
26484-6 [3001604]
26484-6 [3001604]
5.3e-01
1.1e+00
2.3e+00
—
3.7e+00
2.4e+00
1.6e+00
cases:15.83%
controls:9.98%
cases:17.76%
controls:6.50%
cases:9.58%
controls:1.09%
—
—
cases:25.43%
controls:0.87%
cases:42.38%
controls:6.23%
cases:45.75%
controls:14.83%
79
495
420
4466
89
323
412
4648
48
54
453
4917
—
119
43
349
4926
153
305
208
4587
97
607
115
3486
Basophils [#/volume] in Blood
26444-0 [3006315]
26444-0 [3006315]
5.1e-01
1.1e+00
2.3e+00
—
3.6e+00
2.4e+00
1.6e+00
cases:15.63%
controls:10.04%
cases:17.76%
controls:6.48%
cases:9.58%
controls:1.09%
—
—
cases:25.43%
controls:0.89%
cases:42.66%
controls:6.28%
cases:45.75%
controls:14.90%
78
498
421
4463
89
322
412
4649
48
54
453
4917
—
119
44
349
4925
154
307
207
4585
97
610
115
3483
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
26474-7 [3019198]
4.9e-01
1.2e+00
2.3e+00
—
3.6e+00
2.4e+00
1.5e+00
cases:16.03%
controls:10.46%
cases:18.76%
controls:6.76%
cases:10.38%
controls:1.17%
—
—
cases:25.64%
controls:0.91%
cases:43.21%
controls:6.38%
cases:45.75%
controls:15.27%
80
519
419
4442
94
336
407
4635
52
58
449
4913
—
120
45
348
4924
156
312
205
4580
97
625
115
3468
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
14804-9 [3022250]
1.2e+00
2.4e+00
—
1.0e+50
—
4.6e+00
3.3e+00
cases:5.21%
controls:1.55%
cases:8.78%
controls:0.89%
—
—
cases:16.37%
controls:0.00%
—
—
cases:41.00%
controls:0.72%
cases:39.62%
controls:2.39%
26
77
473
4884
44
44
457
4927
—
82
0
419
4971
—
148
35
213
4857
84
98
128
3995
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
5894-1 [3033658]
2.3e-01
5.0e-01
3.1e+00
—
4.9e+00
2.4e+00
1.1e+00
cases:6.41%
controls:5.18%
cases:3.99%
controls:2.45%
cases:4.39%
controls:0.20%
—
—
cases:19.02%
controls:0.18%
cases:19.11%
controls:2.19%
cases:16.04%
controls:5.89%
32
257
467
4704
20
122
481
4849
22
10
479
4961
—
89
9
379
4960
69
107
292
4785
34
241
178
3852
Internal Medicine
11 [38004456]
11 [38004456]
3.5e-01
8.1e-01
3.0e+00
—
3.2e+00
2.5e+00
1.4e+00
cases:32.06%
controls:24.93%
cases:20.76%
controls:10.44%
cases:23.75%
controls:1.59%
—
—
cases:29.27%
controls:1.65%
cases:56.79%
controls:9.46%
cases:54.72%
controls:22.38%
160
1237
339
3724
104
519
397
4452
119
79
382
4892
—
137
82
331
4887
205
463
156
4429
116
916
96
3177
Outpatient Visit
OP [9202]
OP [9202]
2.2e-01
3.5e-01
1.3e+00
3.8e+00
1.6e+00
2.3e+00
1.6e+00
cases:76.55%
controls:72.30%
cases:59.48%
controls:50.90%
cases:31.14%
controls:10.98%
cases:14.97%
controls:0.38%
cases:35.68%
controls:10.14%
cases:91.14%
controls:51.80%
cases:94.34%
controls:77.11%
382
3587
117
1374
298
2530
203
2441
156
546
345
4425
75
19
426
4952
167
504
301
4465
329
2534
32
2358
200
3156
12
937
Intravenous
ZX120 [2001311495]
ZX120 [2001311495]
1.4e+00
2.0e+00
—
1.0e+50
—
4.2e+00
3.2e+00
cases:3.01%
controls:0.79%
cases:1.60%
controls:0.22%
—
—
cases:2.79%
controls:0.00%
—
—
cases:15.24%
controls:0.27%
cases:14.15%
controls:0.64%
15
39
484
4922
8
11
493
4960
—
14
0
487
4971
—
55
13
306
4879
30
26
182
4067
Anaemia, unspecified
D64.9 [45600610]
D64.9 [45600610]
1.8e+00
2.3e+00
4.7e+00
1.0e+50
—
2.1e+00
7.1e-01
cases:7.01%
controls:1.29%
cases:7.98%
controls:0.84%
cases:9.58%
controls:0.10%
cases:6.79%
controls:0.00%
—
—
cases:4.99%
controls:0.65%
cases:4.72%
controls:2.37%
35
64
464
4897
40
42
461
4929
48
5
453
4966
34
0
467
4971
—
18
32
343
4860
10
97
202
3996
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
24357-6 [3037467]
1.5e-01
2.0e-01
1.7e+00
4.4e+00
3.3e+00
1.5e+00
3.5e-01
cases:20.24%
controls:17.90%
cases:11.18%
controls:9.35%
cases:7.39%
controls:1.49%
cases:7.39%
controls:0.10%
cases:22.44%
controls:1.07%
cases:29.64%
controls:8.83%
cases:29.25%
controls:22.50%
101
888
398
4073
56
465
445
4506
37
74
464
4897
37
5
464
4966
105
53
363
4916
107
432
254
4460
62
921
150
3172
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
1742-6 [3006923]
3.6e-02
2.6e-01
2.0e+00
4.9e+00
2.7e+00
8.2e-01
1.9e-03
cases:36.47%
controls:35.64%
cases:32.14%
controls:26.71%
cases:24.55%
controls:4.06%
cases:22.55%
controls:0.22%
cases:38.46%
controls:4.21%
cases:47.37%
controls:28.29%
cases:47.64%
controls:47.59%
182
1768
317
3193
161
1328
340
3643
123
202
378
4769
113
11
388
4960
180
209
288
4760
171
1384
190
3508
101
1948
111
2145
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
6768-6 [3035995]
4.5e-01
7.9e-01
2.7e+00
—
3.6e+00
1.9e+00
9.7e-01
cases:26.85%
controls:18.97%
cases:22.55%
controls:11.63%
cases:21.16%
controls:1.73%
—
—
cases:37.18%
controls:1.63%
cases:45.71%
controls:11.65%
cases:46.70%
controls:24.85%
134
941
365
4020
113
578
388
4393
106
86
395
4885
—
174
81
294
4888
165
570
196
4322
99
1017
113
3076
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
19072-8 [3016431]
3.1e-01
6.3e-01
2.5e+00
—
4.0e+00
2.2e+00
1.1e+00
cases:14.23%
controls:10.82%
cases:11.18%
controls:6.28%
cases:9.38%
controls:0.87%
—
—
cases:31.84%
controls:0.89%
cases:38.78%
controls:6.38%
cases:35.85%
controls:16.20%
71
537
428
4424
56
312
445
4659
47
43
454
4928
—
149
44
319
4925
140
312
221
4580
76
663
136
3430
Medical doctor
Z2221 [2001311556]
Z2221 [2001311556]
3.2e-01
4.7e-01
2.3e+00
1.0e+50
2.9e+00
2.7e+00
2.3e+00
cases:5.01%
controls:3.69%
cases:1.80%
controls:1.13%
cases:1.20%
controls:0.12%
cases:2.40%
controls:0.00%
cases:2.14%
controls:0.12%
cases:11.63%
controls:0.86%
cases:17.92%
controls:2.17%
25
183
474
4778
9
56
492
4915
6
6
495
4965
12
0
489
4971
10
6
458
4963
42
42
319
4850
38
89
174
4004
Short blood count panel - Blood
55429-5 [40758558]
55429-5 [40758558]
6.0e-01
8.9e-01
2.5e+00
—
3.5e+00
1.9e+00
8.2e-01
cases:8.42%
controls:4.80%
cases:5.39%
controls:2.29%
cases:4.79%
controls:0.42%
—
—
cases:7.69%
controls:0.24%
cases:13.02%
controls:2.25%
cases:14.62%
controls:6.99%
42
238
457
4723
27
114
474
4857
24
21
477
4950
—
36
12
432
4957
47
110
314
4782
31
286
181
3807
Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma
48065-7 [3051714]
48065-7 [3051714]
5.0e-01
6.9e-01
2.3e+00
1.0e+50
5.6e+00
2.2e+00
7.4e-01
cases:6.01%
controls:3.75%
cases:3.59%
controls:1.83%
cases:2.79%
controls:0.28%
cases:9.38%
controls:0.00%
cases:25.43%
controls:0.12%
cases:11.91%
controls:1.47%
cases:9.91%
controls:4.98%
30
186
469
4775
18
91
483
4880
14
14
487
4957
47
0
454
4971
119
6
349
4963
43
72
318
4820
21
204
191
3889
Protein [Mass/volume] in Serum or Plasma
2885-2 [3020630]
2885-2 [3020630]
4.8e-01
1.7e+00
—
1.0e+50
4.7e+00
2.4e+00
1.4e+00
cases:2.20%
controls:1.37%
cases:3.79%
controls:0.72%
—
—
cases:3.99%
controls:0.00%
cases:11.32%
controls:0.12%
cases:7.76%
controls:0.74%
cases:7.55%
controls:2.03%
11
68
488
4893
19
36
482
4935
—
20
0
481
4971
53
6
415
4963
28
36
333
4856
16
83
196
4010
Office Visit
OMOP4822458 [581477]
OMOP4822458 [581477]
3.2e-01
6.6e-01
2.1e+00
1.0e+50
3.9e+00
2.6e+00
1.5e+00
cases:11.82%
controls:8.89%
cases:4.99%
controls:2.66%
cases:2.99%
controls:0.38%
cases:1.40%
controls:0.00%
cases:11.97%
controls:0.28%
cases:23.55%
controls:2.19%
cases:25.47%
controls:6.89%
59
441
440
4520
25
132
476
4839
15
19
486
4952
7
0
494
4971
56
14
412
4955
85
107
276
4785
54
282
158
3811
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2951-2 [3019550]
1.2e-02
2.4e-01
1.9e+00
5.0e+00
2.5e+00
7.5e-01
9.3e-02
cases:36.27%
controls:36.00%
cases:32.93%
controls:27.78%
cases:26.55%
controls:5.23%
cases:29.14%
controls:0.28%
cases:40.81%
controls:5.45%
cases:47.92%
controls:30.23%
cases:49.06%
controls:46.74%
181
1786
318
3175
165
1381
336
3590
133
260
368
4711
146
14
355
4957
191
271
277
4698
173
1479
188
3413
104
1913
108
2180
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2823-3 [3023103]
1.2e-02
2.2e-01
1.9e+00
5.0e+00
2.5e+00
7.5e-01
8.4e-02
cases:36.47%
controls:36.20%
cases:32.93%
controls:28.32%
cases:26.75%
controls:5.35%
cases:29.14%
controls:0.28%
cases:41.03%
controls:5.51%
cases:48.20%
controls:30.58%
cases:49.06%
controls:46.96%
182
1796
317
3165
165
1408
336
3563
134
266
367
4705
146
14
355
4957
192
274
276
4695
174
1496
187
3396
104
1922
108
2171
Platelets [#/volume] in Blood
26515-7 [3007461]
26515-7 [3007461]
4.2e-02
2.5e-01
2.0e+00
5.0e+00
2.4e+00
6.2e-01
-4.1e-02
cases:40.68%
controls:39.67%
cases:38.32%
controls:32.67%
cases:34.93%
controls:6.94%
cases:37.33%
controls:0.38%
cases:43.59%
controls:6.68%
cases:49.86%
controls:34.77%
cases:50.94%
controls:51.97%
203
1968
296
2993
192
1624
309
3347
175
345
326
4626
187
19
314
4952
204
332
264
4637
180
1701
181
3191
108
2127
104
1966
Cytomegalovirus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
72493-0 [43055120]
72493-0 [43055120]
—
2.1e+00
—
1.0e+50
1.0e+50
5.6e+00
4.4e+00
—
—
cases:1.00%
controls:0.12%
—
—
cases:1.80%
controls:0.00%
cases:12.61%
controls:0.00%
cases:21.61%
controls:0.10%
cases:18.40%
controls:0.27%
—
5
6
496
4965
—
9
0
492
4971
59
0
409
4969
78
5
283
4887
39
11
173
4082
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
30428-7 [3024731]
4.0e-02
2.4e-01
2.0e+00
5.0e+00
2.4e+00
6.2e-01
-6.2e-02
cases:40.68%
controls:39.73%
cases:38.32%
controls:32.73%
cases:34.93%
controls:7.00%
cases:37.33%
controls:0.38%
cases:43.59%
controls:6.74%
cases:49.86%
controls:34.79%
cases:50.47%
controls:52.02%
203
1971
296
2990
192
1627
309
3344
175
348
326
4623
187
19
314
4952
204
335
264
4634
180
1702
181
3190
107
2129
105
1964
MCH [Entitic mass]
28539-5 [3035941]
28539-5 [3035941]
3.8e-02
2.4e-01
2.0e+00
5.0e+00
2.4e+00
6.2e-01
-6.2e-02
cases:40.68%
controls:39.77%
cases:38.32%
controls:32.75%
cases:34.93%
controls:7.02%
cases:37.33%
controls:0.38%
cases:43.59%
controls:6.74%
cases:49.86%
controls:34.81%
cases:50.47%
controls:52.02%
203
1973
296
2988
192
1628
309
3343
175
349
326
4622
187
19
314
4952
204
335
264
4634
180
1703
181
3189
107
2129
105
1964
Outpatient Hospital
22 [8756]
22 [8756]
3.3e-01
5.8e-01
2.0e+00
—
3.8e+00
2.6e+00
1.0e+00
cases:32.67%
controls:25.94%
cases:11.78%
controls:6.98%
cases:5.99%
controls:0.87%
—
—
cases:20.73%
controls:0.58%
cases:45.71%
controls:5.68%
cases:37.26%
controls:17.93%
163
1287
336
3674
59
347
442
4624
30
43
471
4928
—
97
29
371
4940
165
278
196
4614
79
734
133
3359
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
718-7 [3000963]
4.5e-02
2.4e-01
2.0e+00
5.0e+00
2.4e+00
6.2e-01
-4.4e-02
cases:40.88%
controls:39.81%
cases:38.32%
controls:32.79%
cases:34.93%
controls:7.02%
cases:37.33%
controls:0.38%
cases:43.59%
controls:6.78%
cases:49.86%
controls:34.83%
cases:50.94%
controls:52.04%
204
1975
295
2986
192
1630
309
3341
175
349
326
4622
187
19
314
4952
204
337
264
4632
180
1704
181
3188
108
2130
104
1963
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
26453-1 [3026361]
3.8e-02
2.4e-01
2.0e+00
5.0e+00
2.4e+00
6.2e-01
-4.3e-02
cases:40.68%
controls:39.77%
cases:38.32%
controls:32.75%
cases:34.93%
controls:7.02%
cases:37.33%
controls:0.38%
cases:43.59%
controls:6.78%
cases:49.86%
controls:34.85%
cases:50.94%
controls:52.02%
203
1973
296
2988
192
1628
309
3343
175
349
326
4622
187
19
314
4952
204
337
264
4632
180
1705
181
3187
108
2129
104
1964
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
20570-8 [3009542]
3.8e-02
2.4e-01
2.0e+00
5.0e+00
2.4e+00
6.2e-01
-4.3e-02
cases:40.68%
controls:39.77%
cases:38.32%
controls:32.77%
cases:34.93%
controls:7.06%
cases:37.33%
controls:0.38%
cases:43.59%
controls:6.80%
cases:49.86%
controls:34.83%
cases:50.94%
controls:52.02%
203
1973
296
2988
192
1629
309
3342
175
351
326
4620
187
19
314
4952
204
338
264
4631
180
1704
181
3188
108
2129
104
1964
Leukocytes [#/volume] in Blood
26464-8 [3010813]
26464-8 [3010813]
4.4e-02
2.3e-01
1.9e+00
5.0e+00
2.4e+00
6.2e-01
-4.2e-02
cases:40.88%
controls:39.83%
cases:38.12%
controls:32.83%
cases:34.73%
controls:7.04%
cases:37.33%
controls:0.38%
cases:43.38%
controls:6.78%
cases:49.86%
controls:34.85%
cases:50.94%
controls:51.99%
204
1976
295
2985
191
1632
310
3339
174
350
327
4621
187
19
314
4952
203
337
265
4632
180
1705
181
3187
108
2128
104
1965
Complement+Immunoglobulin [Units/volume] in Red Blood Cells
4533-6 [3024403]
4533-6 [3024403]
1.5e+00
3.1e+00
—
1.0e+50
—
4.4e+00
2.5e+00
cases:1.20%
controls:0.26%
cases:2.59%
controls:0.12%
—
—
cases:3.59%
controls:0.00%
—
—
cases:9.14%
controls:0.12%
cases:5.66%
controls:0.51%
6
13
493
4948
13
6
488
4965
—
18
0
483
4971
—
33
6
328
4886
12
21
200
4072
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
1995-0 [3021347]
2.2e-01
4.5e-01
2.5e+00
—
4.1e+00
2.3e+00
1.1e+00
cases:11.82%
controls:9.70%
cases:8.18%
controls:5.37%
cases:8.38%
controls:0.76%
—
—
cases:27.56%
controls:0.64%
cases:34.90%
controls:5.21%
cases:31.13%
controls:13.34%
59
481
440
4480
41
267
460
4704
42
38
459
4933
—
129
32
339
4937
126
255
235
4637
66
546
146
3547
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
30385-9 [3002385]
9.6e-02
3.3e-01
1.9e+00
4.9e+00
2.4e+00
7.4e-01
9.4e-02
cases:25.85%
controls:24.05%
cases:25.55%
controls:19.84%
cases:23.55%
controls:4.35%
cases:25.15%
controls:0.26%
cases:31.62%
controls:4.13%
cases:36.29%
controls:21.34%
cases:37.26%
controls:35.08%
129
1193
370
3768
128
986
373
3985
118
216
383
4755
126
13
375
4958
148
205
320
4764
131
1044
230
3848
79
1436
133
2657
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
14682-9 [3020564]
-2.5e-02
2.3e-01
1.9e+00
4.9e+00
2.4e+00
6.5e-01
-2.7e-03
cases:37.88%
controls:38.46%
cases:36.33%
controls:31.10%
cases:30.54%
controls:6.16%
cases:31.94%
controls:0.34%
cases:41.88%
controls:6.26%
cases:49.31%
controls:33.67%
cases:49.53%
controls:49.60%
189
1908
310
3053
182
1546
319
3425
153
306
348
4665
160
17
341
4954
196
311
272
4658
178
1647
183
3245
105
2030
107
2063
INR in Blood by Coagulation assay
34714-6 [3032080]
34714-6 [3032080]
3.2e-01
3.3e-01
1.0e+00
5.0e+00
2.2e+00
1.5e+00
4.6e-01
cases:17.23%
controls:13.16%
cases:10.38%
controls:7.68%
cases:7.19%
controls:2.78%
cases:12.77%
controls:0.10%
cases:20.30%
controls:2.62%
cases:26.04%
controls:7.44%
cases:23.11%
controls:15.93%
86
653
413
4308
52
382
449
4589
36
138
465
4833
64
5
437
4966
95
130
373
4839
94
364
267
4528
49
652
163
3441
ursodeoxycholic acid; oral
A05AA02 [21600513]
A05AA02 [21600513]
—
—
—
—
—
5.4e+00
4.3e+00
—
—
—
—
—
—
—
—
—
—
cases:17.73%
controls:0.10%
cases:13.21%
controls:0.20%
—
—
—
—
—
64
5
297
4887
28
8
184
4085
Emergency Room Visit
ER [9203]
ER [9203]
2.3e-01
6.0e-01
2.5e+00
—
3.2e+00
2.2e+00
1.2e+00
cases:40.48%
controls:35.11%
cases:20.56%
controls:12.45%
cases:14.97%
controls:1.43%
—
—
cases:22.22%
controls:1.11%
cases:52.91%
controls:11.37%
cases:59.91%
controls:31.71%
202
1742
297
3219
103
619
398
4352
75
71
426
4900
—
104
55
364
4914
191
556
170
4336
127
1298
85
2795
Reticulocytes [#/volume] in Blood
14196-0 [3023520]
14196-0 [3023520]
1.0e+00
2.1e+00
—
1.0e+50
—
3.9e+00
2.6e+00
cases:4.01%
controls:1.45%
cases:5.39%
controls:0.66%
—
—
cases:12.18%
controls:0.00%
—
—
cases:29.09%
controls:0.82%
cases:24.06%
controls:2.37%
20
72
479
4889
27
33
474
4938
—
61
0
440
4971
—
105
40
256
4852
51
97
161
3996
sulfamethoxazole and trimethoprim
J01EE01 [21602961]
J01EE01 [21602961]
1.3e+00
1.3e+00
—
—
—
5.1e+00
4.4e+00
cases:1.60%
controls:0.42%
cases:1.00%
controls:0.26%
—
—
—
—
—
—
cases:30.75%
controls:0.27%
cases:27.83%
controls:0.46%
8
21
491
4940
5
13
496
4958
—
—
—
111
13
250
4879
59
19
153
4074
Folate [Moles/volume] in Red Blood Cells
14731-4 [3019309]
14731-4 [3019309]
4.8e-01
1.1e+00
3.2e+00
1.0e+50
2.7e+00
1.4e+00
1.0e+00
cases:9.42%
controls:6.05%
cases:5.99%
controls:2.05%
cases:3.39%
controls:0.14%
cases:1.60%
controls:0.00%
cases:2.99%
controls:0.20%
cases:5.26%
controls:1.29%
cases:8.49%
controls:3.30%
47
300
452
4661
30
102
471
4869
17
7
484
4964
8
0
493
4971
14
10
454
4959
19
63
342
4829
18
135
194
3958
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
62238-1 [40764999]
1.7e-01
3.4e-01
1.9e+00
4.8e+00
2.1e+00
7.4e-01
8.6e-02
cases:28.66%
controls:25.38%
cases:27.54%
controls:21.32%
cases:21.16%
controls:4.02%
cases:20.16%
controls:0.20%
cases:26.07%
controls:4.27%
cases:39.61%
controls:23.86%
cases:40.57%
controls:38.50%
143
1259
356
3702
138
1060
363
3911
106
200
395
4771
101
10
400
4961
122
212
346
4757
143
1167
218
3725
86
1576
126
2517
Folate [Moles/volume] in Serum or Plasma
14732-2 [3021960]
14732-2 [3021960]
2.2e-01
1.0e+00
3.4e+00
—
4.0e+00
1.2e+00
2.9e-01
cases:3.21%
controls:2.58%
cases:5.99%
controls:2.29%
cases:6.59%
controls:0.24%
—
—
cases:10.47%
controls:0.22%
cases:9.14%
controls:3.07%
cases:14.62%
controls:11.36%
16
128
483
4833
30
114
471
4857
33
12
468
4959
—
49
11
419
4958
33
150
328
4742
31
465
181
3628
CBC panel - Blood by Automated count
58410-2 [40761511]
58410-2 [40761511]
3.0e-02
2.0e-01
1.8e+00
4.8e+00
2.3e+00
6.1e-01
7.7e-02
cases:34.67%
controls:33.99%
cases:26.15%
controls:22.47%
cases:21.16%
controls:4.33%
cases:19.16%
controls:0.20%
cases:28.63%
controls:3.88%
cases:35.46%
controls:23.06%
cases:41.98%
controls:40.12%
173
1686
326
3275
131
1117
370
3854
106
215
395
4756
96
10
405
4961
134
193
334
4776
128
1128
233
3764
89
1642
123
2451
Fever, unspecified
R50.9 [45582716]
R50.9 [45582716]
1.0e+00
1.9e+00
—
1.0e+50
—
4.3e+00
2.2e+00
cases:3.41%
controls:1.25%
cases:2.59%
controls:0.40%
—
—
cases:1.40%
controls:0.00%
—
—
cases:18.28%
controls:0.31%
cases:16.51%
controls:2.05%
17
62
482
4899
13
20
488
4951
—
7
0
494
4971
—
66
15
295
4877
35
84
177
4009
pH of Serum or Plasma
2753-2 [3018418]
2753-2 [3018418]
1.6e-01
4.9e-01
2.3e+00
—
3.9e+00
2.1e+00
1.1e+00
cases:6.21%
controls:5.36%
cases:5.19%
controls:3.26%
cases:4.99%
controls:0.50%
—
—
cases:18.59%
controls:0.46%
cases:22.99%
controls:3.52%
cases:22.64%
controls:9.11%
31
266
468
4695
26
162
475
4809
25
25
476
4946
—
87
23
381
4946
83
172
278
4720
48
373
164
3720
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
14879-1 [3003458]
4.1e-01
1.1e-01
1.4e+00
1.0e+50
4.4e+00
3.1e+00
1.9e+00
cases:3.61%
controls:2.42%
cases:2.00%
controls:1.79%
cases:1.40%
controls:0.36%
cases:4.39%
controls:0.00%
cases:29.27%
controls:0.52%
cases:29.09%
controls:1.80%
cases:19.81%
controls:3.49%
18
120
481
4841
10
89
491
4882
7
18
494
4953
22
0
479
4971
137
26
331
4943
105
88
256
4804
42
143
170
3950
Body CT examination
JN4AD [2001310897]
JN4AD [2001310897]
2.5e+00
2.0e+00
—
1.0e+50
1.0e+50
3.1e+00
1.8e+00
cases:2.20%
controls:0.18%
cases:2.00%
controls:0.28%
—
—
cases:6.79%
controls:0.00%
cases:4.49%
controls:0.00%
cases:7.76%
controls:0.37%
cases:5.66%
controls:1.03%
11
9
488
4952
10
14
491
4957
—
34
0
467
4971
21
0
447
4969
28
18
333
4874
12
42
200
4051
ciclosporin; oral, parenteral
L04AD01 [21603924]
L04AD01 [21603924]
—
—
—
—
—
4.8e+00
4.5e+00
—
—
—
—
—
—
—
—
—
—
cases:13.57%
controls:0.12%
cases:17.45%
controls:0.24%
—
—
—
—
—
49
6
312
4886
37
10
175
4083
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
1751-7 [3024561]
3.8e-01
5.6e-01
2.2e+00
—
3.8e+00
2.2e+00
1.1e+00
cases:13.03%
controls:9.31%
cases:8.78%
controls:5.19%
cases:6.59%
controls:0.80%
—
—
cases:29.49%
controls:0.95%
cases:34.07%
controls:5.42%
cases:32.55%
controls:13.71%
65
462
434
4499
44
258
457
4713
33
40
468
4931
—
138
47
330
4922
123
265
238
4627
69
561
143
3532
Inpatient Visit
IP [9201]
IP [9201]
6.2e-01
2.6e-01
1.6e+00
—
3.8e+00
2.5e+00
7.1e-01
cases:12.02%
controls:6.87%
cases:4.59%
controls:3.58%
cases:2.20%
controls:0.44%
—
—
cases:13.89%
controls:0.36%
cases:27.70%
controls:3.15%
cases:18.40%
controls:9.97%
60
341
439
4620
23
178
478
4793
11
22
490
4949
—
65
18
403
4951
100
154
261
4738
39
408
173
3685
Cathetrisation of vein
TPH04 [2001309597]
TPH04 [2001309597]
1.6e-01
7.3e-01
2.3e+00
—
3.1e+00
2.4e+00
1.4e+00
cases:4.01%
controls:3.45%
cases:2.40%
controls:1.17%
cases:1.20%
controls:0.12%
—
—
cases:2.99%
controls:0.14%
cases:10.53%
controls:1.06%
cases:10.85%
controls:2.96%
20
171
479
4790
12
58
489
4913
6
6
495
4965
—
14
7
454
4962
38
52
323
4840
23
121
189
3972
Band form neutrophils/Leukocytes in Blood
26508-2 [3004809]
26508-2 [3004809]
2.5e+00
3.1e+00
1.0e+50
1.0e+50
—
—
3.5e+00
cases:2.20%
controls:0.18%
cases:2.20%
controls:0.10%
cases:5.59%
controls:0.00%
cases:6.39%
controls:0.00%
—
—
—
—
cases:7.55%
controls:0.24%
11
9
488
4952
11
5
490
4966
28
0
473
4971
32
0
469
4971
—
—
16
10
196
4083
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
A03FA01 [21600484]
1.5e+00
8.6e-01
—
—
3.0e+00
2.9e+00
1.8e+00
cases:7.41%
controls:1.81%
cases:1.80%
controls:0.76%
—
—
—
—
cases:2.35%
controls:0.12%
cases:10.80%
controls:0.70%
cases:8.96%
controls:1.66%
37
90
462
4871
9
38
492
4933
—
—
11
6
457
4963
39
34
322
4858
19
68
193
4025
Inpatient Hospital
21 [8717]
21 [8717]
3.0e-01
5.8e-01
2.0e+00
—
3.4e+00
2.3e+00
7.0e-01
cases:40.48%
controls:33.52%
cases:18.96%
controls:11.63%
cases:13.17%
controls:1.95%
—
—
cases:33.12%
controls:1.55%
cases:52.08%
controls:10.12%
cases:41.51%
controls:26.04%
202
1663
297
3298
95
578
406
4393
66
97
435
4874
—
155
77
313
4892
188
495
173
4397
88
1066
124
3027
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
28540-3 [3003338]
-3.9e-02
1.2e-01
1.7e+00
4.7e+00
2.1e+00
4.9e-01
1.3e-02
cases:28.66%
controls:29.47%
cases:24.55%
controls:22.37%
cases:21.36%
controls:4.55%
cases:22.16%
controls:0.26%
cases:27.35%
controls:4.41%
cases:33.24%
controls:23.34%
cases:37.74%
controls:37.43%
143
1462
356
3499
123
1112
378
3859
107
226
394
4745
111
13
390
4958
128
219
340
4750
120
1142
241
3750
80
1532
132
2561
Bacterial infection, unspecified
A49.9 [45590816]
A49.9 [45590816]
1.2e+00
1.5e+00
—
1.0e+50
—
4.0e+00
2.3e+00
cases:2.81%
controls:0.89%
cases:2.40%
controls:0.52%
—
—
cases:2.00%
controls:0.00%
—
—
cases:20.22%
controls:0.45%
cases:15.57%
controls:1.91%
14
44
485
4917
12
26
489
4945
—
10
0
491
4971
—
73
22
288
4870
33
78
179
4015
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
1920-8 [3013721]
5.1e-01
5.3e-01
2.7e+00
—
3.9e+00
1.6e+00
7.7e-01
cases:9.42%
controls:5.87%
cases:4.79%
controls:2.88%
cases:4.19%
controls:0.28%
—
—
cases:15.38%
controls:0.38%
cases:13.85%
controls:3.19%
cases:17.45%
controls:8.89%
47
291
452
4670
24
143
477
4828
21
14
480
4957
—
72
19
396
4950
50
156
311
4736
37
364
175
3729
pH of Specimen
17433-4 [3019225]
17433-4 [3019225]
3.9e-01
1.0e+00
1.8e+00
1.0e+50
4.2e+00
2.3e+00
1.4e+00
cases:3.61%
controls:2.48%
cases:3.19%
controls:1.17%
cases:1.20%
controls:0.20%
cases:2.59%
controls:0.00%
cases:6.41%
controls:0.10%
cases:9.14%
controls:1.02%
cases:8.96%
controls:2.39%
18
123
481
4838
16
58
485
4913
6
10
495
4961
13
0
488
4971
30
5
438
4964
33
50
328
4842
19
98
193
3995
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
GD1UA [2001303652]
3.1e-01
8.1e-01
—
1.0e+50
4.1e+00
3.3e+00
1.5e+00
cases:3.21%
controls:2.38%
cases:2.20%
controls:0.99%
—
—
cases:5.99%
controls:0.00%
cases:5.77%
controls:0.10%
cases:14.40%
controls:0.61%
cases:9.43%
controls:2.35%
16
118
483
4843
11
49
490
4922
—
30
0
471
4971
27
5
441
4964
52
30
309
4862
20
96
192
3997
ABO and Rh group [Type] in Blood
882-1 [3003694]
882-1 [3003694]
4.7e-01
1.7e-01
—
1.0e+50
5.5e+00
2.3e+00
9.2e-01
cases:6.01%
controls:3.85%
cases:1.40%
controls:1.19%
—
—
cases:6.79%
controls:0.00%
cases:19.66%
controls:0.10%
cases:10.25%
controls:1.08%
cases:11.32%
controls:4.84%
30
191
469
4770
7
59
494
4912
—
34
0
467
4971
92
5
376
4964
37
53
324
4839
24
198
188
3895
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
2276-4 [3001122]
2.7e-01
9.4e-01
2.9e+00
—
2.2e+00
1.5e+00
1.1e+00
cases:9.42%
controls:7.38%
cases:10.98%
controls:4.59%
cases:9.98%
controls:0.60%
—
—
cases:5.56%
controls:0.62%
cases:19.67%
controls:5.17%
cases:33.02%
controls:13.63%
47
366
452
4595
55
228
446
4743
50
30
451
4941
—
26
31
442
4938
71
253
290
4639
70
558
142
3535
Extensive structural and functional ultrasound examination of heart
FM1EE [2001303307]
FM1EE [2001303307]
4.2e-01
9.9e-01
1.7e+00
—
3.0e+00
1.5e+00
1.4e+00
cases:7.01%
controls:4.72%
cases:4.99%
controls:1.91%
cases:1.80%
controls:0.32%
—
—
cases:5.56%
controls:0.28%
cases:7.48%
controls:1.82%
cases:19.34%
controls:5.33%
35
234
464
4727
25
95
476
4876
9
16
492
4955
—
26
14
442
4955
27
89
334
4803
41
218
171
3875
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
J01MA12 [21603019]
8.7e-01
2.0e+00
—
—
—
3.6e+00
2.1e+00
cases:5.81%
controls:2.52%
cases:3.39%
controls:0.46%
—
—
—
—
—
—
cases:26.04%
controls:0.98%
cases:19.81%
controls:2.81%
29
125
470
4836
17
23
484
4948
—
—
—
94
48
267
4844
42
115
170
3978
Immunohistochemistry procedure
117617002 [4035726]
117617002 [4035726]
1.9e+00
1.8e+00
—
1.0e+50
—
3.8e+00
2.9e+00
cases:4.01%
controls:0.65%
cases:1.00%
controls:0.16%
—
—
cases:4.79%
controls:0.00%
—
—
cases:4.99%
controls:0.12%
cases:4.72%
controls:0.27%
20
32
479
4929
5
8
496
4963
—
24
0
477
4971
—
18
6
343
4886
10
11
202
4082
12 lead EKG panel
34534-8 [3044889]
34534-8 [3044889]
-6.7e-02
-1.2e-01
1.2e+00
3.5e+00
3.0e+00
8.1e-01
5.4e-02
cases:18.64%
controls:19.67%
cases:9.58%
controls:10.68%
cases:4.39%
controls:1.35%
cases:3.19%
controls:0.10%
cases:18.16%
controls:1.11%
cases:21.05%
controls:10.61%
cases:25.47%
controls:24.46%
93
976
406
3985
48
531
453
4440
22
67
479
4904
16
5
485
4966
85
55
383
4914
76
519
285
4373
54
1001
158
3092
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
J01MA02 [21603009]
2.9e-01
6.6e-01
2.7e+00
—
2.3e+00
2.5e+00
1.0e+00
cases:8.22%
controls:6.29%
cases:2.79%
controls:1.47%
cases:2.00%
controls:0.14%
—
—
cases:1.71%
controls:0.18%
cases:15.24%
controls:1.43%
cases:14.62%
controls:5.72%
41
312
458
4649
14
73
487
4898
10
7
491
4964
—
8
9
460
4960
55
70
306
4822
31
234
181
3859
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
14749-6 [3013826]
5.2e-02
2.4e-01
2.2e+00
—
3.4e+00
2.0e+00
8.4e-01
cases:15.23%
controls:14.57%
cases:8.38%
controls:6.74%
cases:7.58%
controls:0.91%
—
—
cases:21.79%
controls:0.91%
cases:34.35%
controls:6.75%
cases:35.85%
controls:19.40%
76
723
423
4238
42
335
459
4636
38
45
463
4926
—
102
45
366
4924
124
330
237
4562
76
794
136
3299
Pneumonia, unspecified
J18.9 [45601123]
J18.9 [45601123]
4.9e-01
1.1e+00
2.0e+00
—
2.3e+00
2.0e+00
1.1e+00
cases:6.01%
controls:3.77%
cases:4.59%
controls:1.61%
cases:2.20%
controls:0.30%
—
—
cases:2.35%
controls:0.24%
cases:11.63%
controls:1.78%
cases:16.98%
controls:6.65%
30
187
469
4774
23
80
478
4891
11
15
490
4956
—
11
12
457
4957
42
87
319
4805
36
272
176
3821
Vancomycin [Mass/volume] in Serum or Plasma
20578-1 [3005715]
20578-1 [3005715]
—
—
—
—
1.0e+50
5.1e+00
3.1e+00
—
—
—
—
—
—
—
—
cases:11.11%
controls:0.00%
cases:14.96%
controls:0.10%
cases:4.72%
controls:0.22%
—
—
—
—
52
0
416
4969
54
5
307
4887
10
9
202
4084
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
UJD10 [2001304788]
2.1e-01
1.2e+00
2.5e+00
1.0e+50
2.4e+00
1.1e+00
1.1e+00
cases:6.21%
controls:5.10%
cases:3.79%
controls:1.15%
cases:1.40%
controls:0.12%
cases:1.40%
controls:0.00%
cases:1.28%
controls:0.12%
cases:4.16%
controls:1.45%
cases:11.79%
controls:4.45%
31
253
468
4708
19
57
482
4914
7
6
494
4965
7
0
494
4971
6
6
462
4963
15
71
346
4821
25
182
187
3911
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]
10839-9 [3021337]
4.9e-01
3.9e-01
2.8e+00
1.0e+50
3.6e+00
1.7e+00
2.6e-01
cases:7.21%
controls:4.54%
cases:3.99%
controls:2.74%
cases:3.59%
controls:0.22%
cases:3.79%
controls:0.00%
cases:8.97%
controls:0.26%
cases:12.74%
controls:2.49%
cases:8.49%
controls:6.69%
36
225
463
4736
20
136
481
4835
18
11
483
4960
19
0
482
4971
42
13
426
4956
46
122
315
4770
18
274
194
3819
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
72160-5 [43054903]
2.7e-01
7.7e-01
3.3e+00
—
3.2e+00
8.2e-01
3.4e-01
cases:12.02%
controls:9.45%
cases:10.38%
controls:5.07%
cases:10.58%
controls:0.44%
—
—
cases:12.18%
controls:0.54%
cases:11.91%
controls:5.60%
cases:22.64%
controls:17.30%
60
469
439
4492
52
252
449
4719
53
22
448
4949
—
57
27
411
4942
43
274
318
4618
48
708
164
3385
Dentistry
C5 [903277]
C5 [903277]
2.9e-01
1.1e+00
2.5e+00
—
—
3.5e+00
2.1e+00
cases:2.20%
controls:1.65%
cases:1.80%
controls:0.60%
cases:1.40%
controls:0.12%
—
—
—
—
cases:16.07%
controls:0.59%
cases:14.15%
controls:2.00%
11
82
488
4879
9
30
492
4941
7
6
494
4965
—
—
58
29
303
4863
30
82
182
4011
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
2465-3 [3005719]
7.0e-01
1.6e+00
—
1.0e+50
—
3.5e+00
2.9e+00
cases:2.20%
controls:1.11%
cases:2.99%
controls:0.60%
—
—
cases:2.99%
controls:0.00%
—
—
cases:15.51%
controls:0.55%
cases:20.28%
controls:1.44%
11
55
488
4906
15
30
486
4941
—
15
0
486
4971
—
56
27
305
4865
43
59
169
4034
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
50554-5 [3029287]
1.3e-01
1.3e-01
2.2e+00
1.0e+50
2.8e+00
2.1e+00
8.1e-01
cases:8.22%
controls:7.30%
cases:4.39%
controls:3.86%
cases:4.39%
controls:0.48%
cases:4.19%
controls:0.00%
cases:6.84%
controls:0.44%
cases:23.27%
controls:3.58%
cases:22.17%
controls:11.21%
41
362
458
4599
22
192
479
4779
22
24
479
4947
21
0
480
4971
32
22
436
4947
84
175
277
4717
47
459
165
3634
Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay
3255-7 [3016407]
3255-7 [3016407]
—
—
1.0e+50
1.0e+50
1.0e+50
5.1e+00
2.9e+00
—
—
—
—
cases:1.20%
controls:0.00%
cases:7.58%
controls:0.00%
cases:20.73%
controls:0.00%
cases:13.85%
controls:0.10%
cases:8.96%
controls:0.54%
—
—
6
0
495
4971
38
0
463
4971
97
0
371
4969
50
5
311
4887
19
22
193
4071
Bacteria identified in Isolate by Culture
43409-2 [3042936]
43409-2 [3042936]
6.3e-01
-7.9e-03
—
—
3.8e+00
2.9e+00
1.3e+00
cases:4.61%
controls:2.52%
cases:1.20%
controls:1.21%
—
—
—
—
cases:5.77%
controls:0.14%
cases:15.51%
controls:0.98%
cases:10.38%
controls:3.18%
23
125
476
4836
6
60
495
4911
—
—
27
7
441
4962
56
48
305
4844
22
130
190
3963
Mycobacterium tuberculosis DNA [Presence] in Specimen by NAA with probe detection
13956-8 [3014162]
13956-8 [3014162]
1.4e+00
—
—
—
1.0e+50
4.1e+00
2.4e+00
cases:2.00%
controls:0.48%
—
—
—
—
—
—
cases:3.42%
controls:0.00%
cases:8.03%
controls:0.14%
cases:7.55%
controls:0.73%
10
24
489
4937
—
—
—
16
0
452
4969
29
7
332
4885
16
30
196
4063
Laboratory Visit
OMOP4822461 [32036]
OMOP4822461 [32036]
-6.9e-03
1.2e-01
1.5e+00
4.6e+00
1.8e+00
3.5e-01
-1.6e-01
cases:42.89%
controls:43.06%
cases:42.32%
controls:39.41%
cases:39.12%
controls:12.49%
cases:39.52%
controls:0.66%
cases:44.23%
controls:11.87%
cases:50.42%
controls:41.74%
cases:51.42%
controls:55.34%
214
2136
285
2825
212
1959
289
3012
196
621
305
4350
198
33
303
4938
207
590
261
4379
182
2042
179
2850
109
2265
103
1828
darbepoetin alfa; parenteral
B03XA02 [21601134]
B03XA02 [21601134]
—
1.9e+00
—
—
—
2.9e+00
3.0e+00
—
—
cases:1.40%
controls:0.20%
—
—
—
—
—
—
cases:3.60%
controls:0.20%
cases:5.19%
controls:0.27%
—
7
10
494
4961
—
—
—
13
10
348
4882
11
11
201
4082
Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]
60517-0 [40763571]
3.7e-01
8.9e-01
2.2e+00
1.0e+50
2.5e+00
1.2e+00
9.9e-01
cases:3.21%
controls:2.24%
cases:4.19%
controls:1.77%
cases:3.59%
controls:0.40%
cases:1.20%
controls:0.00%
cases:2.14%
controls:0.18%
cases:5.26%
controls:1.72%
cases:11.32%
controls:4.52%
16
111
483
4850
21
88
480
4883
18
20
483
4951
6
0
495
4971
10
9
458
4960
19
84
342
4808
24
185
188
3908
Extensive body CT
JN4BD [2001310899]
JN4BD [2001310899]
2.2e+00
2.5e+00
—
1.0e+50
1.0e+50
—
3.0e+00
cases:4.61%
controls:0.52%
cases:2.59%
controls:0.22%
—
—
cases:3.99%
controls:0.00%
cases:1.50%
controls:0.00%
—
—
cases:4.25%
controls:0.22%
23
26
476
4935
13
11
488
4960
—
20
0
481
4971
7
0
461
4969
—
9
9
203
4084
Insertion of central venous catheter through external or internal jugular vein
TPH15 [2001309600]
TPH15 [2001309600]
5.4e-01
—
—
1.0e+50
—
5.2e+00
2.5e+00
cases:1.20%
controls:0.71%
—
—
—
—
cases:6.79%
controls:0.00%
—
—
cases:15.24%
controls:0.10%
cases:4.72%
controls:0.39%
6
35
493
4926
—
—
34
0
467
4971
—
55
5
306
4887
10
16
202
4077
HIV 1 and 2 tests - Meaningful Use set
75622-1 [46235355]
75622-1 [46235355]
4.5e-01
1.1e+00
3.3e+00
—
—
2.9e+00
1.5e+00
cases:3.41%
controls:2.20%
cases:2.40%
controls:0.78%
cases:2.59%
controls:0.10%
—
—
—
—
cases:13.30%
controls:0.86%
cases:9.91%
controls:2.30%
17
109
482
4852
12
39
489
4932
13
5
488
4966
—
—
48
42
313
4850
21
94
191
3999
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
2000-8 [3015377]
4.9e-01
5.3e-01
2.1e+00
—
3.4e+00
1.4e+00
7.3e-01
cases:9.62%
controls:6.11%
cases:4.79%
controls:2.88%
cases:2.00%
controls:0.24%
—
—
cases:8.55%
controls:0.32%
cases:11.36%
controls:2.94%
cases:16.98%
controls:8.94%
48
303
451
4658
24
143
477
4828
10
12
491
4959
—
40
16
428
4953
41
144
320
4748
36
366
176
3727
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
1798-8 [3016771]
2.6e-01
5.0e-01
2.6e+00
1.0e+50
2.5e+00
1.7e+00
8.6e-01
cases:7.62%
controls:5.99%
cases:4.59%
controls:2.84%
cases:3.39%
controls:0.26%
cases:3.39%
controls:0.00%
cases:4.06%
controls:0.34%
cases:13.85%
controls:2.92%
cases:16.51%
controls:7.72%
38
297
461
4664
23
141
478
4830
17
13
484
4958
17
0
484
4971
19
17
449
4952
50
143
311
4749
35
316
177
3777
fluconazole; oral, parenteral
J02AC01 [21603080]
J02AC01 [21603080]
4.1e-01
3.7e-01
—
—
2.4e+00
3.3e+00
2.0e+00
cases:5.81%
controls:3.93%
cases:1.40%
controls:0.97%
—
—
—
—
cases:1.92%
controls:0.18%
cases:20.22%
controls:0.96%
cases:18.40%
controls:3.08%
29
195
470
4766
7
48
494
4923
—
—
9
9
459
4960
73
47
288
4845
39
126
173
3967
valaciclovir; oral
J05AB11 [21603137]
J05AB11 [21603137]
4.3e-01
6.9e-01
—
—
—
4.5e+00
3.0e+00
cases:2.20%
controls:1.45%
cases:1.60%
controls:0.80%
—
—
—
—
—
—
cases:32.13%
controls:0.51%
cases:29.25%
controls:1.95%
11
72
488
4889
8
40
493
4931
—
—
—
116
25
245
4867
62
80
150
4013
Emergency Room and Inpatient Visit
ERIP [262]
ERIP [262]
1.4e-01
4.2e-01
2.5e+00
—
3.0e+00
2.0e+00
5.0e-01
cases:5.41%
controls:4.74%
cases:5.59%
controls:3.74%
cases:5.99%
controls:0.50%
—
—
cases:8.97%
controls:0.48%
cases:24.38%
controls:4.19%
cases:19.81%
controls:13.07%
27
235
472
4726
28
186
473
4785
30
25
471
4946
—
42
24
426
4945
88
205
273
4687
42
535
170
3558
Urea [Moles/volume] in Serum or Plasma
22664-7 [3020779]
22664-7 [3020779]
-2.8e-01
-1.4e-01
-1.0e+50
1.0e+50
3.4e+00
2.6e+00
1.5e+00
cases:1.20%
controls:1.59%
cases:1.00%
controls:1.15%
cases:0.00%
controls:0.26%
cases:1.00%
controls:0.00%
cases:9.19%
controls:0.32%
cases:13.57%
controls:1.19%
cases:11.79%
controls:2.83%
6
79
493
4882
5
57
496
4914
0
13
501
4958
5
0
496
4971
43
16
425
4953
49
58
312
4834
25
116
187
3977
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
3034-6 [3004789]
3.1e-01
9.0e-01
2.1e+00
1.0e+50
2.4e+00
1.2e+00
9.2e-01
cases:3.21%
controls:2.38%
cases:4.39%
controls:1.83%
cases:3.39%
controls:0.42%
cases:1.40%
controls:0.00%
cases:2.14%
controls:0.20%
cases:5.82%
controls:1.84%
cases:11.79%
controls:5.08%
16
118
483
4843
22
91
479
4880
17
21
484
4950
7
0
494
4971
10
10
458
4959
21
90
340
4802
25
208
187
3885
Gastrointestinal bacterial pathogens panel - Stool by NAA with probe detection
92695-6 [37019628]
92695-6 [37019628]
1.8e+00
—
—
—
1.0e+50
4.1e+00
1.6e+00
cases:1.40%
controls:0.24%
—
—
—
—
—
—
cases:2.78%
controls:0.00%
cases:6.09%
controls:0.10%
cases:4.25%
controls:0.90%
7
12
492
4949
—
—
—
13
0
455
4969
22
5
339
4887
9
37
203
4056
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]
30248-9 [3015399]
4.3e-01
1.1e+00
3.1e+00
1.0e+50
2.0e+00
1.3e+00
4.9e-01
cases:8.02%
controls:5.38%
cases:8.58%
controls:3.04%
cases:6.99%
controls:0.34%
cases:2.79%
controls:0.00%
cases:3.42%
controls:0.46%
cases:9.70%
controls:2.92%
cases:13.21%
controls:8.50%
40
267
459
4694
43
151
458
4820
35
17
466
4954
14
0
487
4971
16
23
452
4946
35
143
326
4749
28
348
184
3745
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
14798-3 [3022948]
4.7e-01
9.8e-01
2.2e+00
1.0e+50
2.4e+00
1.0e+00
8.5e-01
cases:4.21%
controls:2.66%
cases:4.99%
controls:1.93%
cases:3.99%
controls:0.46%
cases:1.40%
controls:0.00%
cases:2.56%
controls:0.24%
cases:5.54%
controls:2.02%
cases:11.79%
controls:5.40%
21
132
478
4829
25
96
476
4875
20
23
481
4948
7
0
494
4971
12
12
456
4957
20
99
341
4793
25
221
187
3872
pH of Capillary blood
2745-8 [3009343]
2745-8 [3009343]
1.2e-01
—
-1.0e+50
—
3.4e+00
2.8e+00
1.2e+00
cases:1.40%
controls:1.25%
—
—
cases:0.00%
controls:0.12%
—
—
cases:2.99%
controls:0.10%
cases:7.48%
controls:0.51%
cases:6.60%
controls:2.08%
7
62
492
4899
—
0
6
501
4965
—
14
5
454
4964
27
25
334
4867
14
85
198
4008
Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection
54067-4 [3051552]
54067-4 [3051552]
1.1e+00
8.4e-01
—
—
—
4.0e+00
2.2e+00
cases:2.81%
controls:0.93%
cases:1.20%
controls:0.52%
—
—
—
—
—
—
cases:18.56%
controls:0.43%
cases:15.57%
controls:1.95%
14
46
485
4915
6
26
495
4945
—
—
—
67
21
294
4871
33
80
179
4013
Carbon dioxide [Partial pressure] in Capillary blood
2020-6 [3023024]
2020-6 [3023024]
1.2e-01
—
-1.0e+50
—
3.4e+00
2.8e+00
1.1e+00
cases:1.40%
controls:1.25%
—
—
cases:0.00%
controls:0.12%
—
—
cases:2.99%
controls:0.10%
cases:7.48%
controls:0.51%
cases:6.60%
controls:2.22%
7
62
492
4899
—
0
6
501
4965
—
14
5
454
4964
27
25
334
4867
14
91
198
4002
Biopsy of skin and subcutaneous tissue
TQX10 [2001310152]
TQX10 [2001310152]
1.2e+00
2.2e+00
—
—
—
2.2e+00
2.9e+00
cases:1.80%
controls:0.54%
cases:1.20%
controls:0.14%
—
—
—
—
—
—
cases:1.66%
controls:0.18%
cases:8.49%
controls:0.49%
9
27
490
4934
6
7
495
4964
—
—
—
6
9
355
4883
18
20
194
4073
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
51483-6 [3030467]
2.1e-01
1.6e-01
2.7e+00
1.0e+50
2.6e+00
2.1e+00
4.8e-01
cases:6.21%
controls:5.08%
cases:3.19%
controls:2.74%
cases:3.59%
controls:0.26%
cases:2.99%
controls:0.00%
cases:4.27%
controls:0.34%
cases:18.01%
controls:2.74%
cases:13.68%
controls:8.97%
31
252
468
4709
16
136
485
4835
18
13
483
4958
15
0
486
4971
20
17
448
4952
65
134
296
4758
29
367
183
3726
Base excess.100% oxygenated [Moles/volume] standard in Capillary blood by calculation
72720-6 [43055554]
72720-6 [43055554]
1.2e-01
—
—
—
3.3e+00
2.6e+00
1.4e+00
cases:1.40%
controls:1.25%
—
—
—
—
—
—
cases:2.56%
controls:0.10%
cases:5.54%
controls:0.45%
cases:6.60%
controls:1.64%
7
62
492
4899
—
—
—
12
5
456
4964
20
22
341
4870
14
67
198
4026
Antithrombin actual/normal in Platelet poor plasma by Chromogenic method
27811-9 [3000515]
27811-9 [3000515]
—
—
—
1.0e+50
1.0e+50
4.5e+00
2.7e+00
—
—
—
—
—
—
cases:3.59%
controls:0.00%
cases:9.83%
controls:0.00%
cases:9.97%
controls:0.12%
cases:7.08%
controls:0.49%
—
—
—
18
0
483
4971
46
0
422
4969
36
6
325
4886
15
20
197
4073
tacrolimus; oral, parenteral
L04AD02 [21603925]
L04AD02 [21603925]
—
—
—
—
—
3.9e+00
3.3e+00
—
—
—
—
—
—
—
—
—
—
cases:4.99%
controls:0.10%
cases:3.77%
controls:0.15%
—
—
—
—
—
18
5
343
4887
8
6
204
4087
aciclovir; oral, parenteral
J05AB01 [21603131]
J05AB01 [21603131]
3.8e-01
6.1e-01
—
—
2.1e+00
3.0e+00
2.1e+00
cases:3.01%
controls:2.08%
cases:1.40%
controls:0.76%
—
—
—
—
cases:1.28%
controls:0.16%
cases:14.68%
controls:0.84%
cases:18.40%
controls:2.69%
15
103
484
4858
7
38
494
4933
—
—
6
8
462
4961
53
41
308
4851
39
110
173
3983
Leukocytes [#/volume] in Urine
30405-5 [3018095]
30405-5 [3018095]
1.5e-01
2.5e-01
2.5e+00
1.0e+50
2.9e+00
1.8e+00
3.6e-01
cases:7.62%
controls:6.65%
cases:4.79%
controls:3.78%
cases:4.19%
controls:0.36%
cases:4.59%
controls:0.00%
cases:8.12%
controls:0.50%
cases:20.22%
controls:3.84%
cases:16.98%
controls:12.44%
38
330
461
4631
24
188
477
4783
21
18
480
4953
23
0
478
4971
38
25
430
4944
73
188
288
4704
36
509
176
3584
Normoblasts [#/volume] in Blood
715-3 [3021589]
715-3 [3021589]
7.6e-02
4.5e-01
2.1e+00
—
2.9e+00
1.4e+00
7.8e-01
cases:8.82%
controls:8.22%
cases:10.98%
controls:7.30%
cases:11.38%
controls:1.59%
—
—
cases:20.30%
controls:1.43%
cases:27.15%
controls:8.18%
cases:27.36%
controls:14.76%
44
408
455
4553
55
363
446
4608
57
79
444
4892
—
95
71
373
4898
98
400
263
4492
58
604
154
3489
Abdominal ultrasound examination
JN3AE [2001305555]
JN3AE [2001305555]
7.2e-01
1.5e+00
1.0e+50
1.0e+50
—
3.6e+00
2.1e+00
cases:2.61%
controls:1.29%
cases:1.80%
controls:0.40%
cases:2.99%
controls:0.00%
cases:6.39%
controls:0.00%
—
—
cases:8.03%
controls:0.25%
cases:9.91%
controls:1.37%
13
64
486
4897
9
20
492
4951
15
0
486
4971
32
0
469
4971
—
29
12
332
4880
21
56
191
4037
enoxaparin; parenteral
B01AB05 [21600976]
B01AB05 [21600976]
5.0e-01
3.1e-01
—
—
3.5e+00
2.6e+00
1.1e+00
cases:7.82%
controls:4.90%
cases:2.40%
controls:1.77%
—
—
—
—
cases:3.85%
controls:0.12%
cases:11.91%
controls:1.02%
cases:10.38%
controls:3.81%
39
243
460
4718
12
88
489
4883
—
—
18
6
450
4963
43
50
318
4842
22
156
190
3937
Epithelial cells.squamous [#/volume] in Urine by Automated count
51486-9 [3029879]
51486-9 [3029879]
-1.1e-01
5.1e-01
2.5e+00
1.0e+50
2.5e+00
2.1e+00
5.1e-01
cases:2.20%
controls:2.46%
cases:2.59%
controls:1.57%
cases:2.00%
controls:0.16%
cases:1.80%
controls:0.00%
cases:2.99%
controls:0.26%
cases:12.47%
controls:1.66%
cases:8.49%
controls:5.30%
11
122
488
4839
13
78
488
4893
10
8
491
4963
9
0
492
4971
14
13
454
4956
45
81
316
4811
18
217
194
3876
SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
94500-6 [706163]
94500-6 [706163]
5.4e-02
2.8e-01
2.1e+00
1.0e+50
2.9e+00
1.6e+00
5.7e-01
cases:6.21%
controls:5.91%
cases:6.39%
controls:4.89%
cases:5.39%
controls:0.70%
cases:6.39%
controls:0.00%
cases:11.32%
controls:0.68%
cases:21.61%
controls:5.52%
cases:23.11%
controls:14.56%
31
293
468
4668
32
243
469
4728
27
35
474
4936
32
0
469
4971
53
34
415
4935
78
270
283
4622
49
596
163
3497
Bacteria [Presence] in Urine
87829-8 [36304419]
87829-8 [36304419]
1.4e-01
1.7e-01
2.5e+00
1.0e+50
2.6e+00
2.0e+00
5.9e-01
cases:5.61%
controls:4.92%
cases:3.19%
controls:2.70%
cases:3.39%
controls:0.30%
cases:2.99%
controls:0.00%
cases:4.06%
controls:0.30%
cases:15.79%
controls:2.39%
cases:13.21%
controls:7.74%
28
244
471
4717
16
134
485
4837
17
15
484
4956
15
0
486
4971
19
15
449
4954
57
117
304
4775
28
317
184
3776
Physiotherapy
R4110 [2001310233]
R4110 [2001310233]
5.5e-02
2.3e-01
—
—
3.6e+00
2.7e+00
8.2e-01
cases:4.61%
controls:4.37%
cases:2.00%
controls:1.59%
—
—
—
—
cases:4.91%
controls:0.14%
cases:15.79%
controls:1.27%
cases:9.91%
controls:4.62%
23
217
476
4744
10
79
491
4892
—
—
23
7
445
4962
57
62
304
4830
21
189
191
3904
Epithelial cells.non-squamous [#/volume] in Urine by Automated count
51485-1 [3030306]
51485-1 [3030306]
-1.6e-01
4.8e-01
2.5e+00
1.0e+50
2.5e+00
2.0e+00
2.6e-01
cases:2.00%
controls:2.34%
cases:2.40%
controls:1.49%
cases:2.00%
controls:0.16%
cases:1.80%
controls:0.00%
cases:2.99%
controls:0.24%
cases:11.91%
controls:1.78%
cases:7.55%
controls:5.91%
10
116
489
4845
12
74
489
4897
10
8
491
4963
9
0
492
4971
14
12
454
4957
43
87
318
4805
16
242
196
3851
Abdominal CT examination
JN3AD [2001305554]
JN3AD [2001305554]
5.1e-01
—
—
1.0e+50
3.1e+00
2.7e+00
1.3e+00
cases:1.40%
controls:0.85%
—
—
—
—
cases:1.80%
controls:0.00%
cases:2.14%
controls:0.10%
cases:5.26%
controls:0.39%
cases:7.55%
controls:2.13%
7
42
492
4919
—
—
9
0
492
4971
10
5
458
4964
19
19
342
4873
16
87
196
4006
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
30391-7 [3002582]
2.2e-01
2.8e-01
2.5e+00
1.0e+50
2.4e+00
2.1e+00
3.8e-01
cases:7.21%
controls:5.87%
cases:4.19%
controls:3.20%
cases:4.19%
controls:0.34%
cases:3.99%
controls:0.00%
cases:4.91%
controls:0.46%
cases:20.50%
controls:3.13%
cases:15.09%
controls:10.80%
36
291
463
4670
21
159
480
4812
21
17
480
4954
20
0
481
4971
23
23
445
4946
74
153
287
4739
32
442
180
3651
Blood transfusion
WW500 [2001310603]
WW500 [2001310603]
2.4e+00
1.0e+50
1.0e+50
1.0e+50
1.0e+50
—
4.6e+00
cases:1.80%
controls:0.16%
cases:3.59%
controls:0.00%
cases:1.60%
controls:0.00%
cases:2.20%
controls:0.00%
cases:7.48%
controls:0.00%
—
—
cases:14.62%
controls:0.17%
9
8
490
4953
18
0
483
4971
8
0
493
4971
11
0
490
4971
35
0
433
4969
—
31
7
181
4086
ondansetron; oral, parenteral, rectal
A04AA01 [21600493]
A04AA01 [21600493]
2.7e+00
—
—
—
—
—
4.3e+00
cases:1.80%
controls:0.12%
—
—
—
—
—
—
—
—
—
—
cases:17.92%
controls:0.29%
9
6
490
4955
—
—
—
—
—
38
12
174
4081
Supplier / Service Provider
OMOP5117446 [33004]
OMOP5117446 [33004]
-2.7e-01
-3.2e-01
4.8e-01
—
—
3.5e+00
3.5e+00
cases:20.24%
controls:24.91%
cases:5.79%
controls:7.83%
cases:1.20%
controls:0.74%
—
—
—
—
cases:12.74%
controls:0.45%
cases:25.47%
controls:0.98%
101
1236
398
3725
29
389
472
4582
6
37
495
4934
—
—
46
22
315
4870
54
40
158
4053
IgM [Mass/volume] in Serum or Plasma
2472-9 [3028026]
2472-9 [3028026]
6.4e-01
1.6e+00
—
1.0e+50
—
3.2e+00
2.2e+00
cases:1.40%
controls:0.75%
cases:2.00%
controls:0.40%
—
—
cases:2.99%
controls:0.00%
—
—
cases:7.20%
controls:0.31%
cases:8.02%
controls:1.00%
7
37
492
4924
10
20
491
4951
—
15
0
486
4971
—
26
15
335
4877
17
41
195
4052
High resolution CT examination of lungs
GD1DD [2001303632]
GD1DD [2001303632]
5.1e-01
—
—
1.0e+50
1.0e+50
4.0e+00
2.9e+00
cases:1.00%
controls:0.60%
—
—
—
—
cases:3.99%
controls:0.00%
cases:5.13%
controls:0.00%
cases:12.19%
controls:0.25%
cases:8.96%
controls:0.51%
5
30
494
4931
—
—
20
0
481
4971
24
0
444
4969
44
12
317
4880
19
21
193
4072
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
30383-4 [3000850]
3.9e-01
1.2e-01
2.6e+00
1.0e+50
2.4e+00
1.9e+00
3.2e-01
cases:5.61%
controls:3.87%
cases:2.00%
controls:1.77%
cases:2.59%
controls:0.20%
cases:2.20%
controls:0.00%
cases:2.14%
controls:0.20%
cases:10.53%
controls:1.66%
cases:8.02%
controls:5.96%
28
192
471
4769
10
88
491
4883
13
10
488
4961
11
0
490
4971
10
10
458
4959
38
81
323
4811
17
244
195
3849
mycophenolic acid; oral, parenteral
L04AA06 [21603896]
L04AA06 [21603896]
—
—
—
—
—
3.4e+00
3.5e+00
—
—
—
—
—
—
—
—
—
—
cases:6.09%
controls:0.22%
cases:6.60%
controls:0.22%
—
—
—
—
—
22
11
339
4881
14
9
198
4084
Paranasal sinuses X-ray examination in one projection
DM1QA [2001301761]
DM1QA [2001301761]
—
—
—
1.0e+50
1.0e+50
3.6e+00
3.2e+00
—
—
—
—
—
—
cases:1.20%
controls:0.00%
cases:1.07%
controls:0.00%
cases:4.43%
controls:0.12%
cases:6.13%
controls:0.27%
—
—
—
6
0
495
4971
5
0
463
4969
16
6
345
4886
13
11
199
4082
moxifloxacin; oral, parenteral
J01MA14 [21603021]
J01MA14 [21603021]
8.2e-01
1.7e+00
—
—
—
4.0e+00
2.8e+00
cases:2.40%
controls:1.07%
cases:1.20%
controls:0.22%
—
—
—
—
—
—
cases:8.59%
controls:0.16%
cases:8.49%
controls:0.59%
12
53
487
4908
6
11
495
4960
—
—
—
31
8
330
4884
18
24
194
4069
oxycodone; oral, parenteral
N02AA05 [21604260]
N02AA05 [21604260]
4.4e-01
5.6e-01
1.7e+00
—
2.3e+00
3.1e+00
1.4e+00
cases:2.20%
controls:1.43%
cases:1.40%
controls:0.80%
cases:1.40%
controls:0.26%
—
—
cases:2.56%
controls:0.26%
cases:14.40%
controls:0.78%
cases:10.85%
controls:2.86%
11
71
488
4890
7
40
494
4931
7
13
494
4958
—
12
13
456
4956
52
38
309
4854
23
117
189
3976
HIV 1 RNA [Units/volume] (viral load) in Serum or Plasma by Probe with amplification
10351-5 [3013180]
10351-5 [3013180]
—
-1.0e+50
—
—
—
3.8e+00
3.0e+00
—
—
cases:0.00%
controls:0.10%
—
—
—
—
—
—
cases:5.82%
controls:0.14%
cases:2.36%
controls:0.12%
—
0
5
501
4966
—
—
—
21
7
340
4885
5
5
207
4088
General Practice Dentistry
1223G0001X [38003675]
1223G0001X [38003675]
—
—
—
—
—
3.8e+00
2.9e+00
—
—
—
—
—
—
—
—
—
—
cases:4.99%
controls:0.12%
cases:6.13%
controls:0.34%
—
—
—
—
—
18
6
343
4886
13
14
199
4079
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
51480-2 [3031040]
1.4e-01
1.9e-01
2.0e+00
—
3.0e+00
1.6e+00
4.9e-01
cases:18.44%
controls:16.39%
cases:10.18%
controls:8.59%
cases:8.78%
controls:1.31%
—
—
cases:19.66%
controls:1.15%
cases:31.02%
controls:8.32%
cases:30.19%
controls:20.86%
92
813
407
4148
51
427
450
4544
44
65
457
4906
—
92
57
376
4912
112
407
249
4485
64
854
148
3239
Haptoglobin [Mass/volume] in Serum or Plasma
4542-7 [3012336]
4542-7 [3012336]
8.8e-01
1.7e+00
—
1.0e+50
1.0e+50
3.4e+00
1.5e+00
cases:1.40%
controls:0.58%
cases:1.80%
controls:0.32%
—
—
cases:4.39%
controls:0.00%
cases:8.12%
controls:0.00%
cases:9.14%
controls:0.33%
cases:5.66%
controls:1.37%
7
29
492
4932
9
16
492
4955
—
22
0
479
4971
38
0
430
4969
33
16
328
4876
12
56
200
4037
Osmolality of Urine
2695-5 [3026782]
2695-5 [3026782]
1.2e-01
-2.9e-01
2.1e+00
1.0e+50
2.6e+00
1.9e+00
5.6e-01
cases:5.21%
controls:4.66%
cases:1.60%
controls:2.13%
cases:2.59%
controls:0.32%
cases:1.60%
controls:0.00%
cases:1.92%
controls:0.14%
cases:9.70%
controls:1.66%
cases:8.96%
controls:5.33%
26
231
473
4730
8
106
493
4865
13
16
488
4955
8
0
493
4971
9
7
459
4962
35
81
326
4811
19
218
193
3875
amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]
J01CR02 [21602863]
1.9e-01
1.0e-01
1.9e+00
—
2.6e+00
2.6e+00
1.4e+00
cases:8.82%
controls:7.42%
cases:2.20%
controls:1.99%
cases:1.20%
controls:0.18%
—
—
cases:2.35%
controls:0.18%
cases:18.28%
controls:1.59%
cases:22.17%
controls:6.79%
44
368
455
4593
11
99
490
4872
6
9
495
4962
—
11
9
457
4960
66
78
295
4814
47
278
165
3815
Norovirus RNA [Presence] in Stool by NAA with probe detection
7974-9 [3008909]
7974-9 [3008909]
9.2e-01
-1.0e+50
—
—
—
4.2e+00
2.4e+00
cases:1.00%
controls:0.40%
cases:0.00%
controls:0.14%
—
—
—
—
—
—
cases:9.42%
controls:0.16%
cases:8.49%
controls:0.83%
5
20
494
4941
0
7
501
4964
—
—
—
34
8
327
4884
18
34
194
4059
Bacteria identified in Skin by Aerobe culture
620-5 [3007853]
620-5 [3007853]
-1.1e-01
9.8e-02
—
—
2.6e+00
2.8e+00
1.1e+00
cases:2.20%
controls:2.46%
cases:1.00%
controls:0.91%
—
—
—
—
cases:2.35%
controls:0.18%
cases:12.19%
controls:0.84%
cases:8.02%
controls:2.76%
11
122
488
4839
5
45
496
4926
—
—
11
9
457
4960
44
41
317
4851
17
113
195
3980
Erythropoietin (EPO) [Units/volume] in Serum or Plasma
15061-5 [3024172]
15061-5 [3024172]
2.2e+00
2.5e+00
1.0e+50
—
1.0e+50
—
1.9e+00
cases:1.20%
controls:0.14%
cases:1.40%
controls:0.12%
cases:1.80%
controls:0.00%
—
—
cases:2.14%
controls:0.00%
—
—
cases:3.30%
controls:0.51%
6
7
493
4954
7
6
494
4965
9
0
492
4971
—
10
0
458
4969
—
7
21
205
4072
Measurement of bone density from two or more locations with X-ray
NK6QA [2001308500]
NK6QA [2001308500]
—
—
—
—
—
3.3e+00
3.2e+00
—
—
—
—
—
—
—
—
—
—
cases:3.88%
controls:0.14%
cases:12.26%
controls:0.59%
—
—
—
—
—
14
7
347
4885
26
24
186
4069
Leukocyte morphology finding [Identifier] in Blood
11156-7 [3008757]
11156-7 [3008757]
2.5e+00
—
1.0e+50
1.0e+50
—
—
3.9e+00
cases:2.00%
controls:0.16%
—
—
cases:3.39%
controls:0.00%
cases:3.59%
controls:0.00%
—
—
—
—
cases:7.08%
controls:0.15%
10
8
489
4953
—
17
0
484
4971
18
0
483
4971
—
—
15
6
197
4087
Extended examination of mouth
SAA03 [2001310276]
SAA03 [2001310276]
2.6e-01
-6.4e-02
1.6e+00
—
3.2e+00
2.1e+00
1.2e+00
cases:8.22%
controls:6.43%
cases:1.40%
controls:1.49%
cases:1.00%
controls:0.20%
—
—
cases:3.63%
controls:0.16%
cases:10.80%
controls:1.53%
cases:15.57%
controls:5.13%
41
319
458
4642
7
74
494
4897
5
10
496
4961
—
17
8
451
4961
39
75
322
4817
33
210
179
3883
Coagulation factor VIII activity actual/normal in Platelet poor plasma by Coagulation assay
3209-4 [3019250]
3209-4 [3019250]
—
—
—
1.0e+50
1.0e+50
4.0e+00
2.4e+00
—
—
—
—
—
—
cases:2.59%
controls:0.00%
cases:8.12%
controls:0.00%
cases:5.26%
controls:0.10%
cases:4.25%
controls:0.39%
—
—
—
13
0
488
4971
38
0
430
4969
19
5
342
4887
9
16
203
4077
Reticulocyte production index
31111-8 [3000012]
31111-8 [3000012]
—
—
—
1.0e+50
—
3.5e+00
2.9e+00
—
—
—
—
—
—
cases:2.99%
controls:0.00%
—
—
cases:7.20%
controls:0.22%
cases:6.13%
controls:0.37%
—
—
—
15
0
486
4971
—
26
11
335
4881
13
15
199
4078
Case Management Agency
251B00000X [38004193]
251B00000X [38004193]
7.7e-02
2.2e-01
1.1e+00
3.2e+00
1.5e+00
6.9e-01
-1.5e-01
cases:64.93%
controls:63.15%
cases:59.68%
controls:54.27%
cases:45.11%
controls:22.31%
cases:24.75%
controls:1.37%
cases:56.62%
controls:22.60%
cases:72.85%
controls:57.28%
cases:71.23%
controls:74.25%
324
3133
175
1828
299
2698
202
2273
226
1109
275
3862
124
68
377
4903
265
1123
203
3846
263
2802
98
2090
151
3039
61
1054
nystatin; oral
A07AA02 [21600604]
A07AA02 [21600604]
1.2e+00
-1.0e+50
—
—
—
3.7e+00
2.7e+00
cases:1.80%
controls:0.56%
cases:0.00%
controls:0.32%
—
—
—
—
—
—
cases:11.91%
controls:0.35%
cases:11.79%
controls:0.86%
9
28
490
4933
0
16
501
4955
—
—
—
43
17
318
4875
25
35
187
4058
Bone marrow biopsy
XW000 [2001310618]
XW000 [2001310618]
—
—
1.0e+50
1.0e+50
1.0e+50
—
6.3e+00
—
—
—
—
cases:7.78%
controls:0.00%
cases:17.76%
controls:0.00%
cases:11.75%
controls:0.00%
—
—
cases:49.53%
controls:0.17%
—
—
39
0
462
4971
89
0
412
4971
55
0
413
4969
—
105
7
107
4086
pH of Urine
2756-5 [3015736]
2756-5 [3015736]
-1.2e-01
-6.6e-02
1.7e+00
—
3.2e+00
1.4e+00
1.3e-01
cases:7.62%
controls:8.47%
cases:4.19%
controls:4.47%
cases:3.59%
controls:0.66%
—
—
cases:11.11%
controls:0.48%
cases:15.51%
controls:4.54%
cases:15.57%
controls:13.90%
38
420
461
4541
21
222
480
4749
18
33
483
4938
—
52
24
416
4945
56
222
305
4670
33
569
179
3524
Natriuretic peptide B [Mass/volume] in Serum or Plasma
30934-4 [3011960]
30934-4 [3011960]
4.4e-01
3.2e-01
2.0e+00
—
3.1e+00
1.2e+00
6.0e-01
cases:4.21%
controls:2.74%
cases:1.80%
controls:1.31%
cases:1.20%
controls:0.16%
—
—
cases:2.56%
controls:0.12%
cases:3.88%
controls:1.19%
cases:4.25%
controls:2.37%
21
136
478
4825
9
65
492
4906
6
8
495
4963
—
12
6
456
4963
14
58
347
4834
9
97
203
3996
Hemoglobin [Entitic mass] in Reticulocytes
42810-2 [3029080]
42810-2 [3029080]
—
—
—
1.0e+50
1.0e+50
3.4e+00
2.9e+00
—
—
—
—
—
—
cases:2.20%
controls:0.00%
cases:3.42%
controls:0.00%
cases:4.16%
controls:0.14%
cases:5.66%
controls:0.34%
—
—
—
11
0
490
4971
16
0
452
4969
15
7
346
4885
12
14
200
4079
Bacteria identified in Urine by Culture
630-4 [3026008]
630-4 [3026008]
3.7e-01
6.1e-02
1.6e+00
—
2.9e+00
1.8e+00
5.2e-01
cases:8.62%
controls:6.13%
cases:3.39%
controls:3.20%
cases:2.99%
controls:0.60%
—
—
cases:8.76%
controls:0.54%
cases:18.01%
controls:3.62%
cases:15.57%
controls:9.85%
43
304
456
4657
17
159
484
4812
15
30
486
4941
—
41
27
427
4942
65
177
296
4715
33
403
179
3690
Carcinoembryonic Ag [Mass/volume] in Serum or Plasma
2039-6 [3003785]
2039-6 [3003785]
1.5e+00
2.3e+00
—
—
—
2.5e+00
—
cases:4.41%
controls:1.01%
cases:3.39%
controls:0.36%
—
—
—
—
—
—
cases:3.05%
controls:0.27%
—
—
22
50
477
4911
17
18
484
4953
—
—
—
11
13
350
4879
—
Scheduled procedure
ZXD10 [2001311387]
ZXD10 [2001311387]
3.2e-01
-3.6e-02
—
—
2.4e+00
2.4e+00
1.4e+00
cases:8.22%
controls:6.13%
cases:1.40%
controls:1.45%
—
—
—
—
cases:1.07%
controls:0.10%
cases:8.31%
controls:0.80%
cases:12.26%
controls:3.20%
41
304
458
4657
7
72
494
4899
—
—
5
5
463
4964
30
39
331
4853
26
131
186
3962
Protein [Presence] in Urine by Test strip
20454-5 [3014051]
20454-5 [3014051]
1.0e-01
1.8e-01
1.5e+00
1.0e+50
3.4e+00
1.3e+00
-1.2e-01
cases:4.61%
controls:4.17%
cases:3.19%
controls:2.68%
cases:1.80%
controls:0.40%
cases:1.80%
controls:0.00%
cases:6.62%
controls:0.24%
cases:10.53%
controls:3.03%
cases:8.49%
controls:9.43%
23
207
476
4754
16
133
485
4838
9
20
492
4951
9
0
492
4971
31
12
437
4957
38
148
323
4744
18
386
194
3707
Segmented neutrophils/Leukocytes in Blood
26505-8 [3017354]
26505-8 [3017354]
2.4e+00
—
1.0e+50
1.0e+50
—
1.0e+50
3.7e+00
cases:1.60%
controls:0.14%
—
—
cases:3.99%
controls:0.00%
cases:4.59%
controls:0.00%
—
—
cases:9.97%
controls:0.00%
cases:5.66%
controls:0.15%
8
7
491
4954
—
20
0
481
4971
23
0
478
4971
—
36
0
325
4892
12
6
200
4087
Essential (primary) hypertension
I10 [45591453]
I10 [45591453]
-1.8e-02
-3.2e-01
8.2e-01
3.9e+00
1.4e+00
3.9e-01
-4.7e-01
cases:21.04%
controls:21.35%
cases:8.38%
controls:11.20%
cases:4.39%
controls:1.99%
cases:4.79%
controls:0.10%
cases:7.69%
controls:1.97%
cases:17.17%
controls:12.29%
cases:20.75%
controls:29.61%
105
1059
394
3902
42
557
459
4414
22
99
479
4872
24
5
477
4966
36
98
432
4871
62
601
299
4291
44
1212
168
2881
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
4537-7 [3013707]
1.5e-01
6.6e-01
2.3e+00
—
2.6e+00
5.7e-01
2.2e-01
cases:21.44%
controls:19.03%
cases:17.76%
controls:10.06%
cases:13.97%
controls:1.59%
—
—
cases:15.17%
controls:1.35%
cases:16.34%
controls:9.98%
cases:27.83%
controls:23.70%
107
944
392
4017
89
500
412
4471
70
79
431
4892
—
71
67
397
4902
59
488
302
4404
59
970
153
3123
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
2514-8 [3035350]
-3.3e-02
-1.9e-02
1.7e+00
—
3.2e+00
1.2e+00
4.2e-02
cases:9.82%
controls:10.12%
cases:5.79%
controls:5.89%
cases:4.99%
controls:0.93%
—
—
cases:13.03%
controls:0.62%
cases:18.28%
controls:6.36%
cases:19.34%
controls:18.69%
49
502
450
4459
29
293
472
4678
25
46
476
4925
—
61
31
407
4938
66
311
295
4581
41
765
171
3328
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
25428-4 [3009261]
2.0e-02
-1.2e-02
1.7e+00
—
3.1e+00
1.2e+00
7.1e-02
cases:10.42%
controls:10.24%
cases:5.99%
controls:6.06%
cases:4.99%
controls:0.93%
—
—
cases:12.82%
controls:0.64%
cases:18.56%
controls:6.36%
cases:19.81%
controls:18.71%
52
508
447
4453
30
301
471
4670
25
46
476
4925
—
60
32
408
4937
67
311
294
4581
42
766
170
3327
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
5802-4 [3021601]
-1.3e-02
-4.9e-02
1.7e+00
—
3.1e+00
1.2e+00
9.5e-02
cases:9.82%
controls:9.94%
cases:5.59%
controls:5.85%
cases:4.79%
controls:0.91%
—
—
cases:12.61%
controls:0.62%
cases:18.28%
controls:6.38%
cases:19.81%
controls:18.35%
49
493
450
4468
28
291
473
4680
24
45
477
4926
—
59
31
409
4938
66
312
295
4580
42
751
170
3342
Palliative care
Z51.5 [45547323]
Z51.5 [45547323]
—
—
—
1.0e+50
—
3.2e+00
2.8e+00
—
—
—
—
—
—
cases:1.40%
controls:0.00%
—
—
cases:5.26%
controls:0.22%
cases:7.55%
controls:0.49%
—
—
—
7
0
494
4971
—
19
11
342
4881
16
20
196
4073
Thorax CT examination
GD1AD [2001303618]
GD1AD [2001303618]
—
—
—
1.0e+50
—
3.7e+00
2.3e+00
—
—
—
—
—
—
cases:1.40%
controls:0.00%
—
—
cases:6.93%
controls:0.18%
cases:6.60%
controls:0.71%
—
—
—
7
0
494
4971
—
25
9
336
4883
14
29
198
4064
Thorax extensive CT-examination
GD1BD [2001303621]
GD1BD [2001303621]
9.2e-01
—
—
—
—
3.0e+00
3.0e+00
cases:1.00%
controls:0.40%
—
—
—
—
—
—
—
—
cases:1.94%
controls:0.10%
cases:2.36%
controls:0.12%
5
20
494
4941
—
—
—
—
7
5
354
4887
5
5
207
4088
Chloride [Moles/volume] in Serum or Plasma
2075-0 [3014576]
2075-0 [3014576]
1.6e-01
2.4e-01
2.6e+00
1.0e+50
—
2.2e+00
1.1e+00
cases:2.61%
controls:2.24%
cases:1.20%
controls:0.95%
cases:1.40%
controls:0.10%
cases:1.60%
controls:0.00%
—
—
cases:9.70%
controls:1.19%
cases:10.85%
controls:3.91%
13
111
486
4850
6
47
495
4924
7
5
494
4966
8
0
493
4971
—
35
58
326
4834
23
160
189
3933
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
2324-2 [3026910]
1.6e-01
3.4e-01
2.0e+00
—
2.7e+00
1.2e+00
4.0e-01
cases:16.83%
controls:14.67%
cases:9.58%
controls:7.00%
cases:5.39%
controls:0.74%
—
—
cases:10.04%
controls:0.74%
cases:19.11%
controls:6.93%
cases:25.00%
controls:18.20%
84
728
415
4233
48
348
453
4623
27
37
474
4934
—
47
37
421
4932
69
339
292
4553
53
745
159
3348
Thrombin time
3243-3 [3036489]
3243-3 [3036489]
—
—
—
1.0e+50
1.0e+50
3.9e+00
2.0e+00
—
—
—
—
—
—
cases:2.99%
controls:0.00%
cases:8.55%
controls:0.00%
cases:5.54%
controls:0.12%
cases:4.72%
controls:0.66%
—
—
—
15
0
486
4971
40
0
428
4969
20
6
341
4886
10
27
202
4066
Upper gastrointestinal surgery
106 [44777669]
106 [44777669]
4.1e-01
5.0e-01
2.3e+00
—
1.6e+00
1.3e+00
7.1e-01
cases:12.83%
controls:8.87%
cases:4.79%
controls:2.96%
cases:2.79%
controls:0.30%
—
—
cases:1.92%
controls:0.38%
cases:10.53%
controls:3.19%
cases:17.92%
controls:9.72%
64
440
435
4521
24
147
477
4824
14
15
487
4956
—
9
19
459
4950
38
156
323
4736
38
398
174
3695
Protein electrophoresis panel - Serum or Plasma
24351-9 [3004588]
24351-9 [3004588]
6.6e-01
1.7e+00
—
1.0e+50
4.1e+00
1.0e+00
9.5e-01
cases:2.20%
controls:1.15%
cases:2.99%
controls:0.54%
—
—
cases:3.39%
controls:0.00%
cases:6.84%
controls:0.12%
cases:1.66%
controls:0.61%
cases:4.25%
controls:1.69%
11
57
488
4904
15
27
486
4944
—
17
0
484
4971
32
6
436
4963
6
30
355
4862
9
69
203
4024
nystatin; vaginal
G01AA01 [21602363]
G01AA01 [21602363]
1.2e+00
-1.0e+50
—
—
—
3.1e+00
2.7e+00
cases:1.20%
controls:0.38%
cases:0.00%
controls:0.14%
—
—
—
—
—
—
cases:4.43%
controls:0.20%
cases:6.13%
controls:0.44%
6
19
493
4942
0
7
501
4964
—
—
—
16
10
345
4882
13
18
199
4075
nystatin
D01AA01 [21601911]
D01AA01 [21601911]
1.2e+00
-1.0e+50
—
—
—
3.1e+00
2.7e+00
cases:1.20%
controls:0.38%
cases:0.00%
controls:0.14%
—
—
—
—
—
—
cases:4.43%
controls:0.20%
cases:6.13%
controls:0.44%
6
19
493
4942
0
7
501
4964
—
—
—
16
10
345
4882
13
18
199
4075
metronidazole and furazolidone
P01AB51 [45893518]
P01AB51 [45893518]
1.2e+00
-1.0e+50
—
—
—
3.1e+00
2.7e+00
cases:1.20%
controls:0.38%
cases:0.00%
controls:0.14%
—
—
—
—
—
—
cases:4.43%
controls:0.20%
cases:6.13%
controls:0.44%
6
19
493
4942
0
7
501
4964
—
—
—
16
10
345
4882
13
18
199
4075
Hepatitis B virus core Ab [Presence] in Serum
16933-4 [3021879]
16933-4 [3021879]
4.2e-01
1.5e+00
—
—
—
3.7e+00
2.1e+00
cases:1.40%
controls:0.93%
cases:1.40%
controls:0.30%
—
—
—
—
—
—
cases:12.47%
controls:0.35%
cases:6.13%
controls:0.81%
7
46
492
4915
7
15
494
4956
—
—
—
45
17
316
4875
13
33
199
4060
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
3016-3 [3009201]
-5.7e-02
3.1e-02
1.3e+00
3.2e+00
1.2e+00
-1.3e-01
-8.8e-02
cases:26.05%
controls:27.17%
cases:16.17%
controls:15.75%
cases:6.79%
controls:1.95%
cases:2.99%
controls:0.12%
cases:6.41%
controls:1.99%
cases:14.96%
controls:16.70%
cases:33.96%
controls:35.96%
130
1348
369
3613
81
783
420
4188
34
97
467
4874
15
6
486
4965
30
99
438
4870
54
817
307
4075
72
1472
140
2621
metronidazole; oral, rectal
P01AB01 [21604857]
P01AB01 [21604857]
4.2e-01
6.5e-01
2.8e+00
—
—
2.1e+00
8.7e-01
cases:8.22%
controls:5.56%
cases:2.59%
controls:1.37%
cases:2.20%
controls:0.14%
—
—
—
—
cases:9.97%
controls:1.33%
cases:11.32%
controls:5.08%
41
276
458
4685
13
68
488
4903
11
7
490
4964
—
—
36
65
325
4827
24
208
188
3885
allopurinol; oral, parenteral
M04AA01 [21604131]
M04AA01 [21604131]
6.0e-01
4.4e-01
4.0e-01
—
2.7e+00
1.8e+00
1.3e+00
cases:6.81%
controls:3.87%
cases:4.79%
controls:3.14%
cases:1.40%
controls:0.95%
—
—
cases:11.75%
controls:0.93%
cases:17.17%
controls:3.39%
cases:14.15%
controls:4.42%
34
192
465
4769
24
156
477
4815
7
47
494
4924
—
55
46
413
4923
62
166
299
4726
30
181
182
3912
Emergency Medicine
93 [38004510]
93 [38004510]
2.1e-01
4.0e-01
2.3e+00
—
2.0e+00
1.4e+00
3.3e-01
cases:17.43%
controls:14.63%
cases:11.98%
controls:8.33%
cases:10.58%
controls:1.21%
—
—
cases:8.76%
controls:1.23%
cases:27.70%
controls:8.79%
cases:30.66%
controls:24.21%
87
726
412
4235
60
414
441
4557
53
60
448
4911
—
41
61
427
4908
100
430
261
4462
65
991
147
3102
Tissue Pathology biopsy report
66121-5 [40768804]
66121-5 [40768804]
7.3e-01
6.5e-01
—
—
2.8e+00
1.2e+00
9.0e-01
cases:12.02%
controls:6.17%
cases:4.39%
controls:2.33%
—
—
—
—
cases:1.92%
controls:0.12%
cases:5.82%
controls:1.82%
cases:12.74%
controls:5.59%
60
306
439
4655
22
116
479
4855
—
—
9
6
459
4963
21
89
340
4803
27
229
185
3864
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
50949-7 [3029937]
-2.1e-02
-2.3e-01
1.8e+00
—
2.8e+00
1.0e+00
6.7e-02
cases:5.81%
controls:5.93%
cases:2.59%
controls:3.24%
cases:3.19%
controls:0.54%
—
—
cases:6.41%
controls:0.42%
cases:8.59%
controls:3.33%
cases:10.38%
controls:9.77%
29
294
470
4667
13
161
488
4810
16
27
485
4944
—
30
21
438
4948
31
163
330
4729
22
400
190
3693
FEV1
20150-9 [3024653]
20150-9 [3024653]
3.2e-01
1.2e+00
—
—
—
2.9e+00
2.7e+00
cases:3.21%
controls:2.36%
cases:2.40%
controls:0.76%
—
—
—
—
—
—
cases:7.48%
controls:0.45%
cases:12.74%
controls:0.98%
16
117
483
4844
12
38
489
4933
—
—
—
27
22
334
4870
27
40
185
4053
FEV1/FVC
19926-5 [3011505]
19926-5 [3011505]
3.2e-01
1.2e+00
—
—
—
2.9e+00
2.7e+00
cases:3.21%
controls:2.36%
cases:2.40%
controls:0.76%
—
—
—
—
—
—
cases:7.48%
controls:0.45%
cases:12.74%
controls:0.98%
16
117
483
4844
12
38
489
4933
—
—
—
27
22
334
4870
27
40
185
4053
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
19870-5 [3020158]
3.2e-01
1.2e+00
—
—
—
2.9e+00
2.7e+00
cases:3.21%
controls:2.36%
cases:2.40%
controls:0.76%
—
—
—
—
—
—
cases:7.48%
controls:0.45%
cases:12.74%
controls:0.98%
16
117
483
4844
12
38
489
4933
—
—
—
27
22
334
4870
27
40
185
4053
triamcinolone and antiinfectives
S02CA04 [21605176]
S02CA04 [21605176]
1.1e+00
—
—
—
—
3.0e+00
2.5e+00
cases:1.20%
controls:0.40%
—
—
—
—
—
—
—
—
cases:4.43%
controls:0.22%
cases:6.13%
controls:0.54%
6
20
493
4941
—
—
—
—
16
11
345
4881
13
22
199
4071
Pediatric Medicine
37 [38004477]
37 [38004477]
-7.1e-02
—
—
—
2.3e+00
1.7e+00
1.5e+00
cases:1.20%
controls:1.29%
—
—
—
—
—
—
cases:2.35%
controls:0.24%
cases:3.32%
controls:0.65%
cases:5.19%
controls:1.15%
6
64
493
4897
—
—
—
11
12
457
4957
12
32
349
4860
11
47
201
4046
Procalcitonin [Mass/volume] in Serum or Plasma
33959-8 [3046279]
33959-8 [3046279]
1.2e+00
—
—
—
—
3.4e+00
2.1e+00
cases:1.40%
controls:0.44%
—
—
—
—
—
—
—
—
cases:7.48%
controls:0.27%
cases:8.49%
controls:1.15%
7
22
492
4939
—
—
—
—
27
13
334
4879
18
47
194
4046
Bilirubin.conjugated [Moles/volume] in Serum or Plasma
29760-6 [3005772]
29760-6 [3005772]
8.1e-01
1.1e+00
—
1.0e+50
—
3.2e+00
2.3e+00
cases:3.21%
controls:1.45%
cases:2.00%
controls:0.68%
—
—
cases:2.00%
controls:0.00%
—
—
cases:13.85%
controls:0.65%
cases:17.45%
controls:2.10%
16
72
483
4889
10
34
491
4937
—
10
0
491
4971
—
50
32
311
4860
37
86
175
4007
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
207NI0002X [38003841]
5.4e-01
9.6e-01
1.0e+00
—
1.9e+00
1.4e+00
1.2e+00
cases:9.82%
controls:5.97%
cases:6.39%
controls:2.55%
cases:1.20%
controls:0.44%
—
—
cases:1.92%
controls:0.28%
cases:8.86%
controls:2.35%
cases:16.98%
controls:5.84%
49
296
450
4665
32
127
469
4844
6
22
495
4949
—
9
14
459
4955
32
115
329
4777
36
239
176
3854
Influenza virus B RNA [Presence] in Nasopharynx by NAA with probe detection
76080-1 [46235759]
76080-1 [46235759]
1.4e+00
1.1e+00
—
1.0e+50
—
3.6e+00
1.9e+00
cases:2.00%
controls:0.52%
cases:1.00%
controls:0.32%
—
—
cases:2.20%
controls:0.00%
—
—
cases:8.86%
controls:0.27%
cases:6.60%
controls:1.08%
10
26
489
4935
5
16
496
4955
—
11
0
490
4971
—
32
13
329
4879
14
44
198
4049
Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma
14685-2 [3009035]
14685-2 [3009035]
1.4e-01
6.0e-01
2.1e+00
1.0e+50
2.3e+00
1.1e+00
1.9e-01
cases:6.21%
controls:5.44%
cases:4.19%
controls:2.35%
cases:1.80%
controls:0.22%
cases:1.00%
controls:0.00%
cases:2.14%
controls:0.22%
cases:5.82%
controls:2.11%
cases:7.08%
controls:5.94%
31
270
468
4691
21
117
480
4854
9
11
492
4960
5
0
496
4971
10
11
458
4958
21
103
340
4789
15
243
197
3850
methylprednisolone; oral, parenteral
H02AB04 [21602732]
H02AB04 [21602732]
1.4e-01
5.1e-01
-1.0e+50
—
-1.0e+50
3.1e+00
2.4e+00
cases:2.40%
controls:2.10%
cases:1.20%
controls:0.72%
cases:0.00%
controls:0.12%
—
—
cases:0.00%
controls:0.10%
cases:10.53%
controls:0.55%
cases:16.98%
controls:1.83%
12
104
487
4857
6
36
495
4935
0
6
501
4965
—
0
5
468
4964
38
27
323
4865
36
75
176
4018
magnesium hydroxide; oral
G04BX01 [21602658]
G04BX01 [21602658]
1.2e+00
—
—
—
—
3.6e+00
1.7e+00
cases:1.00%
controls:0.30%
—
—
—
—
—
—
—
—
cases:7.20%
controls:0.20%
cases:4.72%
controls:0.86%
5
15
494
4946
—
—
—
—
26
10
335
4882
10
35
202
4058
magnesium hydroxide; oral
A02AA04 [21600052]
A02AA04 [21600052]
1.2e+00
—
—
—
—
3.6e+00
1.7e+00
cases:1.00%
controls:0.30%
—
—
—
—
—
—
—
—
cases:7.20%
controls:0.20%
cases:4.72%
controls:0.86%
5
15
494
4946
—
—
—
—
26
10
335
4882
10
35
202
4058
Panorama tomography of teeth and jaws or similar X-ray examination
EB1HA [2001301913]
EB1HA [2001301913]
6.1e-02
8.7e-02
2.3e+00
1.0e+50
—
2.0e+00
1.0e+00
cases:9.02%
controls:8.53%
cases:1.80%
controls:1.65%
cases:1.60%
controls:0.16%
cases:6.39%
controls:0.00%
—
—
cases:10.25%
controls:1.47%
cases:16.98%
controls:6.87%
45
423
454
4538
9
82
492
4889
8
8
493
4963
32
0
469
4971
—
37
72
324
4820
36
281
176
3812
prednisolone; oral, parenteral
H02AB06 [21602734]
H02AB06 [21602734]
3.2e-01
6.5e-01
1.2e+00
—
1.3e+00
1.5e+00
7.4e-01
cases:15.43%
controls:11.71%
cases:9.78%
controls:5.37%
cases:2.99%
controls:0.95%
—
—
cases:4.06%
controls:1.17%
cases:20.50%
controls:5.42%
cases:24.06%
controls:13.10%
77
581
422
4380
49
267
452
4704
15
47
486
4924
—
19
58
449
4911
74
265
287
4627
51
536
161
3557
Treatment plan or consultation
WZC00 [2001310885]
WZC00 [2001310885]
1.0e+00
7.6e-01
—
1.0e+50
—
2.9e+00
1.5e+00
cases:8.42%
controls:3.29%
cases:2.59%
controls:1.23%
—
—
cases:1.00%
controls:0.00%
—
—
cases:14.40%
controls:0.94%
cases:18.87%
controls:5.06%
42
163
457
4798
13
61
488
4910
—
5
0
496
4971
—
52
46
309
4846
40
207
172
3886
lorazepam; oral, parenteral, sublingual
N05BA06 [21604571]
N05BA06 [21604571]
6.4e-01
8.4e-01
—
—
—
3.6e+00
1.7e+00
cases:1.40%
controls:0.75%
cases:1.20%
controls:0.52%
—
—
—
—
—
—
cases:14.68%
controls:0.47%
cases:6.60%
controls:1.22%
7
37
492
4924
6
26
495
4945
—
—
—
53
23
308
4869
14
50
198
4043
prednisolone
A07EA01 [21600653]
A07EA01 [21600653]
3.1e-01
6.4e-01
1.2e+00
—
1.3e+00
1.5e+00
7.4e-01
cases:15.43%
controls:11.77%
cases:9.78%
controls:5.43%
cases:2.99%
controls:0.95%
—
—
cases:4.06%
controls:1.17%
cases:20.50%
controls:5.42%
cases:24.06%
controls:13.10%
77
584
422
4377
49
270
452
4701
15
47
486
4924
—
19
58
449
4911
74
265
287
4627
51
536
161
3557
Extensive abdominal CT
JN3BD [2001305556]
JN3BD [2001305556]
7.6e-01
—
—
1.0e+50
—
3.1e+00
2.2e+00
cases:2.61%
controls:1.23%
—
—
—
—
cases:1.00%
controls:0.00%
—
—
cases:2.77%
controls:0.12%
cases:3.77%
controls:0.44%
13
61
486
4900
—
—
5
0
496
4971
—
10
6
351
4886
8
18
204
4075
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
2157-6 [3007220]
-2.1e-01
5.2e-01
1.8e+00
—
2.5e+00
1.1e+00
4.7e-01
cases:5.61%
controls:6.81%
cases:4.39%
controls:2.66%
cases:1.40%
controls:0.24%
—
—
cases:2.99%
controls:0.26%
cases:8.03%
controls:2.92%
cases:14.15%
controls:9.31%
28
338
471
4623
22
132
479
4839
7
12
494
4959
—
14
13
454
4956
29
143
332
4749
30
381
182
3712
Respiratory syncytial virus RNA [Presence] in Specimen by NAA with probe detection
40988-8 [3044254]
40988-8 [3044254]
9.7e-01
—
—
1.0e+50
—
3.4e+00
1.9e+00
cases:1.00%
controls:0.38%
—
—
—
—
cases:2.00%
controls:0.00%
—
—
cases:7.20%
controls:0.27%
cases:6.13%
controls:0.95%
5
19
494
4942
—
—
10
0
491
4971
—
26
13
335
4879
13
39
199
4054
Psychiatry
26 [38004469]
26 [38004469]
6.9e-02
-2.3e-01
9.8e-01
—
2.2e+00
1.7e+00
1.3e+00
cases:4.01%
controls:3.75%
cases:1.20%
controls:1.51%
cases:1.60%
controls:0.60%
—
—
cases:5.34%
controls:0.62%
cases:8.86%
controls:1.72%
cases:12.26%
controls:3.52%
20
186
479
4775
6
75
495
4896
8
30
493
4941
—
25
31
443
4938
32
84
329
4808
26
144
186
3949
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
53292-9 [3041096]
1.6e-01
1.8e-01
1.9e+00
—
2.4e+00
9.8e-01
1.3e-01
cases:6.21%
controls:5.36%
cases:3.59%
controls:3.02%
cases:3.19%
controls:0.50%
—
—
cases:2.99%
controls:0.28%
cases:7.76%
controls:3.05%
cases:9.91%
controls:8.77%
31
266
468
4695
18
150
483
4821
16
25
485
4946
—
14
14
454
4955
28
149
333
4743
21
359
191
3734
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
16128-1 [3017143]
6.2e-01
7.8e-01
—
—
—
3.3e+00
2.0e+00
cases:3.21%
controls:1.75%
cases:1.40%
controls:0.64%
—
—
—
—
—
—
cases:12.19%
controls:0.53%
cases:8.49%
controls:1.29%
16
87
483
4874
7
32
494
4939
—
—
—
44
26
317
4866
18
53
194
4040
EKG study
11524-6 [3013512]
11524-6 [3013512]
2.7e-01
2.8e-01
1.6e+00
1.0e+50
2.7e+00
9.3e-01
2.2e-01
cases:11.42%
controls:8.95%
cases:6.39%
controls:4.89%
cases:3.19%
controls:0.66%
cases:4.19%
controls:0.00%
cases:8.33%
controls:0.62%
cases:11.91%
controls:5.07%
cases:15.09%
controls:12.48%
57
444
442
4517
32
243
469
4728
16
33
485
4938
21
0
480
4971
39
31
429
4938
43
248
318
4644
32
511
180
3582
Morphology [Interpretation] in Bone marrow Narrative
51628-6 [3042111]
51628-6 [3042111]
—
—
1.0e+50
1.0e+50
1.0e+50
1.0e+50
5.2e+00
—
—
—
—
cases:4.59%
controls:0.00%
cases:8.58%
controls:0.00%
cases:21.79%
controls:0.00%
cases:27.98%
controls:0.00%
cases:25.47%
controls:0.20%
—
—
23
0
478
4971
43
0
458
4971
102
0
366
4969
101
0
260
4892
54
8
158
4085
Oral Surgery
19 [38004464]
19 [38004464]
—
—
—
—
—
3.3e+00
1.8e+00
—
—
—
—
—
—
—
—
—
—
cases:4.43%
controls:0.16%
cases:3.77%
controls:0.64%
—
—
—
—
—
16
8
345
4884
8
26
204
4067
Base excess in Arterial blood by calculation
1925-7 [3003396]
1925-7 [3003396]
4.3e-01
—
—
1.0e+50
3.3e+00
1.8e+00
3.0e-01
cases:3.41%
controls:2.24%
—
—
—
—
cases:1.20%
controls:0.00%
cases:2.78%
controls:0.10%
cases:5.26%
controls:0.92%
cases:4.25%
controls:3.18%
17
111
482
4850
—
—
6
0
495
4971
13
5
455
4964
19
45
342
4847
9
130
203
3963
Bacteria identified based on 16S rRNA gene [Identifier] in Specimen by Sequencing
66885-5 [40769539]
66885-5 [40769539]
—
—
—
—
—
3.3e+00
1.8e+00
—
—
—
—
—
—
—
—
—
—
cases:3.88%
controls:0.14%
cases:3.30%
controls:0.59%
—
—
—
—
—
14
7
347
4885
7
24
205
4069
Hepatitis B virus surface Ag [Presence] in Serum
5195-3 [3019284]
5195-3 [3019284]
4.8e-01
9.8e-01
—
—
—
3.3e+00
1.7e+00
cases:2.81%
controls:1.75%
cases:1.60%
controls:0.60%
—
—
—
—
—
—
cases:13.85%
controls:0.57%
cases:9.43%
controls:1.78%
14
87
485
4874
8
30
493
4941
—
—
—
50
28
311
4864
20
73
192
4020
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Blood
47598-8 [3048816]
47598-8 [3048816]
2.2e-01
4.6e-01
—
1.0e+50
3.5e+00
1.6e+00
6.1e-01
cases:1.40%
controls:1.13%
cases:1.40%
controls:0.89%
—
—
cases:1.60%
controls:0.00%
cases:5.13%
controls:0.16%
cases:4.71%
controls:1.02%
cases:4.25%
controls:2.35%
7
56
492
4905
7
44
494
4927
—
8
0
493
4971
24
8
444
4961
17
50
344
4842
9
96
203
3997
FEV1/FVC --post bronchodilation
69970-2 [42868459]
69970-2 [42868459]
1.3e-01
9.5e-01
—
—
—
2.6e+00
2.4e+00
cases:2.40%
controls:2.12%
cases:1.40%
controls:0.54%
—
—
—
—
—
—
cases:4.43%
controls:0.33%
cases:8.96%
controls:0.88%
12
105
487
4856
7
27
494
4944
—
—
—
16
16
345
4876
19
36
193
4057
FVC percent change Respiratory system
69982-7 [42868471]
69982-7 [42868471]
1.3e-01
9.5e-01
—
—
—
2.6e+00
2.4e+00
cases:2.40%
controls:2.12%
cases:1.40%
controls:0.54%
—
—
—
—
—
—
cases:4.43%
controls:0.33%
cases:8.96%
controls:0.88%
12
105
487
4856
7
27
494
4944
—
—
—
16
16
345
4876
19
36
193
4057
FEV1 --post bronchodilation
20155-8 [3023550]
20155-8 [3023550]
1.3e-01
9.5e-01
—
—
—
2.6e+00
2.4e+00
cases:2.40%
controls:2.12%
cases:1.40%
controls:0.54%
—
—
—
—
—
—
cases:4.43%
controls:0.33%
cases:8.96%
controls:0.88%
12
105
487
4856
7
27
494
4944
—
—
—
16
16
345
4876
19
36
193
4057
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
19875-4 [3001668]
1.3e-01
9.5e-01
—
—
—
2.6e+00
2.4e+00
cases:2.40%
controls:2.12%
cases:1.40%
controls:0.54%
—
—
—
—
—
—
cases:4.43%
controls:0.33%
cases:8.96%
controls:0.88%
12
105
487
4856
7
27
494
4944
—
—
—
16
16
345
4876
19
36
193
4057
FEV1 percent change
69983-5 [42868472]
69983-5 [42868472]
1.3e-01
9.5e-01
—
—
—
2.6e+00
2.4e+00
cases:2.40%
controls:2.12%
cases:1.40%
controls:0.54%
—
—
—
—
—
—
cases:4.43%
controls:0.33%
cases:8.96%
controls:0.88%
12
105
487
4856
7
27
494
4944
—
—
—
16
16
345
4876
19
36
193
4057
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
60026-2 [40763086]
5.8e-02
-8.2e-02
1.8e+00
—
2.5e+00
8.0e-01
1.3e-01
cases:9.22%
controls:8.75%
cases:4.39%
controls:4.75%
cases:4.59%
controls:0.80%
—
—
cases:5.56%
controls:0.50%
cases:10.25%
controls:4.89%
cases:14.62%
controls:13.05%
46
434
453
4527
22
236
479
4735
23
40
478
4931
—
26
25
442
4944
37
239
324
4653
31
534
181
3559
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
6598-7 [3019800]
2.6e-02
3.2e-01
1.7e+00
1.0e+50
2.4e+00
9.3e-01
2.8e-01
cases:9.82%
controls:9.59%
cases:5.99%
controls:4.41%
cases:3.99%
controls:0.76%
cases:4.59%
controls:0.00%
cases:5.56%
controls:0.52%
cases:11.36%
controls:4.80%
cases:16.51%
controls:13.00%
49
476
450
4485
30
219
471
4752
20
38
481
4933
23
0
478
4971
26
26
442
4943
41
235
320
4657
35
532
177
3561
pH of Arterial blood
2744-1 [3019977]
2744-1 [3019977]
3.8e-01
—
—
1.0e+50
3.3e+00
1.8e+00
3.9e-01
cases:3.21%
controls:2.22%
—
—
—
—
cases:1.00%
controls:0.00%
cases:2.56%
controls:0.10%
cases:5.26%
controls:0.94%
cases:4.72%
controls:3.25%
16
110
483
4851
—
—
5
0
496
4971
12
5
456
4964
19
46
342
4846
10
133
202
3960
Neck ultrasound examination
EP1AE [2001302284]
EP1AE [2001302284]
1.3e+00
—
—
—
—
2.6e+00
2.4e+00
cases:1.20%
controls:0.32%
—
—
—
—
—
—
—
—
cases:1.94%
controls:0.14%
cases:3.30%
controls:0.32%
6
16
493
4945
—
—
—
—
7
7
354
4885
7
13
205
4080
Extensive CT examination of arteria pulmonalis
FB1BD [2001302407]
FB1BD [2001302407]
9.5e-01
—
—
—
—
2.9e+00
2.0e+00
cases:2.00%
controls:0.79%
—
—
—
—
—
—
—
—
cases:3.32%
controls:0.18%
cases:4.72%
controls:0.66%
10
39
489
4922
—
—
—
—
12
9
349
4883
10
27
202
4066
Gastroenterology
10 [38004455]
10 [38004455]
3.8e-01
6.4e-01
2.2e+00
—
1.6e+00
1.1e+00
5.2e-01
cases:7.62%
controls:5.32%
cases:4.19%
controls:2.25%
cases:2.40%
controls:0.26%
—
—
cases:1.92%
controls:0.40%
cases:5.82%
controls:2.11%
cases:9.43%
controls:5.81%
38
264
461
4697
21
112
480
4859
12
13
489
4958
—
9
20
459
4949
21
103
340
4789
20
238
192
3855
Cells panel - Urine sediment
58434-2 [40761535]
58434-2 [40761535]
-5.9e-03
—
2.0e+00
—
2.8e+00
7.8e-01
9.1e-01
cases:2.00%
controls:2.02%
—
—
cases:1.20%
controls:0.16%
—
—
cases:1.92%
controls:0.12%
cases:1.94%
controls:0.90%
cases:4.72%
controls:1.95%
10
100
489
4861
—
6
8
495
4963
—
9
6
459
4963
7
44
354
4848
10
80
202
4013
cefalexin; oral
J01DB01 [21602870]
J01DB01 [21602870]
3.7e-01
7.1e-01
1.9e+00
—
9.6e-01
1.2e+00
6.1e-01
cases:34.07%
controls:26.26%
cases:15.77%
controls:8.45%
cases:5.99%
controls:0.99%
—
—
cases:2.78%
controls:1.09%
cases:23.55%
controls:8.12%
cases:39.62%
controls:26.19%
170
1303
329
3658
79
420
422
4551
30
49
471
4922
—
13
54
455
4915
85
397
276
4495
84
1072
128
3021
One hour or less
ZXE00 [2001311394]
ZXE00 [2001311394]
1.0e-01
4.1e-01
—
1.0e+50
—
3.1e+00
1.7e+00
cases:6.81%
controls:6.19%
cases:2.00%
controls:1.33%
—
—
cases:3.39%
controls:0.00%
—
—
cases:19.94%
controls:1.10%
cases:16.04%
controls:3.44%
34
307
465
4654
10
66
491
4905
—
17
0
484
4971
—
72
54
289
4838
34
141
178
3952
Immunization
WW200 [2001310599]
WW200 [2001310599]
—
—
—
—
—
—
4.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:16.98%
controls:0.17%
—
—
—
—
—
—
36
7
176
4086
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
13317-3 [3019902]
4.3e-01
2.0e-01
—
1.0e+50
3.5e+00
1.3e+00
2.1e-01
cases:2.81%
controls:1.83%
cases:1.20%
controls:0.99%
—
—
cases:1.60%
controls:0.00%
cases:3.21%
controls:0.10%
cases:3.32%
controls:0.94%
cases:2.83%
controls:2.30%
14
91
485
4870
6
49
495
4922
—
8
0
493
4971
15
5
453
4964
12
46
349
4846
6
94
206
3999
Ultrasound examination of lower leg veins
PH2AE [2001309451]
PH2AE [2001309451]
3.2e-01
—
—
1.0e+50
—
3.1e+00
1.7e+00
cases:1.60%
controls:1.17%
—
—
—
—
cases:1.40%
controls:0.00%
—
—
cases:7.20%
controls:0.35%
cases:7.08%
controls:1.42%
8
58
491
4903
—
—
7
0
494
4971
—
26
17
335
4875
15
58
197
4035
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
14979-9 [3018677]
1.3e-01
-5.7e-02
—
1.0e+50
—
3.2e+00
1.6e+00
cases:3.81%
controls:3.37%
cases:1.20%
controls:1.27%
—
—
cases:9.18%
controls:0.00%
—
—
cases:19.94%
controls:1.02%
cases:16.04%
controls:3.81%
19
167
480
4794
6
63
495
4908
—
46
0
455
4971
—
72
50
289
4842
34
156
178
3937
Extensive MRI examination of brain with high intensity magnet
AA1CG [2001300116]
AA1CG [2001300116]
—
-1.0e+50
—
—
1.0e+50
2.6e+00
2.1e+00
—
—
cases:0.00%
controls:0.12%
—
—
—
—
cases:1.28%
controls:0.00%
cases:1.66%
controls:0.12%
cases:4.72%
controls:0.61%
—
0
6
501
4965
—
—
6
0
462
4969
6
6
355
4886
10
25
202
4068
Urinary tract ultrasound examination
KH1AE [2001306329]
KH1AE [2001306329]
—
—
—
—
—
3.0e+00
1.6e+00
—
—
—
—
—
—
—
—
—
—
cases:3.32%
controls:0.16%
cases:3.77%
controls:0.78%
—
—
—
—
—
12
8
349
4884
8
32
204
4061
CD3+CD4+ (T4 helper) cells [#/volume] in Blood
24467-3 [3028167]
24467-3 [3028167]
—
—
—
—
—
—
4.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.32%
controls:0.12%
—
—
—
—
—
—
24
5
188
4088
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
40987-0 [3043924]
-1.0e-01
5.1e-01
—
1.0e+50
—
3.1e+00
1.5e+00
cases:1.40%
controls:1.55%
cases:1.40%
controls:0.84%
—
—
cases:5.19%
controls:0.00%
—
—
cases:20.50%
controls:1.17%
cases:17.92%
controls:4.45%
7
77
492
4884
7
42
494
4929
—
26
0
475
4971
—
74
57
287
4835
38
182
174
3911
Paranasal sinuses X-ray examination without contrast
DM1AA [2001301740]
DM1AA [2001301740]
—
—
—
1.0e+50
1.0e+50
4.6e+00
—
—
—
—
—
—
—
cases:1.20%
controls:0.00%
cases:1.50%
controls:0.00%
cases:9.42%
controls:0.10%
—
—
—
—
—
6
0
495
4971
7
0
461
4969
34
5
327
4887
—
Physiotherapist
Z3226 [2001311560]
Z3226 [2001311560]
-1.3e-01
—
—
1.0e+50
—
2.9e+00
1.6e+00
cases:1.60%
controls:1.81%
—
—
—
—
cases:1.20%
controls:0.00%
—
—
cases:6.93%
controls:0.39%
cases:6.60%
controls:1.34%
8
90
491
4871
—
—
6
0
495
4971
—
25
19
336
4873
14
55
198
4038
pantoprazole; oral, parenteral
A02BC02 [21600097]
A02BC02 [21600097]
2.0e-01
3.8e-01
8.9e-01
—
1.1e+00
1.7e+00
8.8e-01
cases:21.44%
controls:18.20%
cases:14.97%
controls:10.70%
cases:5.19%
controls:2.19%
—
—
cases:6.62%
controls:2.25%
cases:39.61%
controls:10.79%
cases:39.62%
controls:21.35%
107
903
392
4058
75
532
426
4439
26
109
475
4862
—
31
112
437
4857
143
528
218
4364
84
874
128
3219
antibiotics in combination with corticosteroids
D01AA20 [21601918]
D01AA20 [21601918]
9.5e-01
—
—
—
—
2.2e+00
1.4e+00
cases:3.61%
controls:1.43%
—
—
—
—
—
—
—
—
cases:4.99%
controls:0.57%
cases:7.08%
controls:1.78%
18
71
481
4890
—
—
—
—
18
28
343
4864
15
73
197
4020
Ultrasound examination of upper part of abdomen
JN1AE [2001305517]
JN1AE [2001305517]
3.5e-01
—
—
1.0e+50
—
2.4e+00
2.2e+00
cases:1.20%
controls:0.85%
—
—
—
—
cases:2.20%
controls:0.00%
—
—
cases:2.22%
controls:0.20%
cases:5.19%
controls:0.61%
6
42
493
4919
—
—
11
0
490
4971
—
8
10
353
4882
11
25
201
4068
Fungus identified in Specimen by Culture
580-1 [3000494]
580-1 [3000494]
4.3e-01
—
—
—
—
3.3e+00
1.3e+00
cases:3.21%
controls:2.12%
—
—
—
—
—
—
—
—
cases:13.85%
controls:0.61%
cases:9.43%
controls:2.71%
16
105
483
4856
—
—
—
—
50
30
311
4862
20
111
192
3982
Bicarbonate [Moles/volume] standard in Capillary blood
19231-0 [3004490]
19231-0 [3004490]
—
—
—
—
—
2.9e+00
1.7e+00
—
—
—
—
—
—
—
—
—
—
cases:4.99%
controls:0.29%
cases:4.25%
controls:0.83%
—
—
—
—
—
18
14
343
4878
9
34
203
4059
Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]
40982-1 [3038288]
-1.9e-01
4.6e-01
—
1.0e+50
—
3.0e+00
1.5e+00
cases:1.40%
controls:1.69%
cases:1.40%
controls:0.89%
—
—
cases:4.19%
controls:0.00%
—
—
cases:19.11%
controls:1.12%
cases:15.57%
controls:4.03%
7
84
492
4877
7
44
494
4927
—
21
0
480
4971
—
69
55
292
4837
33
165
179
3928
Hemoglobin [Presence] in Urine by Test strip
5794-3 [3011397]
5794-3 [3011397]
-3.7e-01
-3.1e-01
1.4e+00
—
3.4e+00
1.1e+00
-9.1e-02
cases:3.21%
controls:4.58%
cases:2.00%
controls:2.70%
cases:1.60%
controls:0.38%
—
—
cases:8.12%
controls:0.30%
cases:8.86%
controls:3.03%
cases:7.55%
controls:8.21%
16
227
483
4734
10
134
491
4837
8
19
493
4952
—
38
15
430
4954
32
148
329
4744
16
336
196
3757
Flexible bronchoscopy
UGC12 [2001303610]
UGC12 [2001303610]
1.0e+00
—
—
—
1.0e+50
2.9e+00
1.6e+00
cases:2.00%
controls:0.75%
—
—
—
—
—
—
cases:1.28%
controls:0.00%
cases:3.88%
controls:0.22%
cases:3.77%
controls:0.78%
10
37
489
4924
—
—
—
6
0
462
4969
14
11
347
4881
8
32
204
4061
macrogol; oral
A06AD15 [21600575]
A06AD15 [21600575]
4.8e-01
—
—
—
2.4e+00
2.1e+00
3.8e-01
cases:1.80%
controls:1.13%
—
—
—
—
—
—
cases:1.07%
controls:0.10%
cases:6.09%
controls:0.78%
cases:3.77%
controls:2.61%
9
56
490
4905
—
—
—
5
5
463
4964
22
38
339
4854
8
107
204
3986
Base excess in Venous blood by calculation
1927-3 [3002032]
1927-3 [3002032]
-4.4e-01
4.7e-01
—
1.0e+50
3.1e+00
1.4e+00
4.9e-01
cases:1.20%
controls:1.85%
cases:1.60%
controls:1.01%
—
—
cases:1.40%
controls:0.00%
cases:3.85%
controls:0.18%
cases:4.99%
controls:1.33%
cases:5.66%
controls:3.54%
6
92
493
4869
8
50
493
4921
—
7
0
494
4971
18
9
450
4960
18
65
343
4827
12
145
200
3948
Infiltration anesthesia
WX110 [2001310767]
WX110 [2001310767]
2.0e-01
6.5e-02
7.5e-01
—
1.9e+00
1.7e+00
8.2e-01
cases:20.04%
controls:17.05%
cases:6.99%
controls:6.58%
cases:1.40%
controls:0.66%
—
—
cases:5.56%
controls:0.87%
cases:27.70%
controls:6.42%
cases:33.96%
controls:18.49%
100
846
399
4115
35
327
466
4644
7
33
494
4938
—
26
43
442
4926
100
314
261
4578
72
757
140
3336
pH of Venous blood
2746-6 [3012544]
2746-6 [3012544]
-3.3e-01
3.7e-01
—
1.0e+50
3.1e+00
1.3e+00
3.8e-01
cases:1.40%
controls:1.94%
cases:1.60%
controls:1.11%
—
—
cases:1.60%
controls:0.00%
cases:3.85%
controls:0.18%
cases:5.26%
controls:1.45%
cases:5.66%
controls:3.93%
7
96
492
4865
8
55
493
4916
—
8
0
493
4971
18
9
450
4960
19
71
342
4821
12
161
200
3932
Excision of other lesion extending through all layers of skin in head or neck
QAE10 [2001309784]
QAE10 [2001309784]
1.9e+00
2.3e+00
—
—
—
—
2.5e+00
cases:2.00%
controls:0.30%
cases:1.00%
controls:0.10%
—
—
—
—
—
—
—
—
cases:2.36%
controls:0.20%
10
15
489
4946
5
5
496
4966
—
—
—
—
5
8
207
4085
tacrolimus
D11AH01 [21602338]
D11AH01 [21602338]
-1.0e+50
—
—
—
—
2.6e+00
1.8e+00
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
cases:2.49%
controls:0.18%
cases:3.77%
controls:0.66%
0
32
499
4929
—
—
—
—
9
9
352
4883
8
27
204
4066
CD4 cells/Lymphocytes in Specimen
80223-1 [21494815]
80223-1 [21494815]
—
—
—
—
—
—
4.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.79%
controls:0.17%
—
—
—
—
—
—
25
7
187
4086
Monitored bed care
WX892 [2001310850]
WX892 [2001310850]
3.6e-01
—
—
—
—
2.7e+00
1.6e+00
cases:1.80%
controls:1.27%
—
—
—
—
—
—
—
—
cases:2.49%
controls:0.16%
cases:3.77%
controls:0.81%
9
63
490
4898
—
—
—
—
9
8
352
4884
8
33
204
4060
Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]
2021-4 [3021447]
-4.3e-01
4.3e-01
—
1.0e+50
3.1e+00
1.2e+00
5.1e-01
cases:1.20%
controls:1.83%
cases:1.60%
controls:1.05%
—
—
cases:1.60%
controls:0.00%
cases:3.85%
controls:0.18%
cases:4.43%
controls:1.41%
cases:6.13%
controls:3.76%
6
91
493
4870
8
52
493
4919
—
8
0
493
4971
18
9
450
4960
16
69
345
4823
13
154
199
3939
CD3 cells [#/volume] in Blood
8122-4 [3011412]
8122-4 [3011412]
—
—
—
—
—
—
4.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.43%
controls:0.15%
—
—
—
—
—
—
20
6
192
4087
Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection
95941-1 [36031861]
95941-1 [36031861]
—
—
—
1.0e+50
—
2.9e+00
1.3e+00
—
—
—
—
—
—
cases:2.59%
controls:0.00%
—
—
cases:10.25%
controls:0.61%
cases:7.55%
controls:2.10%
—
—
—
13
0
488
4971
—
37
30
324
4862
16
86
196
4007
Supine thorax X-ray examination
GD1QA [2001303648]
GD1QA [2001303648]
1.0e-01
-2.8e-02
—
1.0e+50
2.2e+00
2.1e+00
5.3e-02
cases:2.61%
controls:2.36%
cases:1.00%
controls:1.03%
—
—
cases:2.20%
controls:0.00%
cases:1.71%
controls:0.20%
cases:8.03%
controls:1.10%
cases:5.19%
controls:4.94%
13
117
486
4844
5
51
496
4920
—
11
0
490
4971
8
10
460
4959
29
54
332
4838
11
202
201
3891
CD3+CD8+ (T8 suppressor) cells [#/volume] in Blood
14135-8 [3001405]
14135-8 [3001405]
—
—
—
—
—
1.0e+50
4.2e+00
—
—
—
—
—
—
—
—
—
—
cases:4.43%
controls:0.00%
cases:8.96%
controls:0.15%
—
—
—
—
—
16
0
345
4892
19
6
193
4087
CD3+CD4+ (T4 helper) cells/cells in Blood
8123-2 [3014037]
8123-2 [3014037]
—
—
—
—
—
—
4.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.55%
controls:0.12%
—
—
—
—
—
—
16
5
196
4088
Hemoglobin A1c/Hemoglobin.total in Blood
4548-4 [3004410]
4548-4 [3004410]
-1.0e-01
-5.1e-02
1.0e+00
2.9e+00
1.1e+00
-8.6e-01
-2.8e-01
cases:26.85%
controls:28.87%
cases:18.76%
controls:19.55%
cases:6.99%
controls:2.64%
cases:2.20%
controls:0.12%
cases:7.69%
controls:2.66%
cases:10.53%
controls:21.81%
cases:33.96%
controls:40.39%
134
1432
365
3529
94
972
407
3999
35
131
466
4840
11
6
490
4965
36
132
432
4837
38
1067
323
3825
72
1653
140
2440
Specific gravity of Urine by Refractometry
5810-7 [3019150]
5810-7 [3019150]
-1.4e-01
-3.4e-01
1.7e+00
—
2.5e+00
6.3e-01
-8.3e-02
cases:4.61%
controls:5.26%
cases:2.00%
controls:2.78%
cases:2.40%
controls:0.46%
—
—
cases:3.42%
controls:0.28%
cases:5.54%
controls:3.03%
cases:8.02%
controls:8.65%
23
261
476
4700
10
138
491
4833
12
23
489
4948
—
16
14
452
4955
20
148
341
4744
17
354
195
3739
Epstein Barr virus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
43730-1 [3043849]
43730-1 [3043849]
—
2.3e+00
—
1.0e+50
1.0e+50
—
4.2e+00
—
—
cases:1.00%
controls:0.10%
—
—
cases:1.60%
controls:0.00%
cases:10.90%
controls:0.00%
—
—
cases:12.74%
controls:0.22%
—
5
5
496
4966
—
8
0
493
4971
51
0
417
4969
—
27
9
185
4084
clindamycin; oral, parenteral
J01FF01 [21602985]
J01FF01 [21602985]
4.3e-01
4.2e-01
—
—
—
2.7e+00
1.4e+00
cases:5.01%
controls:3.31%
cases:1.40%
controls:0.93%
—
—
—
—
—
—
cases:9.14%
controls:0.67%
cases:9.91%
controls:2.52%
25
164
474
4797
7
46
494
4925
—
—
—
33
33
328
4859
21
103
191
3990
tranexamic acid; oral, parenteral
B02AA02 [21601036]
B02AA02 [21601036]
—
—
—
—
—
2.6e+00
1.5e+00
—
—
—
—
—
—
—
—
—
—
cases:3.88%
controls:0.31%
cases:3.77%
controls:0.83%
—
—
—
—
—
14
15
347
4877
8
34
204
4059
Neoplasm of uncertain or unknown behaviour: Skin
D48.5 [45586113]
D48.5 [45586113]
1.6e+00
2.5e+00
—
—
—
—
—
cases:1.60%
controls:0.32%
cases:1.20%
controls:0.10%
—
—
—
—
—
—
—
—
—
—
8
16
491
4945
6
5
495
4966
—
—
—
—
—
Chronic apical periodontitis
K04.5 [45586691]
K04.5 [45586691]
1.5e-01
3.6e-02
—
—
2.5e+00
1.6e+00
8.4e-01
cases:4.81%
controls:4.15%
cases:1.40%
controls:1.35%
—
—
—
—
cases:1.71%
controls:0.14%
cases:5.82%
controls:1.27%
cases:8.96%
controls:4.08%
24
206
475
4755
7
67
494
4904
—
—
8
7
460
4962
21
62
340
4830
19
167
193
3926
testosterone; oral, parenteral, rectal, sublingual, transdermal
G03BA03 [21602510]
G03BA03 [21602510]
—
—
-1.0e+50
—
-1.0e+50
2.1e+00
1.9e+00
—
—
—
—
cases:0.00%
controls:0.18%
—
—
cases:0.00%
controls:0.12%
cases:5.26%
controls:0.65%
cases:6.13%
controls:0.93%
—
—
0
9
501
4962
—
0
6
468
4963
19
32
342
4860
13
38
199
4055
Lysozyme [Mass/volume] in Serum or Plasma
2589-0 [3012110]
2589-0 [3012110]
1.2e+00
2.1e+00
1.0e+50
1.0e+50
1.0e+50
2.0e+00
2.0e+00
cases:1.60%
controls:0.48%
cases:1.00%
controls:0.12%
cases:1.20%
controls:0.00%
cases:2.40%
controls:0.00%
cases:7.48%
controls:0.00%
cases:1.66%
controls:0.22%
cases:3.30%
controls:0.44%
8
24
491
4937
5
6
496
4965
6
0
495
4971
12
0
489
4971
35
0
433
4969
6
11
355
4881
7
18
205
4075
Infectious Disease
44 [38004484]
44 [38004484]
5.0e-01
7.9e-01
2.3e+00
—
—
2.4e+00
1.6e+00
cases:2.81%
controls:1.71%
cases:1.80%
controls:0.82%
cases:1.00%
controls:0.10%
—
—
—
—
cases:6.65%
controls:0.65%
cases:8.49%
controls:1.78%
14
85
485
4876
9
41
492
4930
5
5
496
4966
—
—
24
32
337
4860
18
73
194
4020
Neutrophils [#/volume] in Blood
26499-4 [3017732]
26499-4 [3017732]
2.2e-01
5.4e-01
2.6e+00
1.0e+50
—
1.4e+00
8.6e-01
cases:1.40%
controls:1.13%
cases:1.00%
controls:0.58%
cases:1.40%
controls:0.10%
cases:1.00%
controls:0.00%
—
—
cases:3.88%
controls:1.02%
cases:7.55%
controls:3.35%
7
56
492
4905
5
29
496
4942
7
5
494
4966
5
0
496
4971
—
14
50
347
4842
16
137
196
3956
General Practice
1 [38004446]
1 [38004446]
-3.6e-02
2.8e-01
1.1e+00
—
2.0e+00
9.2e-01
3.5e-02
cases:15.43%
controls:15.90%
cases:9.18%
controls:7.10%
cases:2.99%
controls:1.05%
—
—
cases:7.05%
controls:1.01%
cases:16.90%
controls:7.52%
cases:22.17%
controls:21.57%
77
789
422
4172
46
353
455
4618
15
52
486
4919
—
33
50
435
4919
61
368
300
4524
47
883
165
3210
dexamethasone and antiinfectives
S02CA06 [21605178]
S02CA06 [21605178]
1.0e+00
-1.0e+50
—
—
—
2.5e+00
1.5e+00
cases:1.80%
controls:0.65%
cases:0.00%
controls:0.18%
—
—
—
—
—
—
cases:4.71%
controls:0.41%
cases:7.08%
controls:1.66%
9
32
490
4929
0
9
501
4962
—
—
—
17
20
344
4872
15
68
197
4025
Rhinovirus RNA [Presence] in Specimen by NAA with probe detection
7993-9 [3025023]
7993-9 [3025023]
1.4e+00
—
—
—
1.0e+50
—
4.0e+00
cases:1.00%
controls:0.24%
—
—
—
—
—
—
cases:5.98%
controls:0.00%
—
—
cases:8.49%
controls:0.17%
5
12
494
4949
—
—
—
28
0
440
4969
—
18
7
194
4086
Enterovirus RNA [Presence] in Specimen by NAA with probe detection
29591-5 [3016881]
29591-5 [3016881]
1.3e+00
—
—
—
1.0e+50
—
4.0e+00
cases:1.00%
controls:0.26%
—
—
—
—
—
—
cases:5.98%
controls:0.00%
—
—
cases:8.49%
controls:0.17%
5
13
494
4948
—
—
—
28
0
440
4969
—
18
7
194
4086
Abnormal findings on diagnostic imaging of lung
R91 [45548995]
R91 [45548995]
7.8e-01
1.1e+00
—
—
1.0e+50
2.5e+00
1.4e+00
cases:2.81%
controls:1.31%
cases:1.60%
controls:0.56%
—
—
—
—
cases:1.50%
controls:0.00%
cases:4.99%
controls:0.41%
cases:5.19%
controls:1.29%
14
65
485
4896
8
28
493
4943
—
—
7
0
461
4969
18
20
343
4872
11
53
201
4040
Telephone, letter or other consultation without direct patient contact
ZY020 [2001311600]
ZY020 [2001311600]
1.5e+00
2.4e+00
—
—
—
1.7e+00
1.7e+00
cases:3.41%
controls:0.77%
cases:1.60%
controls:0.14%
—
—
—
—
—
—
cases:1.39%
controls:0.25%
cases:2.36%
controls:0.44%
17
38
482
4923
8
7
493
4964
—
—
—
5
12
356
4880
5
18
207
4075
Plastic And Reconstructive Surgery
24 [38004467]
24 [38004467]
9.9e-01
1.5e+00
—
—
-1.0e+50
1.5e+00
1.1e+00
cases:4.21%
controls:1.61%
cases:2.59%
controls:0.60%
—
—
—
—
cases:0.00%
controls:0.10%
cases:2.49%
controls:0.57%
cases:4.72%
controls:1.69%
21
80
478
4881
13
30
488
4941
—
—
0
5
468
4964
9
28
352
4864
10
69
202
4024
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
33762-6 [3029187]
3.6e-01
4.7e-01
9.7e-01
—
2.9e+00
9.7e-01
1.1e-01
cases:8.82%
controls:6.31%
cases:5.79%
controls:3.68%
cases:2.00%
controls:0.76%
—
—
cases:11.32%
controls:0.66%
cases:11.36%
controls:4.62%
cases:13.68%
controls:12.44%
44
313
455
4648
29
183
472
4788
10
38
491
4933
—
53
33
415
4936
41
226
320
4666
29
509
183
3584
mercaptopurine
L01BB02 [21601428]
L01BB02 [21601428]
—
—
—
—
—
—
3.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.49%
controls:0.20%
—
—
—
—
—
—
18
8
194
4085
Intravenous general anesthesia
WX404 [2001310807]
WX404 [2001310807]
4.4e-01
—
—
—
—
2.1e+00
1.8e+00
cases:3.61%
controls:2.36%
—
—
—
—
—
—
—
—
cases:2.22%
controls:0.29%
cases:5.66%
controls:1.00%
18
117
481
4844
—
—
—
—
8
14
353
4878
12
41
200
4052
Zoster without complication
B02.9 [45581143]
B02.9 [45581143]
2.7e-01
—
—
—
—
2.2e+00
1.6e+00
cases:1.00%
controls:0.77%
—
—
—
—
—
—
—
—
cases:2.22%
controls:0.25%
cases:5.19%
controls:1.08%
5
38
494
4923
—
—
—
—
8
12
353
4880
11
44
201
4049
Toxoplasma gondii IgM Ab [Units/volume] in Serum
8040-8 [3027529]
8040-8 [3027529]
—
—
—
1.0e+50
1.0e+50
—
3.8e+00
—
—
—
—
—
—
cases:3.59%
controls:0.00%
cases:21.58%
controls:0.00%
—
—
cases:5.19%
controls:0.12%
—
—
—
18
0
483
4971
101
0
367
4969
—
11
5
201
4088
Toxoplasma gondii IgG Ab [Units/volume] in Serum
8039-0 [3014959]
8039-0 [3014959]
—
—
—
1.0e+50
1.0e+50
—
3.8e+00
—
—
—
—
—
—
cases:3.59%
controls:0.00%
cases:21.58%
controls:0.00%
—
—
cases:5.19%
controls:0.12%
—
—
—
18
0
483
4971
101
0
367
4969
—
11
5
201
4088
Insertion of central venous catheter through subclavian or brachiocephalic vein
TPH20 [2001309601]
TPH20 [2001309601]
—
—
—
1.0e+50
1.0e+50
—
3.8e+00
—
—
—
—
—
—
cases:6.59%
controls:0.00%
cases:8.97%
controls:0.00%
—
—
cases:7.08%
controls:0.17%
—
—
—
33
0
468
4971
42
0
426
4969
—
15
7
197
4086
LabWAS
↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
216
39
95.48
307.65
6.1
1.3
—
—
—
0
0
163
52
45.64
261.36
1.6
1.5
141.90
152.66
au/ml
0.25
41
19
160
58
39.77
246.31
12.8
6.1
436.03
819.33
iu/ml
—
29
6
152
49
43.80
242.28
4.4
3.9
629.62
490.25
u/ml
—
13
8
305
422
16.54
237.69
24.6
2.1
346.70
234.19
u/l
4.82
299
398
147
62
32.93
213.89
1.4
1.3
250.56
201.38
u/ml
0.51
88
29
152
98
21.69
183.99
4.6
1.3
—
—
—
0
0
103
34
37.73
160.94
12.5
2.5
0.78
0.57
%
0.40
98
28
251
422
10.76
160.58
8.3
2.2
60.14
65.94
e9/l
1.14
208
330
205
268
12.13
159.78
3.2
2.1
9.97
11.27
g/l
3.22
200
251
139
99
18.94
158.99
1.7
1.6
—
—
—
0
0
138
97
19.15
158.94
4.3
1.4
—
—
—
0
0
116
63
23.55
150.82
4.9
1.3
—
—
—
0
0
175
217
11.77
140.48
1.5
1.3
1.14
1.19
g/l
0.21
169
207
84
33
30.29
123.25
5.4
1.3
—
—
—
0
0
79
28
33.21
119.87
1.9
1.0
—
—
—
0
0
84
36
27.75
119.37
5.5
1.3
—
—
—
0
0
154
204
10.39
116.17
1.7
1.7
1.52
1.53
g/l
0.06
136
179
247
571
7.46
112.92
15.6
5.1
1.09
1.03
mmol/l
2.96
242
512
94
0
+∞
101.53
1.0
0.0
—
—
—
0
0
72
34
24.50
98.12
1.2
1.0
—
—
—
0
0
242
634
6.37
94.57
4.9
1.9
29.00
29.78
s
1.12
237
612
93
88
12.71
88.15
2.2
1.4
—
—
—
0
0
234
633
5.99
87.19
13.0
2.9
0.80
0.83
mmol/l
3.12
226
586
172
357
6.77
84.93
2.3
1.5
65.79
66.81
g/l
0.87
167
325
67
39
19.63
83.08
4.7
2.4
—
—
—
0
0
155
296
7.09
83.01
4.0
1.5
—
—
—
0
0
302
1075
5.45
80.05
11.5
2.5
309.07
356.33
umol/l
7.29
293
914
66
43
17.49
77.34
2.4
1.4
—
—
—
0
0
68
47
16.54
77.28
2.6
1.3
—
—
—
0
0
79
75
12.28
74.35
2.0
1.3
—
—
—
0
0
56
30
20.85
71.90
1.8
1.4
—
—
—
0
0
58
34
19.12
71.46
6.1
1.1
—
—
—
0
0
58
34
19.12
71.46
6.1
1.1
—
—
—
0
0
58
34
19.12
71.46
6.1
1.1
—
—
—
0
0
70
5
161.86
67.81
1.3
1.0
—
—
—
0
0
233
768
4.75
65.33
5.5
1.9
—
—
—
0
0
45
20
24.59
62.23
1.4
1.7
—
—
—
0
0
45
20
24.59
62.23
1.4
1.6
—
—
—
0
0
44
19
25.25
61.50
7.3
1.1
—
—
—
0
0
44
19
25.25
61.50
7.3
1.1
—
—
—
0
0
44
19
25.25
61.50
7.3
1.1
—
—
—
0
0
44
19
25.25
61.50
7.2
1.1
—
—
—
0
0
82
106
9.03
61.31
1.5
2.2
28.91
12.01
mg/l
1.36
66
99
242
855
4.49
61.19
3.4
1.7
3.86
1.29
mg/l
3.53
219
664
67
71
10.72
58.14
1.3
1.2
191.66
16.89
u/l
4.43
61
62
89
135
7.78
58.03
2.5
1.2
—
—
—
0
0
66
78
9.57
52.73
2.4
1.3
—
—
—
0
0
60
63
10.66
52.28
2.5
1.4
—
—
—
0
0
38
17
24.08
52.25
1.4
1.1
—
—
—
0
0
180
583
4.23
49.64
3.7
1.8
—
—
—
0
0
83
139
6.94
49.13
3.5
3.6
—
—
—
0
0
203
742
3.89
46.73
1.5
1.3
2.42
2.72
g/l
1.59
180
435
36
19
20.31
46.14
2.3
1.8
40.24
47.24
%
0.71
17
11
169
551
4.09
45.72
3.7
1.9
—
—
—
0
0
45
51
9.58
36.84
5.9
1.9
33.24
33.16
pg
0.04
45
51
135
435
3.86
36.29
16.5
2.4
8.14
8.70
umol/l
0.10
130
378
42
9
50.72
35.28
8.8
2.7
1.24
1.22
%
—
42
9
347
2010
3.28
34.86
34.4
4.0
11.43
12.37
umol/l
1.06
342
1895
208
906
3.19
34.42
17.5
2.0
—
—
—
0
0
313
1724
3.12
34.06
18.4
2.4
—
—
estimate
—
0
0
42
12
38.00
33.34
7.4
1.1
—
—
—
0
0
42
12
38.00
33.34
7.4
1.1
—
—
—
0
0
42
12
38.00
33.34
7.4
1.2
—
—
—
0
0
353
2114
3.19
32.49
59.9
6.4
3.22
4.33
e9/l
2.10
335
1820
311
1806
2.86
28.96
18.7
3.9
32.39
35.43
g/l
15.88
302
1669
335
2036
2.89
28.35
30.2
5.6
0.11
0.20
e9/l
23.51
301
1764
55
107
5.64
27.56
3.9
1.2
—
—
—
0
0
37
48
8.23
27.13
5.1
1.1
—
—
—
0
0
37
48
8.23
27.13
5.1
1.1
—
—
—
0
0
37
48
8.23
27.13
5.1
1.1
—
—
—
0
0
316
1897
2.76
26.80
19.4
5.8
1.20
1.21
mmol/l
2.61
306
1713
60
133
4.98
25.95
1.3
1.2
30.38
48.96
mg/l
3.53
51
115
56
117
5.25
25.92
1.3
1.2
1.36
1.41
ratio
0.12
38
72
338
2138
2.73
25.16
23.7
6.2
1.20
1.21
mmol/l
1.35
296
1845
34
44
8.21
24.95
5.4
1.1
—
—
—
0
0
34
45
8.02
24.48
5.4
1.1
—
—
—
0
0
34
45
8.02
24.48
5.4
1.1
—
—
—
0
0
58
133
4.79
24.06
1.3
1.2
26.54
35.72
mg/l
1.59
50
116
30
9
35.30
23.60
2.9
1.3
—
—
—
0
0
30
9
35.30
23.60
2.9
1.3
—
—
—
0
0
32
13
26.16
23.34
1.1
1.3
—
—
—
0
0
32
16
21.25
21.97
2.8
1.3
—
—
—
0
0
32
16
21.25
21.97
2.8
1.3
—
—
—
0
0
66
180
4.06
21.88
7.8
1.6
—
—
—
0
0
40
72
5.94
21.67
2.0
1.3
—
—
—
0
0
60
167
3.94
19.29
3.6
1.5
—
—
—
0
0
143
670
2.58
18.85
1.9
2.5
2.01
2.25
g/l
6.26
137
614
83
293
3.19
18.55
3.7
1.6
—
—
—
0
0
220
1259
2.32
18.52
6.7
2.7
29.38
34.33
u/l
1.50
212
1185
133
614
2.58
17.98
1.9
2.6
36.20
23.07
%
9.21
126
567
22
7
32.75
17.16
2.0
1.1
—
—
—
0
0
39
85
4.89
17.10
1.6
1.7
—
—
—
0
0
23
11
21.82
16.11
2.8
2.3
—
—
—
0
0
23
33
7.25
15.38
2.6
1.3
—
—
—
0
0
26
44
6.17
14.93
3.0
1.7
2.50
10463.90
u/l
—
6
9
35
79
4.68
14.71
1.1
1.3
74.09
302.02
miu/ml
—
7
26
338
2436
2.15
14.67
14.1
4.7
6.81
6.78
mmol/l
0.11
333
2320
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
46
130
3.79
14.41
3.3
2.9
0.31
0.40
iu/ml
0.75
21
74
19
7
28.11
14.37
1.2
1.1
—
—
—
0
0
66
242
2.98
13.68
1.7
1.5
—
—
—
0
0
197
1186
2.08
13.63
2.3
2.3
2.94
2.86
mg/l
0.16
166
1009
293
2046
2.02
13.29
15.6
18.3
1.28
1.34
inr
1.36
272
1724
271
1846
2.00
13.14
4.3
3.0
711.23
125.71
ug/l
7.01
260
1709
36
96
3.96
12.22
1.1
1.3
—
—
—
0
0
48
158
3.25
11.92
1.2
1.3
0.20
0.42
g/l
0.49
43
138
155
904
2.03
11.32
4.5
4.4
65.92
359.66
ng/l
2.83
127
761
40
123
3.44
11.06
1.3
1.3
0.00
0.00
g/l
-0.00
40
116
197
1275
1.89
10.44
4.0
2.3
47.61
61.55
u/l
2.91
184
1172
53
205
2.77
9.92
4.3
1.4
3.10
2.70
ug/l
0.29
40
151
205
1372
1.83
9.58
5.7
2.1
2.30
2.35
mmol/l
5.08
187
1183
19
22
8.93
9.36
3.7
1.3
—
—
—
0
0
18
20
9.29
9.09
2.3
2.6
1620.56
704.15
u/ml
1.32
18
20
73
345
2.30
8.98
1.8
2.1
0.21
0.20
g/l
0.36
65
315
12
5
24.51
8.94
8.7
1.6
2.08
3.60
%
—
12
5
107
594
2.01
8.73
12.6
6.2
104.75
104.27
mmol/l
0.58
107
594
117
679
1.94
8.37
4.7
3.0
2.67
2.56
e6/l
0.04
64
334
8
0
+∞
8.35
11.0
0.0
—
—
—
0
0
28
82
3.56
8.34
1.6
1.3
—
—
—
0
0
28
82
3.56
8.34
1.6
1.3
—
—
—
0
0
201
1385
1.75
8.21
5.1
3.2
49.48
122.32
e6/l
0.75
161
1067
143
896
1.83
8.04
2.0
1.8
1265.36
1153.08
nmol/l
0.71
127
679
17
23
7.61
7.73
2.6
1.2
—
—
—
0
0
103
1649
0.53
7.65
3.0
1.9
1.68
1.30
mmol/l
4.66
95
1376
29
93
3.25
7.53
2.7
1.3
35.38
1440.53
e6/l
0.67
24
79
16
21
7.83
7.44
2.7
1.3
—
—
—
0
0
331
3877
0.58
7.40
5.3
6.3
2.52
2.59
mmol/l
0.68
309
3557
15
18
8.55
7.36
2.8
1.3
—
—
—
0
0
28
92
3.16
7.00
2.8
1.2
13.17
63.36
e6/l
0.46
23
77
27
87
3.22
6.96
2.3
1.3
3.72
3.98
mmol/l
0.72
27
82
57
272
2.23
6.83
6.8
4.3
1.06
2.15
mmol/l
1.90
48
196
172
1186
1.68
6.73
5.0
3.1
0.65
0.44
e6/l
0.33
133
873
267
2065
1.62
6.56
2.4
2.3
90.55
95.67
pmol/l
1.04
203
1046
318
3725
0.61
6.45
5.9
7.2
39.26
40.21
mmol/mol
1.37
299
3456
326
2655
1.63
6.42
7.0
4.9
222.00
3576.53
e6/l
1.42
11
47
29
103
2.93
6.37
2.7
1.2
498.72
522.99
mg/l
0.10
29
96
205
1510
1.60
6.02
3.1
3.4
1171.24
1638.19
ng/l
1.88
193
1301
83
487
1.84
5.62
5.0
3.6
2.05
1.94
mmol/l
0.09
71
425
327
3766
0.63
5.53
4.9
5.3
1.25
1.45
mmol/l
14.30
302
3442
114
747
1.68
5.25
4.8
2.9
1.73
1.18
e6/l
0.40
64
405
5
0
+∞
5.21
3.4
0.0
8.42
—
ng/l
—
5
0
5
0
+∞
5.21
1.2
0.0
—
—
—
0
0
5
0
+∞
5.21
7.8
0.0
—
—
—
0
0
11
16
7.00
4.97
1.6
1.3
—
—
—
0
0
63
353
1.90
4.92
2.3
2.0
80.34
34.25
u/l
0.47
56
287
186
1393
1.53
4.84
2.1
1.8
18.96
20.05
nmol/l
0.48
178
1181
8
7
11.58
4.80
3.0
1.0
—
—
—
0
0
380
4198
0.63
4.76
103.5
23.3
106.90
134.78
g/l
94.25
375
4129
380
4196
0.63
4.71
102.9
23.1
3.59
4.46
e12/l
65.13
372
4070
380
4196
0.63
4.71
103.5
23.6
32.33
40.18
%
79.84
375
4126
380
4196
0.63
4.71
103.1
23.1
156.10
242.23
e9/l
35.36
373
4086
380
4194
0.63
4.66
102.8
23.0
93.68
91.45
fl
10.19
375
4125
335
3797
0.66
4.66
5.4
5.4
4.21
4.48
mmol/l
4.60
315
3494
15
36
4.26
4.55
1.1
1.0
—
—
—
0
0
85
536
1.70
4.48
7.9
6.9
1.32
1.25
mmol/l
0.06
67
441
26
111
2.41
4.06
1.3
1.4
—
—
—
0
0
7
7
10.12
4.02
1.0
1.3
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
10
20
5.08
3.70
1.3
1.3
—
—
—
0
0
342
3810
0.69
3.69
7.1
5.5
6.04
6.06
mmol/l
0.09
320
3445
8
12
6.75
3.68
1.3
1.2
—
—
—
0
0
14
40
3.57
3.63
1.1
1.3
—
—
—
0
0
378
4130
0.67
3.62
80.7
20.4
80.68
81.98
umol/l
0.37
371
4063
324
3632
0.70
3.48
5.6
5.3
2.06
1.95
mu/l
0.58
303
3301
10
22
4.61
3.44
1.1
1.0
—
—
—
0
0
10
22
4.61
3.44
1.3
1.2
—
—
—
0
0
7
10
7.08
3.37
1.0
1.3
—
—
—
0
0
20
83
2.47
3.34
3.0
1.2
14.52
23.77
iu/l
1.03
15
71
331
3681
0.71
3.22
55.5
14.7
78.22
76.06
ml/min/173m2
1.07
316
3404
8
15
5.40
3.20
1.1
1.0
—
—
—
0
0
8
15
5.40
3.20
1.0
1.3
—
—
—
0
0
118
1555
0.69
3.19
3.5
4.2
6.68
7.85
mg/mmol
0.17
79
991
121
1585
0.69
3.16
2.7
3.4
6.96
7.43
mmol/l
0.60
111
1341
13
44
3.01
3.15
4.0
4.3
—
—
—
0
0
23
106
2.23
3.07
6.7
5.0
1.31
1.70
mg/l
2.28
23
93
16
62
2.63
3.07
1.1
1.4
—
—
—
0
0
5
5
10.08
2.98
1.0
1.6
—
—
—
0
0
374
4057
0.71
2.92
50.1
10.4
26.84
25.04
u/l
1.52
365
3896
59
381
1.62
2.86
3.2
2.4
0.67
0.35
e6/l
0.35
59
360
12
40
3.05
2.71
1.2
1.2
1.60
1.54
u/ml
—
5
13
22
108
2.08
2.55
5.8
3.4
5.45
1.39
index
0.70
16
51
328
3606
0.75
2.52
5.8
4.5
1.53
1.26
mmol/l
7.48
307
3257
208
1750
1.32
2.39
4.0
4.2
31.48
91.76
ng/l
1.03
168
1317
334
3006
1.32
2.33
6.4
4.4
24.08
12.36
mm/h
14.53
319
2757
9
28
3.25
2.31
1.1
2.1
17.12
15.44
umol/l
—
9
23
6
13
4.66
2.27
1.2
1.2
—
—
—
0
0
6
13
4.66
2.27
1.2
1.2
—
—
—
0
0
7
18
3.93
2.26
12.6
3.1
0.71
1.06
index
—
7
18
23
121
1.94
2.24
1.4
1.3
—
—
—
0
0
10
35
2.89
2.22
1.1
1.2
—
—
—
0
0
10
35
2.89
2.22
1.1
1.2
—
—
—
0
0
245
2124
1.30
2.21
4.3
2.7
—
—
—
0
0
376
4029
0.74
2.18
75.8
19.5
3.99
4.00
mmol/l
0.41
371
3932
278
2455
1.29
2.16
4.6
3.2
69.32
48.09
u/l
2.22
264
2268
10
37
2.74
2.08
1.1
1.2
—
—
—
0
0
10
37
2.74
2.08
1.1
1.2
—
—
—
0
0
20
104
1.96
2.03
1.8
1.7
—
—
—
0
0
377
4027
0.75
2.02
67.1
19.4
138.75
139.74
mmol/l
11.14
371
3937
169
1415
1.29
1.94
3.1
2.3
113.10
282.09
u/l
2.31
159
1322
7
22
3.21
1.88
1.3
1.0
—
—
—
0
0
11
46
2.42
1.86
1.6
1.2
—
—
—
0
0
11
46
2.42
1.86
1.2
1.2
3.17
4.74
u/ml
—
6
19
5
12
4.20
1.82
1.0
1.2
—
—
—
0
0
65
870
0.71
1.82
1.3
1.3
0.79
1.33
u/ml
1.09
16
240
16
80
2.03
1.82
2.4
1.7
421.64
16.58
u/ml
0.47
16
59
17
89
1.94
1.72
1.3
1.3
—
—
—
0
0
5
13
3.87
1.72
1.2
1.3
—
—
—
0
0
5
13
3.87
1.72
1.0
1.2
—
—
—
0
0
21
119
1.80
1.68
1.4
1.5
16957.21
12982.80
e6/l
0.24
14
81
21
120
1.78
1.64
1.3
1.2
—
—
—
0
0
10
42
2.41
1.62
1.1
1.1
—
—
—
0
0
21
121
1.77
1.61
1.3
1.2
—
—
—
0
0
36
240
1.54
1.60
5.0
3.2
24.47
25.31
mmol/l
0.66
36
233
7
26
2.72
1.58
1.3
1.2
14.00
10.19
u/l
—
7
21
275
3012
0.81
1.56
4.7
4.1
14.74
14.98
pmol/l
0.78
254
2722
16
280
0.56
1.51
1.9
2.1
—
—
—
0
0
9
38
2.39
1.46
4.6
2.0
3.89
100.68
u/ml
—
9
38
70
892
0.75
1.44
3.1
2.9
0.74
0.78
ug/l
0.19
43
597
120
997
1.27
1.43
1.7
1.8
120388797.15
21906369.76
pmol/l
0.38
103
808
10
46
2.20
1.40
1.1
1.2
—
—
—
0
0
6
23
2.63
1.37
1.0
1.3
—
—
—
0
0
69
537
1.33
1.35
1.4
1.5
—
—
—
0
0
0
37
0.00
1.35
0.0
1.6
—
59.53
—
0
30
27
176
1.56
1.34
1.4
1.3
—
—
—
0
0
6
131
0.45
1.30
2.5
2.0
74.83
41.93
nmol/l
—
6
123
5
18
2.79
1.29
5.2
1.1
—
—
—
0
0
15
252
0.58
1.25
1.9
2.0
—
—
—
0
0
10
49
2.06
1.22
1.5
1.2
2250.90
1778.81
e6/l
—
10
32
18
110
1.66
1.17
1.2
1.2
—
—
—
0
0
0
34
0.00
1.16
0.0
1.6
—
0.99
—
0
22
0
34
0.00
1.16
0.0
1.6
—
1.14
—
0
22
0
34
0.00
1.16
0.0
1.6
—
1.01
—
0
22
107
1253
0.82
1.10
4.0
4.1
19.36
24.31
%
2.38
47
602
19
121
1.59
1.07
3.0
3.7
0.87
0.85
nmol/l
0.06
12
102
7
33
2.14
1.06
13.0
2.9
16.86
12.11
index
—
7
18
7
33
2.14
1.06
1.0
1.1
—
—
—
0
0
35
255
1.40
1.06
5.8
3.9
44.50
45.90
%
0.12
35
250
10
178
0.55
1.05
1.2
1.0
—
—
—
0
0
5
107
0.46
1.02
2.8
2.1
186.20
231.35
pmol/l
—
5
100
9
50
1.81
0.97
1.1
1.1
—
1.10
—
0
8
234
2149
1.16
0.95
4.7
4.1
21.56
0.00
estimate
0.49
57
440
6
29
2.08
0.89
1.0
1.0
—
—
—
0
0
6
30
2.01
0.87
1.0
1.1
—
—
—
0
0
235
2172
1.15
0.85
4.7
4.1
0.02
0.01
estimate
0.14
51
426
229
2114
1.15
0.84
4.7
4.1
0.00
0.00
estimate
-0.00
55
429
20
140
1.45
0.78
1.4
1.5
1.29
1.14
g/l
1.03
20
134
24
322
0.73
0.75
1.6
1.5
—
—
—
0
0
7
39
1.81
0.72
1.0
1.1
—
—
—
0
0
7
40
1.76
0.71
1.3
1.1
—
—
—
0
0
52
429
1.24
0.70
2.3
2.6
3.96
7.56
ug/l
1.92
45
369
7
41
1.72
0.70
1.0
1.1
—
—
—
0
0
9
58
1.56
0.70
2.1
2.3
11.08
10.67
mmol/l
—
9
58
7
42
1.68
0.68
1.0
1.1
—
—
—
0
0
49
404
1.24
0.67
6.9
3.3
—
—
—
0
0
0
20
0.00
0.60
0.0
1.2
—
—
—
0
0
143
1556
0.89
0.57
4.4
4.4
1.88
2.08
ug/l
0.50
131
1386
25
318
0.78
0.57
6.6
2.3
56.00
63.47
ml/min/173m2
0.64
11
139
124
1127
1.13
0.56
4.0
3.5
0.00
0.00
estimate
-0.00
40
338
9
62
1.46
0.53
3.9
2.2
1.19
1.19
mmol/l
—
9
62
9
64
1.41
0.51
3.9
2.2
106.33
105.30
mmol/l
—
9
64
60
522
1.17
0.50
3.2
5.3
28.10
32.51
%
2.46
48
327
17
128
1.34
0.48
1.2
1.2
—
26.78
—
0
6
23
182
1.28
0.47
1.3
1.9
4.30
7.75
iu/ml
—
7
45
0
15
0.00
0.41
0.0
1.4
—
8.70
—
0
15
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
16
0.00
0.41
0.0
1.2
—
8.31
—
0
16
8
59
1.36
0.41
1.1
1.5
—
—
—
0
0
0
17
0.00
0.40
0.0
1.1
—
—
—
0
0
0
18
0.00
0.40
0.0
1.1
—
229.09
—
0
11
129
1201
1.10
0.39
4.4
4.2
0.00
0.00
estimate
-0.00
49
395
47
416
1.14
0.34
1.5
1.4
—
—
—
0
0
94
1010
0.91
0.31
4.3
4.4
1.02
1.02
kg/l
0.13
80
659
94
876
1.09
0.29
3.0
2.2
2.44
2.45
mmol/l
0.17
84
762
8
66
1.22
0.27
1.8
3.0
40.54
10.13
pmol/l
—
8
66
13
105
1.24
0.25
1.4
1.3
260.00
315.58
ug/g
—
8
64
378
3843
0.94
0.24
80.5
15.3
34.40
25.44
mg/l
5.39
365
3144
72
670
1.09
0.24
1.3
1.3
1.27
11.49
u/ml
4.46
21
246
26
229
1.14
0.22
5.3
3.6
1.02
1.02
ratio
0.20
26
213
0
10
0.00
0.21
0.0
2.0
—
—
—
0
0
0
13
0.00
0.21
0.0
2.9
—
16.42
—
0
13
28
254
1.11
0.16
5.2
2.7
1.30
1.15
%
0.63
28
254
11
129
0.85
0.15
2.0
2.3
—
—
—
0
0
24
217
1.11
0.15
1.1
1.2
68.17
110.66
u/ml
—
6
87
49
519
0.94
0.13
13.4
7.6
—
—
—
0
0
27
250
1.08
0.11
2.9
2.7
0.71
0.63
%
1.07
27
250
165
1614
1.03
0.11
4.3
4.1
0.00
0.03
estimate
1.22
49
344
6
74
0.81
0.07
1.8
1.5
—
—
—
0
0
7
80
0.87
0.07
2.0
1.4
—
—
—
0
0
10
110
0.91
0.05
1.7
2.2
—
—
—
0
0
191
1890
1.02
0.05
3.0
2.5
75.66
78.08
nmol/l
0.60
177
1666
39
402
0.97
0.04
1.5
1.7
1.53
1.53
%
0.01
32
345
73
727
1.00
0.00
1.2
1.3
17.85
32.82
iu/ml
2.56
26
224
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
8
83
0.96
-0.00
1.8
1.7
324.38
306.50
mu/l
—
8
78
0
6
0.00
-0.00
0.0
2.2
—
0.50
—
0
6
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
10
100
1.00
-0.00
2.5
2.4
30.30
36.45
umol/l
—
10
89
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
9.6
—
5.36
—
0
5
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded (different definition than used in FinnGen).
Relationships between endpoints
↥Index endpoint: C3_AML_WIDE – Acute myeloid leukaemia, including Hilmo
GWS hits: -
This endpoint is excluded (different definition than used in FinnGen).